0000883975 2024-01-01 2024-12-31 0000883975 2024-06-30 0000883975 2025-03-24 0000883975 2024-10-01 2024-12-31 0000883975 2024-12-31 0000883975 2023-12-31 0000883975 2023-01-01 2023-12-31 0000883975 us-gaap:CommonStockMember 2022-12-31 0000883975 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000883975 us-gaap:RetainedEarningsMember 2022-12-31 0000883975 2022-12-31 0000883975 us-gaap:CommonStockMember 2023-12-31 0000883975 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000883975 us-gaap:RetainedEarningsMember 2023-12-31 0000883975 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0000883975 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0000883975 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0000883975 us-gaap:CommonStockMember 2024-01-01 2024-12-31 0000883975 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-12-31 0000883975 us-gaap:RetainedEarningsMember 2024-01-01 2024-12-31 0000883975 us-gaap:CommonStockMember 2024-12-31 0000883975 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0000883975 us-gaap:RetainedEarningsMember 2024-12-31 0000883975 MBOT:AtTheMarketOfferingProgramMember 2024-01-01 2024-12-31 0000883975 MBOT:CollateralLeaseAgreementMember 2024-12-31 0000883975 MBOT:CollateralLeaseAgreementMember 2023-12-31 0000883975 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-12-31 0000883975 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-12-31 0000883975 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-12-31 0000883975 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-12-31 0000883975 srt:MinimumMember MBOT:ResearchEquipmentAndSoftwareMember 2024-12-31 0000883975 srt:MaximumMember MBOT:ResearchEquipmentAndSoftwareMember 2024-12-31 0000883975 MBOT:FurnitureAndOfficeEquipmentMember 2024-12-31 0000883975 us-gaap:LeaseholdImprovementsMember 2024-12-31 0000883975 us-gaap:CashMember 2024-12-31 0000883975 us-gaap:CashMember 2023-12-31 0000883975 us-gaap:MoneyMarketFundsMember 2024-12-31 0000883975 us-gaap:MoneyMarketFundsMember 2023-12-31 0000883975 us-gaap:USTreasurySecuritiesMember 2024-12-31 0000883975 us-gaap:USTreasurySecuritiesMember 2023-12-31 0000883975 us-gaap:MoneyMarketFundsMember MBOT:MarketableSecuritiesMember 2024-12-31 0000883975 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member MBOT:MarketableSecuritiesMember 2024-12-31 0000883975 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member MBOT:MarketableSecuritiesMember 2024-12-31 0000883975 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member MBOT:MarketableSecuritiesMember 2024-12-31 0000883975 MBOT:MarketableSecuritiesMember 2024-12-31 0000883975 us-gaap:FairValueInputsLevel1Member MBOT:MarketableSecuritiesMember 2024-12-31 0000883975 us-gaap:FairValueInputsLevel2Member MBOT:MarketableSecuritiesMember 2024-12-31 0000883975 us-gaap:FairValueInputsLevel3Member MBOT:MarketableSecuritiesMember 2024-12-31 0000883975 us-gaap:USTreasurySecuritiesMember MBOT:MarketableSecuritiesMember 2023-12-31 0000883975 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel1Member MBOT:MarketableSecuritiesMember 2023-12-31 0000883975 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member MBOT:MarketableSecuritiesMember 2023-12-31 0000883975 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel3Member MBOT:MarketableSecuritiesMember 2023-12-31 0000883975 us-gaap:MoneyMarketFundsMember MBOT:MarketableSecuritiesMember 2023-12-31 0000883975 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member MBOT:MarketableSecuritiesMember 2023-12-31 0000883975 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member MBOT:MarketableSecuritiesMember 2023-12-31 0000883975 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member MBOT:MarketableSecuritiesMember 2023-12-31 0000883975 MBOT:MarketableSecuritiesMember 2023-12-31 0000883975 us-gaap:FairValueInputsLevel1Member MBOT:MarketableSecuritiesMember 2023-12-31 0000883975 us-gaap:FairValueInputsLevel2Member MBOT:MarketableSecuritiesMember 2023-12-31 0000883975 us-gaap:FairValueInputsLevel3Member MBOT:MarketableSecuritiesMember 2023-12-31 0000883975 MBOT:ResearchAndDevelopmentNetMember 2024-01-01 2024-12-31 0000883975 MBOT:ResearchAndDevelopmentNetMember 2023-01-01 2023-12-31 0000883975 MBOT:ResearchEquipmentAndSoftwareMember 2024-12-31 0000883975 MBOT:ResearchEquipmentAndSoftwareMember 2023-12-31 0000883975 us-gaap:LeaseholdImprovementsMember 2023-12-31 0000883975 MBOT:FurnitureAndOfficeEquipmentMember 2023-12-31 0000883975 MBOT:TwoThousandThirteenToJuneThirtyTwoThousandTwentyTwoMember MBOT:IsraeliInnovationAuthorityMember 2024-01-01 2024-12-31 0000883975 MBOT:IsraeliInnovationAuthorityMember 2023-12-31 0000883975 MBOT:IsraeliInnovationAuthorityMember 2024-12-31 0000883975 MBOT:CardioSertLtdMember MBOT:IsraeliInnovationAuthorityMember 2022-10-06 2022-10-06 0000883975 srt:MinimumMember MBOT:IsraeliInnovationAuthorityMember 2024-01-01 2024-12-31 0000883975 srt:MaximumMember MBOT:IsraeliInnovationAuthorityMember 2024-01-01 2024-12-31 0000883975 MBOT:IsraeliInnovationAuthorityMember 2022-12-11 0000883975 MBOT:MinistryOfEconomyMember 2024-12-31 0000883975 srt:MinimumMember MBOT:TechnionResearchAndDevelopmentFoundationLimitedMember 2012-06-01 2012-06-30 0000883975 srt:MaximumMember MBOT:TechnionResearchAndDevelopmentFoundationLimitedMember 2012-06-01 2012-06-30 0000883975 MBOT:TechnologyMember MBOT:CardioSertLtdMember 2018-01-04 2018-01-04 0000883975 MBOT:CardioSertMember 2024-07-01 2024-07-31 0000883975 MBOT:AtTheMarketOfferingAgreementMember MBOT:HCWainwrightAndCoLLCMember 2021-06-10 0000883975 us-gaap:CommonStockMember MBOT:AtTheMarketOfferingAgreementMember 2024-07-01 2024-07-01 0000883975 2022-10-03 2022-10-03 0000883975 MBOT:HCWainwrightAndCoLLCMember 2022-10-03 2022-10-03 0000883975 MBOT:AtTheMarketOfferingAgreementMember MBOT:HCWainwrightAndCoLLCMember 2022-10-06 2022-10-06 0000883975 MBOT:DeviceMember 2022-10-06 2022-10-06 0000883975 MBOT:IntegratedProductMember 2022-10-06 2022-10-06 0000883975 MBOT:SecuritiesPurchaseAgreementMember 2024-01-01 2024-12-31 0000883975 2024-01-26 2024-01-26 0000883975 MBOT:LitigationSettlementMember 2024-01-26 2024-01-26 0000883975 MBOT:LitigationSettlementMember 2023-12-31 0000883975 MBOT:LitigationSettlementMember 2024-01-01 2024-03-31 0000883975 us-gaap:CommonStockMember MBOT:LitigationSettlementMember 2024-01-01 2024-03-31 0000883975 MBOT:AllianceInvestmentManagementLtdMember 2019-04-28 2019-04-28 0000883975 MBOT:JosephMonaMember 2021-03-31 2021-03-31 0000883975 MBOT:JosephMonaMember 2023-08-22 2023-08-22 0000883975 srt:MaximumMember srt:ChiefExecutiveOfficerMember 2024-02-29 0000883975 srt:ChiefExecutiveOfficerMember 2024-06-01 2024-06-30 0000883975 srt:ChiefExecutiveOfficerMember 2024-06-30 0000883975 srt:MinimumMember srt:ChiefExecutiveOfficerMember 2024-06-01 2024-06-30 0000883975 srt:MinimumMember srt:ChiefExecutiveOfficerMember 2024-06-30 2024-06-30 0000883975 srt:ChiefExecutiveOfficerMember 2024-07-17 2024-07-17 0000883975 srt:ChiefExecutiveOfficerMember 2024-07-17 0000883975 srt:ChiefExecutiveOfficerMember 2024-09-01 2024-09-30 0000883975 srt:ChiefExecutiveOfficerMember 2024-09-30 0000883975 srt:MinimumMember srt:ChiefExecutiveOfficerMember 2024-09-01 2024-09-30 0000883975 srt:ChiefExecutiveOfficerMember 2024-12-01 2024-12-31 0000883975 MBOT:OtherExecutivesMember 2024-12-31 0000883975 MBOT:OtherExecutivesMember 2024-09-30 2024-09-30 0000883975 MBOT:OtherExecutivesMember 2024-07-01 2024-09-30 0000883975 MBOT:ChiefFinancialOfficerAndChiefTechnologyOfficerMember 2024-07-17 0000883975 MBOT:ChiefExecutiveOfficerAndExecutivesMember 2024-12-31 0000883975 MBOT:CertainEmployeesMember 2024-12-31 0000883975 us-gaap:CommonStockMember MBOT:SeriesAPreferredInvestmentOptionsMember 2022-10-25 2022-10-25 0000883975 us-gaap:CommonStockMember MBOT:SeriesAPreferredInvestmentOptionsMember 2022-10-25 0000883975 us-gaap:CommonStockMember MBOT:SeriesCPreferredInvestmentOptionsMember 2023-06-06 2023-06-06 0000883975 us-gaap:CommonStockMember MBOT:SeriesCPreferredInvestmentOptionsMember 2023-06-06 0000883975 us-gaap:CommonStockMember MBOT:SeriesDPreferredInvestmentOptionsMember 2023-06-26 2023-06-26 0000883975 us-gaap:CommonStockMember MBOT:SeriesDPreferredInvestmentOptionsMember 2023-06-26 0000883975 us-gaap:CommonStockMember MBOT:ExistingPreferredInvestmentOptionsMember 2023-12-29 2023-12-29 0000883975 us-gaap:CommonStockMember MBOT:ExistingPreferredInvestmentOptionsMember 2023-12-29 0000883975 us-gaap:CommonStockMember MBOT:InducementInvestmentOptionsMember 2023-12-29 2023-12-29 0000883975 us-gaap:CommonStockMember MBOT:InducementInvestmentOptionsMember 2023-12-29 0000883975 2023-12-29 2023-12-29 0000883975 MBOT:PreferredInvestmentOptionExerciseInducementOffersLetterMember MBOT:HCWainwrightAndCoLLCMember 2023-12-29 2023-12-29 0000883975 MBOT:PreferredInvestmentOptionExerciseInducementOffersLetterMember MBOT:HCWainwrightAndCoLLCMember 2023-12-29 0000883975 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember MBOT:SecuritiesPurchaseAgreementMember 2023-05-22 2023-05-22 0000883975 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember MBOT:SecuritiesPurchaseAgreementMember 2023-05-22 0000883975 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2023-05-22 2023-05-22 0000883975 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2023-05-22 0000883975 us-gaap:CommonStockMember MBOT:SeriesDPreferredInvestmentOptionsMember 2023-05-22 2023-05-22 0000883975 us-gaap:CommonStockMember MBOT:SecuritiesPurchaseAgreementMember 2023-05-22 0000883975 2023-05-22 2023-05-22 0000883975 us-gaap:CommonStockMember MBOT:SecuritiesPurchaseAgreementMember 2023-05-23 2023-05-23 0000883975 us-gaap:CommonStockMember MBOT:SecuritiesPurchaseAgreementMember 2023-05-23 0000883975 us-gaap:CommonStockMember MBOT:SeriesDPreferredInvestmentOptionsMember 2023-05-23 0000883975 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2023-05-23 2023-05-23 0000883975 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2023-05-23 0000883975 us-gaap:CommonStockMember MBOT:SecuritiesPurchaseAgreementMember 2024-12-31 0000883975 us-gaap:CommonStockMember MBOT:SeriesDPreferredInvestmentOptionsMember 2023-05-23 2023-05-23 0000883975 us-gaap:CommonStockMember MBOT:SecuritiesPurchaseAgreementMember MBOT:WainwrightMember 2023-05-23 0000883975 2023-05-23 2023-05-23 0000883975 us-gaap:CommonStockMember MBOT:SecuritiesPurchaseAgreementMember 2023-06-02 2023-06-02 0000883975 us-gaap:CommonStockMember MBOT:SecuritiesPurchaseAgreementMember 2023-06-02 0000883975 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2023-06-02 2023-06-02 0000883975 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2023-06-02 0000883975 2023-06-02 2023-06-02 0000883975 us-gaap:CommonStockMember MBOT:SeriesCPreferredInvestmentOptionsMember 2023-06-02 2023-06-02 0000883975 us-gaap:CommonStockMember MBOT:SeriesCPreferredInvestmentOptionsMember 2023-06-02 0000883975 us-gaap:CommonStockMember MBOT:SecuritiesPurchaseAgreementMember 2023-06-26 2023-06-26 0000883975 us-gaap:CommonStockMember MBOT:SecuritiesPurchaseAgreementMember 2023-06-26 0000883975 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2023-06-26 2023-06-26 0000883975 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2023-06-26 0000883975 us-gaap:CommonStockMember MBOT:SecuritiesPurchaseAgreementMember MBOT:HCWainwrightAndCoLLCMember 2023-06-26 2023-06-26 0000883975 us-gaap:CommonStockMember MBOT:SecuritiesPurchaseAgreementMember MBOT:HCWainwrightAndCoLLCMember 2023-06-26 0000883975 2023-06-26 2023-06-26 0000883975 us-gaap:CommonStockMember MBOT:SeriesDPreferredInvestmentOptionsMember 2023-06-28 2023-06-28 0000883975 us-gaap:CommonStockMember MBOT:SeriesDPreferredInvestmentOptionsMember 2023-06-28 0000883975 us-gaap:CommonStockMember MBOT:SecuritiesPurchaseAgreementMember 2024-06-03 2024-06-03 0000883975 us-gaap:CommonStockMember MBOT:SecuritiesPurchaseAgreementMember 2024-06-03 0000883975 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2024-06-03 2024-06-03 0000883975 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2024-06-03 0000883975 us-gaap:CommonStockMember MBOT:SeriesFPreferredInvestmentOptionsMember 2024-06-03 2024-06-03 0000883975 us-gaap:CommonStockMember MBOT:SeriesFPreferredInvestmentOptionsMember 2024-06-03 0000883975 us-gaap:CommonStockMember MBOT:HCWainwrightAndCoLLCMember 2024-06-03 2024-06-03 0000883975 us-gaap:CommonStockMember MBOT:HCWainwrightAndCoLLCMember 2024-06-03 0000883975 us-gaap:CommonStockMember MBOT:AtTheMarketOfferingAgreementMember 2024-01-01 2024-12-31 0000883975 us-gaap:CommonStockMember MBOT:SeriesAPreferredInvestmentOptionsMember 2024-01-01 2024-12-31 0000883975 us-gaap:CommonStockMember MBOT:SeriesAPreferredInvestmentOptionsMember 2024-12-31 0000883975 us-gaap:CommonStockMember MBOT:SeriesBPreferredInvestmentOptionsMember 2024-01-01 2024-12-31 0000883975 us-gaap:CommonStockMember MBOT:SeriesBPreferredInvestmentOptionsMember 2024-12-31 0000883975 MBOT:SeriesBPreferredInvestmentOptionsMember 2023-10-25 0000883975 MBOT:SeriesBPreferredInvestmentOptionsMember 2023-10-25 2023-10-25 0000883975 MBOT:SeriesBPreferredInvestmentOptionsMember us-gaap:CommonStockMember 2023-06-16 2023-06-16 0000883975 srt:ChiefExecutiveOfficerMember us-gaap:CommonStockMember 2023-01-01 2023-12-31 0000883975 MBOT:EmployeesConsultantsAndDirectorsMember us-gaap:CommonStockMember 2023-01-01 2023-12-31 0000883975 srt:MinimumMember MBOT:EmployeesConsultantsAndDirectorsMember us-gaap:CommonStockMember 2023-01-01 2023-12-31 0000883975 srt:MaximumMember MBOT:EmployeesConsultantsAndDirectorsMember us-gaap:CommonStockMember 2023-01-01 2023-12-31 0000883975 srt:ChiefExecutiveOfficerMember us-gaap:CommonStockMember 2024-01-01 2024-12-31 0000883975 srt:ManagementMember us-gaap:CommonStockMember 2024-01-01 2024-12-31 0000883975 MBOT:ChiefExecutiveOfficerAndOtherExecutivesMember 2024-02-29 0000883975 MBOT:ChiefExecutiveOfficerAndOtherExecutivesMember 2024-02-01 2024-02-29 0000883975 MBOT:ChiefExecutiveOfficerAndExecutivesMember 2024-01-01 2024-12-31 0000883975 srt:ChiefExecutiveOfficerMember 2024-01-01 2024-12-31 0000883975 MBOT:ChiefExecutiveOfficerEmployeesAndAdvisorsMember 2024-02-29 0000883975 MBOT:AdvisorsMember 2024-01-01 2024-12-31 0000883975 MBOT:AdvisorsMember 2024-12-31 0000883975 srt:ChiefExecutiveOfficerMember 2024-02-01 2024-02-29 0000883975 2024-02-29 2024-02-29 0000883975 srt:ChiefExecutiveOfficerMember 2024-02-29 0000883975 srt:MinimumMember us-gaap:MeasurementInputPriceVolatilityMember 2024-12-31 0000883975 srt:MaximumMember us-gaap:MeasurementInputPriceVolatilityMember 2024-12-31 0000883975 srt:MinimumMember us-gaap:MeasurementInputPriceVolatilityMember 2023-12-31 0000883975 srt:MaximumMember us-gaap:MeasurementInputPriceVolatilityMember 2023-12-31 0000883975 srt:MinimumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-12-31 0000883975 srt:MaximumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-12-31 0000883975 srt:MinimumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-12-31 0000883975 srt:MaximumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-12-31 0000883975 us-gaap:MeasurementInputExpectedDividendRateMember 2024-12-31 0000883975 us-gaap:MeasurementInputExpectedDividendRateMember 2023-12-31 0000883975 srt:MinimumMember us-gaap:MeasurementInputExpectedTermMember 2024-12-31 0000883975 srt:MaximumMember us-gaap:MeasurementInputExpectedTermMember 2024-12-31 0000883975 srt:MinimumMember us-gaap:MeasurementInputExpectedTermMember 2023-12-31 0000883975 srt:MaximumMember us-gaap:MeasurementInputExpectedTermMember 2023-12-31 0000883975 MBOT:EmployeesAndDirectorsMember 2023-12-31 0000883975 MBOT:EmployeesAndDirectorsMember 2024-01-01 2024-12-31 0000883975 MBOT:EmployeesAndDirectorsMember 2024-12-31 0000883975 MBOT:EmployeesAndDirectorsMember 2022-12-31 0000883975 MBOT:EmployeesAndDirectorsMember 2023-01-01 2023-12-31 0000883975 srt:MinimumMember MBOT:ExercisePriceOneMember 2024-01-01 2024-12-31 0000883975 srt:MinimumMember MBOT:ExercisePriceOneMember 2023-01-01 2023-12-31 0000883975 srt:MaximumMember MBOT:ExercisePriceOneMember 2024-01-01 2024-12-31 0000883975 srt:MaximumMember MBOT:ExercisePriceOneMember 2023-01-01 2023-12-31 0000883975 MBOT:ExercisePriceOneMember 2024-12-31 0000883975 MBOT:ExercisePriceOneMember 2023-12-31 0000883975 MBOT:ExercisePriceOneMember 2024-01-01 2024-12-31 0000883975 MBOT:ExercisePriceOneMember 2023-01-01 2023-12-31 0000883975 srt:MinimumMember MBOT:ExercisePriceTwoMember 2024-01-01 2024-12-31 0000883975 srt:MinimumMember MBOT:ExercisePriceTwoMember 2023-01-01 2023-12-31 0000883975 srt:MaximumMember MBOT:ExercisePriceTwoMember 2024-01-01 2024-12-31 0000883975 srt:MaximumMember MBOT:ExercisePriceTwoMember 2023-01-01 2023-12-31 0000883975 MBOT:ExercisePriceTwoMember 2024-12-31 0000883975 MBOT:ExercisePriceTwoMember 2023-12-31 0000883975 MBOT:ExercisePriceTwoMember 2024-01-01 2024-12-31 0000883975 MBOT:ExercisePriceTwoMember 2023-01-01 2023-12-31 0000883975 srt:MinimumMember MBOT:ExercisePriceThreeMember 2024-01-01 2024-12-31 0000883975 srt:MinimumMember MBOT:ExercisePriceThreeMember 2023-01-01 2023-12-31 0000883975 srt:MaximumMember MBOT:ExercisePriceThreeMember 2024-01-01 2024-12-31 0000883975 srt:MaximumMember MBOT:ExercisePriceThreeMember 2023-01-01 2023-12-31 0000883975 MBOT:ExercisePriceThreeMember 2024-12-31 0000883975 MBOT:ExercisePriceThreeMember 2023-12-31 0000883975 MBOT:ExercisePriceThreeMember 2024-01-01 2024-12-31 0000883975 MBOT:ExercisePriceThreeMember 2023-01-01 2023-12-31 0000883975 srt:MinimumMember MBOT:ExercisePriceFourMember 2024-01-01 2024-12-31 0000883975 srt:MinimumMember MBOT:ExercisePriceFourMember 2023-01-01 2023-12-31 0000883975 srt:MaximumMember MBOT:ExercisePriceFourMember 2024-01-01 2024-12-31 0000883975 srt:MaximumMember MBOT:ExercisePriceFourMember 2023-01-01 2023-12-31 0000883975 MBOT:ExercisePriceFourMember 2024-12-31 0000883975 MBOT:ExercisePriceFourMember 2023-12-31 0000883975 MBOT:ExercisePriceFourMember 2024-01-01 2024-12-31 0000883975 MBOT:ExercisePriceFourMember 2023-01-01 2023-12-31 0000883975 srt:MinimumMember MBOT:ExercisePriceFiveMember 2024-01-01 2024-12-31 0000883975 srt:MinimumMember MBOT:ExercisePriceFiveMember 2023-01-01 2023-12-31 0000883975 srt:MaximumMember MBOT:ExercisePriceFiveMember 2024-01-01 2024-12-31 0000883975 srt:MaximumMember MBOT:ExercisePriceFiveMember 2023-01-01 2023-12-31 0000883975 MBOT:ExercisePriceFiveMember 2024-12-31 0000883975 MBOT:ExercisePriceFiveMember 2023-12-31 0000883975 MBOT:ExercisePriceFiveMember 2024-01-01 2024-12-31 0000883975 MBOT:ExercisePriceFiveMember 2023-01-01 2023-12-31 0000883975 srt:MinimumMember 2024-01-01 2024-12-31 0000883975 srt:MaximumMember 2024-01-01 2024-12-31 0000883975 MBOT:SeriesAWarrantOctoberTwoThousandTwentyTwoMember 2024-12-31 0000883975 MBOT:SeriesAWarrantOctoberTwoThousandTwentyTwoMember 2023-12-31 0000883975 MBOT:SeriesAWarrantOctoberTwoThousandTwentyTwoMember 2024-01-01 2024-12-31 0000883975 MBOT:WarrantToUnderwritersOctoberTwoThousandTwentyTwoMember 2024-12-31 0000883975 MBOT:WarrantToUnderwritersOctoberTwoThousandTwentyTwoMember 2023-12-31 0000883975 MBOT:WarrantToUnderwritersOctoberTwoThousandTwentyTwoMember 2024-01-01 2024-12-31 0000883975 MBOT:WarrantToUnderwritersOneMayTwoThousandTwentyThreeMember 2024-12-31 0000883975 MBOT:WarrantToUnderwritersOneMayTwoThousandTwentyThreeMember 2023-12-31 0000883975 MBOT:WarrantToUnderwritersOneMayTwoThousandTwentyThreeMember 2024-01-01 2024-12-31 0000883975 MBOT:WarrantToUnderwritersTwoMayTwoThousandTwentyThreeMember 2024-12-31 0000883975 MBOT:WarrantToUnderwritersTwoMayTwoThousandTwentyThreeMember 2023-12-31 0000883975 MBOT:WarrantToUnderwritersTwoMayTwoThousandTwentyThreeMember 2024-01-01 2024-12-31 0000883975 MBOT:WarrantToUnderwritersOneJuneTwoThousandTwentyThreeMember 2024-12-31 0000883975 MBOT:WarrantToUnderwritersOneJuneTwoThousandTwentyThreeMember 2023-12-31 0000883975 MBOT:WarrantToUnderwritersOneJuneTwoThousandTwentyThreeMember 2024-01-01 2024-12-31 0000883975 MBOT:WarrantSeriesCJuneTwoThousandTwentyThreeMember 2024-12-31 0000883975 MBOT:WarrantSeriesCJuneTwoThousandTwentyThreeMember 2023-12-31 0000883975 MBOT:WarrantSeriesCJuneTwoThousandTwentyThreeMember 2024-01-01 2024-12-31 0000883975 MBOT:WarrantToUnderwritersTwoJuneTwoThousandTwentyThreeMember 2024-12-31 0000883975 MBOT:WarrantToUnderwritersTwoJuneTwoThousandTwentyThreeMember 2023-12-31 0000883975 MBOT:WarrantToUnderwritersTwoJuneTwoThousandTwentyThreeMember 2024-01-01 2024-12-31 0000883975 MBOT:WarrantSeriesDJuneTwoThousandTwentyThreeMember 2024-12-31 0000883975 MBOT:WarrantSeriesDJuneTwoThousandTwentyThreeMember 2023-12-31 0000883975 MBOT:WarrantSeriesDJuneTwoThousandTwentyThreeMember 2024-01-01 2024-12-31 0000883975 MBOT:WarrantSeriesEJanuaryTwoThousandTwentyFourMember 2024-12-31 0000883975 MBOT:WarrantSeriesEJanuaryTwoThousandTwentyFourMember 2023-12-31 0000883975 MBOT:WarrantSeriesEJanuaryTwoThousandTwentyFourMember 2024-01-01 2024-12-31 0000883975 MBOT:WarrantToUnderwritersJanuaryTwoThousandTwentyFourMember 2024-12-31 0000883975 MBOT:WarrantToUnderwritersJanuaryTwoThousandTwentyFourMember 2023-12-31 0000883975 MBOT:WarrantToUnderwritersJanuaryTwoThousandTwentyFourMember 2024-01-01 2024-12-31 0000883975 MBOT:WarrantSeriesFJuneTwoThousandTwentyFourMember 2024-12-31 0000883975 MBOT:WarrantSeriesFJuneTwoThousandTwentyFourMember 2023-12-31 0000883975 MBOT:WarrantSeriesFJuneTwoThousandTwentyFourMember 2024-01-01 2024-12-31 0000883975 MBOT:WarrantToUnderwritersJuneTwoThousandTwentyFourMember 2024-12-31 0000883975 MBOT:WarrantToUnderwritersJuneTwoThousandTwentyFourMember 2023-12-31 0000883975 MBOT:WarrantToUnderwritersJuneTwoThousandTwentyFourMember 2024-01-01 2024-12-31 0000883975 MBOT:SeriesAWarrantOctoberTwoThousandTwentyTwoMember 2024-01-01 2024-12-31 0000883975 MBOT:SeriesAWarrantOctoberTwoThousandTwentyTwoMember 2023-01-01 2023-12-31 0000883975 MBOT:WarrantToUnderwritersOctoberTwoThousandTwentyTwoMember 2024-01-01 2024-12-31 0000883975 MBOT:WarrantToUnderwritersOctoberTwoThousandTwentyTwoMember 2023-01-01 2023-12-31 0000883975 MBOT:WarrantToUnderwritersOneMayTwoThousandTwentyThreeMember 2024-01-01 2024-12-31 0000883975 MBOT:WarrantToUnderwritersOneMayTwoThousandTwentyThreeMember 2023-01-01 2023-12-31 0000883975 MBOT:WarrantToUnderwritersTwoMayTwoThousandTwentyThreeMember 2024-01-01 2024-12-31 0000883975 MBOT:WarrantToUnderwritersTwoMayTwoThousandTwentyThreeMember 2023-01-01 2023-12-31 0000883975 MBOT:WarrantToUnderwritersJuneTwoThousandTwentyThreeMember 2024-01-01 2024-12-31 0000883975 MBOT:WarrantToUnderwritersJuneTwoThousandTwentyThreeMember 2023-01-01 2023-12-31 0000883975 MBOT:WarrantSeriesCJuneTwoThousandTwentyThreeMember 2024-01-01 2024-12-31 0000883975 MBOT:WarrantSeriesCJuneTwoThousandTwentyThreeMember 2023-01-01 2023-12-31 0000883975 MBOT:WarrantToUnderwritersJuneTwoThousandTwentyThreeTwoMember 2024-01-01 2024-12-31 0000883975 MBOT:WarrantToUnderwritersJuneTwoThousandTwentyThreeTwoMember 2023-01-01 2023-12-31 0000883975 MBOT:WarrantSeriesDJuneTwoThousandTwentyThreeMember 2024-01-01 2024-12-31 0000883975 MBOT:WarrantSeriesDJuneTwoThousandTwentyThreeMember 2023-01-01 2023-12-31 0000883975 MBOT:WarrantSeriesEJanuaryTwoThousandTwentyFourMember 2024-01-01 2024-12-31 0000883975 MBOT:WarrantSeriesEJanuaryTwoThousandTwentyFourMember 2023-01-01 2023-12-31 0000883975 MBOT:WarrantToUnderwritersJanuaryTwoThousandTwentyFourMember 2024-01-01 2024-12-31 0000883975 MBOT:WarrantToUnderwritersJanuaryTwoThousandTwentyFourMember 2023-01-01 2023-12-31 0000883975 MBOT:WarrantSeriesFJuneTwoThousandTwentyFourMember 2024-01-01 2024-12-31 0000883975 MBOT:WarrantSeriesFJuneTwoThousandTwentyFourMember 2023-01-01 2023-12-31 0000883975 MBOT:WarrantToUnderwritersJuneTwoThousandTwentyFourMember 2024-01-01 2024-12-31 0000883975 MBOT:WarrantToUnderwritersJuneTwoThousandTwentyFourMember 2023-01-01 2023-12-31 0000883975 us-gaap:StockOptionMember 2024-01-01 2024-12-31 0000883975 us-gaap:StockOptionMember 2023-01-01 2023-12-31 0000883975 country:IL 2024-12-31 0000883975 country:IL 2023-12-31 0000883975 country:US 2024-12-31 0000883975 country:US 2023-12-31 0000883975 MBOT:USTaxAuthorityMember 2024-01-01 2024-12-31 0000883975 MBOT:USTaxAuthorityMember 2023-01-01 2023-12-31 0000883975 MBOT:USTaxAuthorityMember 2024-12-31 0000883975 MBOT:USTaxAuthorityMember 2023-12-31 0000883975 MBOT:PreTwoThousandSeventeenMember 2024-12-31 0000883975 MBOT:PostTwoThousandSeventeenMember 2024-12-31 0000883975 us-gaap:IsraelTaxAuthorityMember 2024-01-01 2024-12-31 0000883975 us-gaap:IsraelTaxAuthorityMember 2023-01-01 2023-12-31 0000883975 us-gaap:IsraelTaxAuthorityMember 2024-12-31 0000883975 us-gaap:IsraelTaxAuthorityMember 2023-12-31 0000883975 us-gaap:CommonStockMember us-gaap:SubsequentEventMember MBOT:SecuritiesPurchaseAgreementMember 2025-01-06 2025-01-06 0000883975 us-gaap:CommonStockMember us-gaap:SubsequentEventMember MBOT:SecuritiesPurchaseAgreementMember 2025-01-06 0000883975 MBOT:SeriesGPreferredInvestmentOptionsMember us-gaap:SubsequentEventMember MBOT:SecuritiesPurchaseAgreementMember 2025-01-06 2025-01-06 0000883975 MBOT:SeriesGPreferredInvestmentOptionsMember us-gaap:SubsequentEventMember MBOT:SecuritiesPurchaseAgreementMember 2025-01-06 0000883975 MBOT:SeriesGPreferredInvestmentOptionsMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2025-01-06 2025-01-06 0000883975 us-gaap:CommonStockMember us-gaap:SubsequentEventMember MBOT:SecuritiesPurchaseAgreementMember 2025-01-07 0000883975 us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2025-01-07 0000883975 us-gaap:CommonStockMember us-gaap:SubsequentEventMember MBOT:SecuritiesPurchaseAgreementMember 2025-01-07 2025-01-07 0000883975 MBOT:SeriesHPreferredInvestmentOptionsMember us-gaap:SubsequentEventMember MBOT:SecuritiesPurchaseAgreementMember 2025-01-06 2025-01-06 0000883975 MBOT:SeriesHPreferredInvestmentOptionsMember us-gaap:SubsequentEventMember MBOT:SecuritiesPurchaseAgreementMember 2025-01-06 0000883975 MBOT:SeriesHPreferredInvestmentOptionsMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2025-01-07 2025-01-07 0000883975 us-gaap:CommonStockMember us-gaap:SubsequentEventMember MBOT:SecuritiesPurchaseAgreementMember 2025-01-10 0000883975 us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2025-01-10 0000883975 us-gaap:CommonStockMember us-gaap:SubsequentEventMember MBOT:SecuritiesPurchaseAgreementMember 2025-02-09 2025-02-09 0000883975 us-gaap:CommonStockMember us-gaap:SubsequentEventMember MBOT:SecuritiesPurchaseAgreementMember 2025-02-09 0000883975 MBOT:SeriesIPreferredInvestmentOptionsMember us-gaap:SubsequentEventMember MBOT:SecuritiesPurchaseAgreementMember 2025-02-09 2025-02-09 0000883975 MBOT:SeriesIPreferredInvestmentOptionsMember us-gaap:SubsequentEventMember MBOT:SecuritiesPurchaseAgreementMember 2025-02-09 0000883975 MBOT:SeriesIPreferredInvestmentOptionsMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2025-02-09 2025-02-09 0000883975 us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2025-02-09 0000883975 us-gaap:CommonStockMember us-gaap:SubsequentEventMember MBOT:ATMAgreementMember 2025-01-01 2025-01-31 0000883975 MBOT:SeriesEPreferredInvestmentOptionsMember us-gaap:SubsequentEventMember MBOT:ExerciseOfInvestmentOptionsMember 2025-01-01 2025-01-31 0000883975 srt:ChiefExecutiveOfficerMember us-gaap:SubsequentEventMember 2025-01-01 2025-01-31 0000883975 MBOT:ExecutivesAndCertainEmployeesMember us-gaap:SubsequentEventMember 2025-01-01 2025-01-31 0000883975 srt:ChiefExecutiveOfficerMember us-gaap:SubsequentEventMember 2025-02-01 2025-02-28 0000883975 MBOT:ExecutivesMember us-gaap:SubsequentEventMember 2025-01-01 2025-01-31 0000883975 MBOT:ExecutivesMember us-gaap:SubsequentEventMember 2025-02-01 2025-02-28 0000883975 MBOT:CertainEmployeesAndCertainBoardMembersMember us-gaap:SubsequentEventMember 2025-01-01 2025-01-31 0000883975 MBOT:CertainEmployeesAndCertainBoardMembersMember us-gaap:SubsequentEventMember 2025-02-01 2025-02-28 0000883975 MBOT:BoardMember us-gaap:SubsequentEventMember 2025-02-01 2025-02-28 0000883975 us-gaap:SubsequentEventMember 2025-03-01 2025-03-31 iso4217:USD shares iso4217:USD shares pure iso4217:ILS false FY 0000883975

http://fasb.org/us-gaap/2024#UsefulLifeTermOfLeaseMember

10-K true 2024-12-31 --12-31 2024 false 000-19871 MICROBOT MEDICAL INC. DE 94-3078125 175 Derby St., Bld. 27 Hingham MA 02043 (781) 875-3605 Common Stock, Par value $0.01 MBOT NASDAQ No No Yes Yes Non-accelerated Filer true false false false false 15900000 34744476 Item 1C. CybersecuritySince our formation, <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_902_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20240101__20241231_z4fhuZX203C7">we have been primarily focused on research and development activities and pursuing FDA approval of our planned products, and recently commenced building our commercial team. <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_903_ecyd--CybersecurityRiskManagementProcessesIntegratedTextBlock_c20240101__20241231_zv3v4X4bo2kj">We have 22 employees and currently use third-party vendors and service providers for certain product development and regulatory approval activities. <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_904_ecyd--CybersecurityRiskManagementThirdPartyEngagedFlag_dbT_c20240101__20241231_ztTXk87detIa">We use a third-party sub-contractor to manage all Information Technology (IT) issues, including protection against, detection, and response to cyberattacks. The measures that are taken to ensure proper protection include: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">All computers are protected using a cloud-powered endpoint security solution that helps enterprises prevent, detect, investigate, and respond to advanced threats on their networks. It offers endpoint protection, endpoint detection and response, mobile threat defense, and integrated vulnerability management. It also provides, among other things, malware and spyware detection and remediation, rootkit detection and remediation and network vulnerability detection.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">All Company computer hard drives are automatically encrypted.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">All Company e-mails are protected by a cloud-based email filtering service designed to protect the Company against advanced threats related to email and collaboration tools.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Periodically, all users on the Company’s computer network are required to perform multi-factor authentication.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Company uses a cloud-based identity and access management service that enables access to external resources.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Backup is performed using a secure, automatic cloud-based backup and restore service.</td></tr></table> Additionally, we believe that our third-party vendors and service providers have their own respective cybersecurity protocols which our management believes to be adequate for protecting any of the Company’s data that might be in their possession from time to time; however, having such protocols is not necessarily a condition for us using or not using the services of any such vendors or providers. <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90D_ecyd--CybersecurityRiskBoardOfDirectorsOversightTextBlock_c20240101__20241231_zSq9TNe2slb8">Our Chief Technology Officer and General Manager is responsible for assessing and managing cybersecurity risks, through his oversight of our IT service provider that manages our IT, but he does not have specific cybersecurity expertise. The Company has an Information Technology Policy that, among other things, governs and provides for cybersecurity policies and processes, including to define safety measures to protect the Company’s confidentiality, integrity and availability of data and other intellectual property, as well as to define the manner in which information is stored, saved and routed in the Company’s network. Additionally, the Board and management believe cybersecurity represents an important component of the Company’s overall approach to risk management and oversight, especially as the Company moves towards commercialization of its first product. Cybersecurity threats have not materially affected, and are not reasonably likely to affect, the Company, including its business strategy, results of operations or financial condition while we are strategically focused on pursuing FDA approval and have pre-commercial operations. <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90B_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbF_c20240101__20241231_zqSHzZ5OIgP3">The Company is not aware of any material security breach to date. Accordingly, the Company has not incurred any material expenses over the last two years relating to information security breaches. The occurrence of cyber-incidents, or a deficiency in our cybersecurity or in those of any of our third-party service providers could negatively impact our business by causing a disruption to our operations, a compromise or corruption of our confidential information and systems, or damage to our business relationships or reputation, all of which could negatively impact our business and results of operations. There can be no assurance that the Company’s third-party vendors’ and service providers’ cybersecurity risk management processes, including their policies, controls or procedures, will be fully implemented, complied with or effective in protecting the Company’s systems and information. true We have 22 employees and currently use third-party vendors and service providers for certain product development and regulatory approval activities. true Our Chief Technology Officer and General Manager is responsible for assessing and managing cybersecurity risks, through his oversight of our IT service provider that manages our IT, but he does not have specific cybersecurity expertise. The Company has an Information Technology Policy that, among other things, governs and provides for cybersecurity policies and processes, including to define safety measures to protect the Company’s confidentiality, integrity and availability of data and other intellectual property, as well as to define the manner in which information is stored, saved and routed in the Company’s network. Additionally, the Board and management believe cybersecurity represents an important component of the Company’s overall approach to risk management and oversight, especially as the Company moves towards commercialization of its first product. false false false false false true 1197 Brightman Almagor Zohar & Co Tel Aviv, Israel

3114000

2468000

2356000

3917000

49000

1335000

300000

152000

5819000

7921000

80000

146000

132000

260000

6031000

8327000

165000

357000

70000

191000

2211000

2225000

1027000

2460000

3786000

41000

40000

2501000

3826000

0.01

60000000

19399513

11707317

195000

118000

94279000

83884000

-90944000

-79501000

3530000

4501000

6031000

8327000

6630000

5724000

4995000

4131000

-11625000

-9855000

182000

228000

-2000

-1111000

-11443000

-10740000

-0.73

-1.05

15644511

10199984

7890628

80000

75970000

-68761000

7289000

3816689

38000

6520000

6558000

1394000

-10740000

11707317

118000

83884000

-79501000

4501000

11707317

118000

83884000

-79501000

4501000

3252351

33000

4386000

4419000

1005965 10000 1101000 1111000 3433880 34000 3483000 3517000

1425000

-11443000

19399513

195000

94279000

-90944000

3530000

19399513

195000

94279000

-90944000

3530000

1075000

661000

239000

-11443000

-10740000

91000

106000

2211000 1000 160000

-2000

1349000

1394000

-69000

-672000

873000

-683000

-1335000 1335000 -1100000

-8827000

-8533000

-3000

25000

33000

2500000

9164000

5120000

10060000

4182000

2899000

1537000

1973000

7936000

6558000

7936000

6558000

646000

-2000

2517000

2519000

3163000

2517000

171000

130000

1111000

98000

50000

76000

NOTE 1 – GENERAL A. Description of business: Microbot Medical Inc. (the “Company”) is a clinical-stage medical device company specializing in the research, design and development of next generation robotic endoluminal surgery devices targeting the minimally invasive surgery space. The Company is primarily focused on leveraging its micro-robotic technologies with the goal of redefining surgical robotics while improving surgical outcomes for patients. The Company incorporated on August 2, 1988 in the State of Delaware under the name Cellular Transplants, Inc. The original Certificate of Incorporation was restated on February 14, 1992 to change the name of the Company to Cyto Therapeutics, Inc. On May 24, 2000, the Certificate of Incorporation as restated was further amended to change the name of the Company to StemCells, Inc. On November 28, 2016, the Company consummated a transaction pursuant to an Agreement and Plan of Merger, dated August 15, 2016, with Microbot Medical Ltd., a private medical device company organized under the laws of the State of Israel (“Microbot Israel”). On the same day and in connection with the Merger, the Company changed its name from StemCells, Inc. to Microbot Medical Inc. On November 29, 2016, the Company’s common stock began trading on the Nasdaq Capital Market under the symbol “MBOT”. The Company and its subsidiary are sometimes collectively referred to as the “Company” as the context may require. B. Risk Factors: To date, the Company has not generated revenues from its operations. As of December 31, 2024, the Company had cash equivalents and marketable securities balance of approximately $5,470, excluding restricted cash. Due to continuing research and development activities, the Company expects to continue to incur additional losses for the foreseeable future. Notwithstanding these conditions, the Company’s management has concluded that the available funds as of the balance sheet date, combined with the capital raises completed subsequent to the balance sheet date, as described in Notes 17A and 17B, are sufficient to fund the Company’s operations for more than twelve months from issuance date of these financial statements. The Company will seek to raise additional funds through future issuances of either debt and/or equity securities and possibly additional grants from the Israeli Innovation Authority and other government institutions. The Company’s ability to raise additional capital in the equity and debt markets is dependent on a number of factors, including, but not limited to, the market demand for the Company’s stock, which itself is subject to a number of development and business risks and uncertainties, as well as the uncertainty that the Company would be able to raise such additional capital at a price or on terms that are favorable to the Company. MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data) B. Risk Factors: Israel-Hamas War On October 7, 2023, the State of Israel, where our research and development and other operations are primarily based, suffered a surprise attack by hostile forces from Gaza, which led to Israeli military operation at first in Gaza and then in Lebanon. These military operations and related activities, such as the recent collapse of the Assad regime in Syria and Israel’s subsequent military operations in Syria, and the recent escalation of military operations by and against the Houthis in Yemen, are on-going as of the issuance date of these financial statements, although there have been temporary cease fires from time to time. The Company has considered various ongoing risks relating to the military operations and related matters, including: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 1in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">That some of our Israeli subcontractors, vendors, suppliers and other companies in which the Company relies, are currently only partially active, as instructed by the relevant authorities; and</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 1in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">A slowdown in the number of international flights in and out of Israel.</td></tr></table> The Company is closely monitoring how the military operations and related activities could adversely affect our anticipated milestones and our Israel-based activities to support future clinical and regulatory milestones, including our ability to import materials that are required to construct the Company’s devices and to ship them outside of Israel. As of the issuance date of these financial statements, the Company has determined that there have not been any materially adverse effects on our business or operations, but the Company continues to monitor the situation, as any collapse of the cease-fire with Hamas or Hezbollah or any future escalation or change could result in a material adverse effect on the ability of our Israeli office to support the Company’s clinical and regulatory activities. The Company do not have any specific contingency plans in the event of any such escalation or change.

1988-08-02

5470000

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The significant accounting policies applied in the preparation of the financial statements are as follows: A. Basis of presentation: The financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“US GAAP”). B. Financial statement in U.S. dollars: The functional currency of the Company is the U.S. dollar (“dollar”) since the dollar is the currency of the primary economic environment in which the Company has operated and expects to continue to operate in the foreseeable future. Transactions and balances denominated in dollars are presented at their original amounts. Transactions and balances denominated in foreign currencies have been re-measured to dollars in accordance with the provisions of Accounting Standards Codification (“ASC”) 830-10, “Foreign Currency Translation”. All transaction gains and losses from re-measurement of monetary balance sheet items denominated in non-dollar currencies are reflected in the statements of comprehensive loss as financial income or expenses, as appropriate. C. Use of estimates: The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions pertaining to transactions and matters whose ultimate effect on the financial statements cannot precisely be determined at the time of financial statements preparation. Although these estimates are based on management’s best judgment, actual results may differ from these estimates. <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-9</td></tr></table></div> <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"> </div> MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data) NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES D. Principles of consolidation: The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. Inter-company balances and transactions have been eliminated in consolidation. E. Reclassification of prior year disclosures: Certain prior year amounts have been reclassified for consistency with the current year disclosures. These reclassifications had no effect on the reported consolidated balance sheets, the related consolidated statements of comprehensive loss, shareholders’ equity and cash flows. F. Cash and cash equivalents: Cash and cash equivalents consist of cash and demand deposits in banks, and other short-term liquid investments (primarily interest-bearing time deposits) with original maturities of three months or less at the date of purchase. G. Restricted cash: Restricted cash of $49 as of December 31, 2024, and 2023 serves as collateral for the Company’s lease agreement. H. Fair value of financial instruments: The carrying values of cash and cash equivalents, other receivable and other accounts payable and accrued liabilities approximate their fair value due to the short-term maturity of these instruments. The Company measures the fair value of certain of its financial instruments (such as marketable securities) on a recurring basis. The method of determining the fair value of marketable securities is discussed in Note 4 below. A fair value hierarchy is used to rank the quality and reliability of the information used to determine fair values. Financial assets and liabilities carried at fair value will be classified and disclosed in one of the following three categories: Level 1 - Quoted prices (unadjusted) in active markets for identical assets and liabilities. Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as unadjusted quoted prices for similar assets and liabilities, unadjusted quoted prices in the markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. I. Concentrations of credit risk: Financial instruments which potentially subject the Company to credit risk consist primarily of cash and cash equivalents and marketable securities. The Company holds these investments in highly rated financial institutions. These amounts at times may exceed federally insured limits. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts, or other hedging arrangements. MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data) NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES J. Property and equipment: Property and equipment are presented at cost less accumulated depreciation. Depreciation is calculated based on the straight-line method over the estimated useful lives of the assets, at the following annual rates: SCHEDULE OF ESTIMATED USEFUL LIVES OF PROPERTY AND EQUIPMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Research equipment and software</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ResearchEquipmentAndSoftwareMember__srt--RangeAxis__srt--MinimumMember_zV3w1m2o0IVg" title="Property, plant and equipment, useful life">25-<span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ResearchEquipmentAndSoftwareMember__srt--RangeAxis__srt--MaximumMember_zhLzV1nl6Jg3" title="Property, plant and equipment, useful life">33</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 76%; text-align: left">Furniture and office equipment</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 20%; text-align: right"><span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_z2eJkNsU2Lo3" title="Property, plant and equipment, useful life">7</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Leasehold improvements</td><td> </td> <td style="text-align: left"> </td><td style="text-align: center"><span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_iI_dxL_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zYMnYQnKRuBl" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2024%23UsefulLifeTermOfLeaseMember">Over the lease period</td><td style="text-align: left"> </td></tr> </table> The Company assesses property and equipment impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. If such circumstances are determined to exist, an estimate of undiscounted future cash flows produced by the property and equipment assets, or the appropriate grouping of assets, is compared to the carrying value to determine whether impairment exists. If an asset is determined to be impaired, the loss is measured based on the difference between the asset’s estimated fair value and its carrying value. For property and equipment assets, the estimate of fair value is typically based on a discounted cash flow model. As of December 31, 2024, and 2023, no impairment charge has been recorded. K. Liabilities due to termination of employment agreements: Under Israeli employment laws, employees of Microbot Israel are included under Article 14 of the Severance Compensation Act, 1963 (“Article 14”). According to Article 14, these employees are entitled to monthly deposits made by Microbot Israel on their behalf with insurance companies. Payments in accordance with Article 14 release Microbot Israel from any future severance payments (under the Israeli Severance Compensation Act, 1963) with respect of those employees. The aforementioned deposits are not recorded as an asset in the Company’s balance sheets. As for the U.S. employees, the Company has certain defined contribution plans, including a 401(k)-retirement plan in the U.S., whereby contributions made by eligible employees are matched by the Company with certain limitations. L. Common stock warrants: The Company accounts for warrants issued to investors as either equity-classified or liability-classified instruments, based on an assessment of the warrant’s specific terms and the applicable authoritative guidance in FASB ASC 480 and FASB ASC 815, “Derivatives and Hedging” (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, or meet all of the requirements for equity classification under FASB ASC 815, including whether the warrants are indexed to the Company’s own shares of common stock and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. M. Basic and diluted net loss per share: Basic net loss per share is calculated by dividing net loss attributable to common stock shareholders by the weighted average number of shares of common stock outstanding during the year without consideration of potentially dilutive securities. For purposes of the diluted net loss per share attributable to common shareholders calculation, stock options and warrants are considered to be common stock equivalents. All common stock equivalents, as detailed in Notes 2P and 10F, have been excluded from the calculation of the diluted loss per share for the years ended December 31, 2024 and December 31, 2023, as their effect would be anti-dilutive. Therefore, basic and diluted net loss per share were the same for both years presented. In the calculation of the basic and diluted net loss, the Company included warrants that would be exercised for no or little consideration and are exercisable with no contingencies. N. Research and development expenses, net: Research and development expenses are charged to the statement of comprehensive loss as incurred. Grants for funding of approved research and development projects and others are recognized at the time the Company is entitled to such grants, on the basis of the costs incurred and applied as a deduction from the research and development expenses. See Note 2U below. Reimbursement of expenses for research and development projects is recognized as the costs are incurred and is netted against research and development expenses in the statement of comprehensive loss. Research and development reimbursements of $83, and $0 were offset against research and development costs in the years ended December 31, 2024 and 2023, respectively O. General and administrative expenses, net: General and administrative expenses are charged to the statement of comprehensive loss as incurred. Insurance loss recoveries are recognized when the amount is determinable and approved by the insurance company and applied as a deduction from general and administrative expenses. General and administrative expenses, net, for the years ended December 31, 2024 and 2023, were offset by insurance loss recoveries in the amounts of approximately $0 and $281, respectively. MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data) NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES P. Share-based compensation: The Company applies ASC 718-10, “Share-Based Payment” (“ASC 718-10”), which requires the measurement and recognition of compensation expenses for all share-based payment awards made to employees and directors including stock options under the Company’s stock plans based on estimated fair values. ASC 718-10 requires companies to estimate the fair value of stock options using an option-pricing model, which is recognized as an expense over the requisite service periods in the Company’s statement of comprehensive loss, based on a straight-line method. The Company recognizes compensation cost for an equity classified award with only service conditions that has a graded vesting schedule on a straight-line basis over the requisite service period for the entire award, provided that the cumulative amount of compensation cost recognized at any date at least equals the portion of the grant date fair value of such award that is vested at that date. The Company recognizes the expense for an equity classified awards subject to performance-based milestone vesting over the remaining service period when management determines that achievement of the milestone is probable. Management evaluates when the achievement of a performance-based milestone is probable based on the expected satisfaction of the performance conditions at each reporting date. If no explicit service period is determined, the Company estimates the implicit service period based on the timing the employee is expected to achieve the related performance condition. When no future services are required to be performed by the grantee in exchange for an award of equity instruments, and if such award does not contain a performance condition, the cost of the award is expensed on the grant date. The Company estimates the fair value of stock options granted as share-based payment awards using a Black-Scholes options pricing model. The option-pricing model requires a number of assumptions, of which the most significant are expected volatility and the expected option term (the time from the grant date until the options are exercised or expire). Expected volatility is estimated based on the standard deviation of the Company’s closing prices according to the expected life (SAB107) for each of the grants. The Company has historically not paid dividends and has no foreseeable plans to issue dividends. The risk-free interest rate is based on the yield from governmental zero-coupon bonds with an equivalent term. For stock options that qualify as “plain-vanilla,” the expected term is calculated using the simplified method. For stock options that do not qualify as “plain-vanilla”, the Company’s management estimated that the expected stock option term is the contractual term of the options. Changes in the determination of each of the inputs can affect the fair value of the stock options granted and the results of operations of the Company. Q. Income taxes: The Company provides for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of December 31, 2024, and 2023, the Company had a full valuation allowance against deferred tax assets. MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data) NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES R. Marketable securities: The Company invests in various debt securities and an equity security. Debt securities consist of U.S. treasury securities. Equity security consist of a mutual fund. The Company records these investments in the consolidated balance sheet at fair value. For all of the Company’s debt securities, the Company elected the fair value option and thus all unrealized gains or losses for these securities are reflected in the statements of comprehensive loss as financial income or expenses, as appropriate. Unrealized gains or losses for the equity security are reflected in the statements of comprehensive loss as financial income or expenses, as appropriate. The Company classifies its investments as current based on the nature of the investments and their availability for use in current operations. S. Leases: The Company determines if an arrangement is a lease at inception. Operating lease assets are presented as operating lease long-term right-of-use assets (“ROU”), and corresponding as lease liabilities (current portion), and as operating long-term lease liabilities, on the Company’s consolidated balance sheets. Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the remaining lease payments over the lease term at commencement date. The Company’s leases do not provide an implicit interest rate. The Company calculates the incremental borrowing rate to reflect the interest rate that it would have to pay to borrow on a collateralized basis an amount equal to the lease payments in a similar economic environment over a similar term and considers the Company’s historical borrowing activities and market data in this determination. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that it will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. The Company has lease agreements with lease and non-lease components, which it accounts for as a single lease component. The Company has elected not to recognize ROU assets and lease liabilities for short-term leases that have a term of 12 months or less. The Company’s lease agreements do not contain any material residual value guarantees or material restrictive covenants. In addition, the Company does not have any related party leases. MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data) NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES T. Contingencies: Management records and discloses legal contingencies in accordance with ASC Topic 450 Contingencies. A provision is recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. The Company monitors the stage of progress of its litigation matters to determine if any adjustments are required. Refer to Note 9G below. The Company carries liability insurance to mitigate its exposure to losses, including litigation losses. The Company records the estimated amount of expected insurance proceeds for litigation losses incurred as an asset (typically a receivable from the insurer) and offset to losses up to the amount of the losses incurred when the amount is determinable and approved by the insurance company. Refer to Note 2O above and Note 9G below. U. Government grants: Government grants which are received from the Israeli Ministry of Economy and Israel Innovation Authority (“IIA”) by way of participation in research and development that is conducted by Microbot Israel, are received in installments as the program progresses based on qualified research spending. Grants received are recognized when the grant becomes receivable, provided there was reasonable assurance that Microbot Israel will comply with the conditions attached to the grant and there was reasonable assurance the grant will be received. The grants are deducted from the research and development expenses as the applicable costs are incurred. Research and development expenses, net, for the years ended December 31, 2024 and 2023, include participation in research and development expenses in the amount of approximately $149 and $279, respectively. V. Segment Reporting The Company has a single operating and reportable segment, which is the development of robotic devices for endoluminal surgery. See Note 1A for further details. The Company’s chief operating decision maker (the “CODM”), the Chief Executive Officer (“CEO”), reviews financial information presented on a consolidated basis for purposes of making operating decisions, assessing performance, and allocating resources. For further details, refer to Note 14. W. Recently Adopted accounting pronouncements: In November 2023, the FASB issued ASU 2023-07, “Segment Reporting (Topic 280), Improvements to Reportable Segment Disclosures” (“ASU 2023-07”) to improve reportable segment disclosure requirements through enhanced disclosures about significant segment expenses on an interim and annual basis. All disclosure requirements of ASU 2023-07 are required also for entities with a single reportable segment. ASU 2023-07 is effective starting January 1, 2024 and should be applied on a retrospective basis to all periods presented. The adoption of this ASU did not have a material impact on the Company’s financial statements. X. Accounting pronouncements not yet effective: In November 2024, the FASB issued ASU 2024-03, “Income Statement–Reporting Comprehensive Income–Expense Disaggregation Disclosures (Subtopic 220- 40): Disaggregation of Income Statement Expenses” (“ASU 2024-03”), which requires the disaggregation of certain expenses in the financial statements notes, to provide enhanced transparency into the expense captions presented on the face of the consolidated statement of operations. ASU 2024-03 is effective for annual reporting periods beginning January 1, 2027 and interim periods beginning January 1, 2028 and may be applied either prospectively or retrospectively. The Company is currently evaluating the impact that ASU 2024-03 will have on its related disclosures.

A. Basis of presentation: The financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“US GAAP”).

B. Financial statement in U.S. dollars: The functional currency of the Company is the U.S. dollar (“dollar”) since the dollar is the currency of the primary economic environment in which the Company has operated and expects to continue to operate in the foreseeable future. Transactions and balances denominated in dollars are presented at their original amounts. Transactions and balances denominated in foreign currencies have been re-measured to dollars in accordance with the provisions of Accounting Standards Codification (“ASC”) 830-10, “Foreign Currency Translation”. All transaction gains and losses from re-measurement of monetary balance sheet items denominated in non-dollar currencies are reflected in the statements of comprehensive loss as financial income or expenses, as appropriate.

C. Use of estimates: The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions pertaining to transactions and matters whose ultimate effect on the financial statements cannot precisely be determined at the time of financial statements preparation. Although these estimates are based on management’s best judgment, actual results may differ from these estimates. <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-9</td></tr></table></div> <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"> </div> MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data) NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

D. Principles of consolidation: The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. Inter-company balances and transactions have been eliminated in consolidation.

E. Reclassification of prior year disclosures: Certain prior year amounts have been reclassified for consistency with the current year disclosures. These reclassifications had no effect on the reported consolidated balance sheets, the related consolidated statements of comprehensive loss, shareholders’ equity and cash flows.

F. Cash and cash equivalents: Cash and cash equivalents consist of cash and demand deposits in banks, and other short-term liquid investments (primarily interest-bearing time deposits) with original maturities of three months or less at the date of purchase.

G. Restricted cash: Restricted cash of $49 as of December 31, 2024, and 2023 serves as collateral for the Company’s lease agreement.

H. Fair value of financial instruments: The carrying values of cash and cash equivalents, other receivable and other accounts payable and accrued liabilities approximate their fair value due to the short-term maturity of these instruments. The Company measures the fair value of certain of its financial instruments (such as marketable securities) on a recurring basis. The method of determining the fair value of marketable securities is discussed in Note 4 below. A fair value hierarchy is used to rank the quality and reliability of the information used to determine fair values. Financial assets and liabilities carried at fair value will be classified and disclosed in one of the following three categories: Level 1 - Quoted prices (unadjusted) in active markets for identical assets and liabilities. Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as unadjusted quoted prices for similar assets and liabilities, unadjusted quoted prices in the markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

I. Concentrations of credit risk: Financial instruments which potentially subject the Company to credit risk consist primarily of cash and cash equivalents and marketable securities. The Company holds these investments in highly rated financial institutions. These amounts at times may exceed federally insured limits. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts, or other hedging arrangements. MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data) NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

J. Property and equipment: Property and equipment are presented at cost less accumulated depreciation. Depreciation is calculated based on the straight-line method over the estimated useful lives of the assets, at the following annual rates: SCHEDULE OF ESTIMATED USEFUL LIVES OF PROPERTY AND EQUIPMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Research equipment and software</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ResearchEquipmentAndSoftwareMember__srt--RangeAxis__srt--MinimumMember_zV3w1m2o0IVg" title="Property, plant and equipment, useful life">25-<span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ResearchEquipmentAndSoftwareMember__srt--RangeAxis__srt--MaximumMember_zhLzV1nl6Jg3" title="Property, plant and equipment, useful life">33</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 76%; text-align: left">Furniture and office equipment</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 20%; text-align: right"><span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_z2eJkNsU2Lo3" title="Property, plant and equipment, useful life">7</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Leasehold improvements</td><td> </td> <td style="text-align: left"> </td><td style="text-align: center"><span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_iI_dxL_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zYMnYQnKRuBl" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2024%23UsefulLifeTermOfLeaseMember">Over the lease period</td><td style="text-align: left"> </td></tr> </table> The Company assesses property and equipment impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. If such circumstances are determined to exist, an estimate of undiscounted future cash flows produced by the property and equipment assets, or the appropriate grouping of assets, is compared to the carrying value to determine whether impairment exists. If an asset is determined to be impaired, the loss is measured based on the difference between the asset’s estimated fair value and its carrying value. For property and equipment assets, the estimate of fair value is typically based on a discounted cash flow model. As of December 31, 2024, and 2023, no impairment charge has been recorded.

Property and equipment are presented at cost less accumulated depreciation. Depreciation is calculated based on the straight-line method over the estimated useful lives of the assets, at the following annual rates: SCHEDULE OF ESTIMATED USEFUL LIVES OF PROPERTY AND EQUIPMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Research equipment and software</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ResearchEquipmentAndSoftwareMember__srt--RangeAxis__srt--MinimumMember_zV3w1m2o0IVg" title="Property, plant and equipment, useful life">25-<span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ResearchEquipmentAndSoftwareMember__srt--RangeAxis__srt--MaximumMember_zhLzV1nl6Jg3" title="Property, plant and equipment, useful life">33</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 76%; text-align: left">Furniture and office equipment</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 20%; text-align: right"><span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_z2eJkNsU2Lo3" title="Property, plant and equipment, useful life">7</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Leasehold improvements</td><td> </td> <td style="text-align: left"> </td><td style="text-align: center"><span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_iI_dxL_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zYMnYQnKRuBl" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2024%23UsefulLifeTermOfLeaseMember">Over the lease period</td><td style="text-align: left"> </td></tr> </table>

P25Y

P33Y

P7Y

K. Liabilities due to termination of employment agreements: Under Israeli employment laws, employees of Microbot Israel are included under Article 14 of the Severance Compensation Act, 1963 (“Article 14”). According to Article 14, these employees are entitled to monthly deposits made by Microbot Israel on their behalf with insurance companies. Payments in accordance with Article 14 release Microbot Israel from any future severance payments (under the Israeli Severance Compensation Act, 1963) with respect of those employees. The aforementioned deposits are not recorded as an asset in the Company’s balance sheets. As for the U.S. employees, the Company has certain defined contribution plans, including a 401(k)-retirement plan in the U.S., whereby contributions made by eligible employees are matched by the Company with certain limitations.

L. Common stock warrants: The Company accounts for warrants issued to investors as either equity-classified or liability-classified instruments, based on an assessment of the warrant’s specific terms and the applicable authoritative guidance in FASB ASC 480 and FASB ASC 815, “Derivatives and Hedging” (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, or meet all of the requirements for equity classification under FASB ASC 815, including whether the warrants are indexed to the Company’s own shares of common stock and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.

M. Basic and diluted net loss per share: Basic net loss per share is calculated by dividing net loss attributable to common stock shareholders by the weighted average number of shares of common stock outstanding during the year without consideration of potentially dilutive securities. For purposes of the diluted net loss per share attributable to common shareholders calculation, stock options and warrants are considered to be common stock equivalents. All common stock equivalents, as detailed in Notes 2P and 10F, have been excluded from the calculation of the diluted loss per share for the years ended December 31, 2024 and December 31, 2023, as their effect would be anti-dilutive. Therefore, basic and diluted net loss per share were the same for both years presented. In the calculation of the basic and diluted net loss, the Company included warrants that would be exercised for no or little consideration and are exercisable with no contingencies. N. Research and development expenses, net: Research and development expenses are charged to the statement of comprehensive loss as incurred. Grants for funding of approved research and development projects and others are recognized at the time the Company is entitled to such grants, on the basis of the costs incurred and applied as a deduction from the research and development expenses. See Note 2U below. Reimbursement of expenses for research and development projects is recognized as the costs are incurred and is netted against research and development expenses in the statement of comprehensive loss. Research and development reimbursements of $83, and $0 were offset against research and development costs in the years ended December 31, 2024 and 2023, respectively

O. General and administrative expenses, net: General and administrative expenses are charged to the statement of comprehensive loss as incurred. Insurance loss recoveries are recognized when the amount is determinable and approved by the insurance company and applied as a deduction from general and administrative expenses. General and administrative expenses, net, for the years ended December 31, 2024 and 2023, were offset by insurance loss recoveries in the amounts of approximately $0 and $281, respectively. MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data) NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

281000

P. Share-based compensation: The Company applies ASC 718-10, “Share-Based Payment” (“ASC 718-10”), which requires the measurement and recognition of compensation expenses for all share-based payment awards made to employees and directors including stock options under the Company’s stock plans based on estimated fair values. ASC 718-10 requires companies to estimate the fair value of stock options using an option-pricing model, which is recognized as an expense over the requisite service periods in the Company’s statement of comprehensive loss, based on a straight-line method. The Company recognizes compensation cost for an equity classified award with only service conditions that has a graded vesting schedule on a straight-line basis over the requisite service period for the entire award, provided that the cumulative amount of compensation cost recognized at any date at least equals the portion of the grant date fair value of such award that is vested at that date. The Company recognizes the expense for an equity classified awards subject to performance-based milestone vesting over the remaining service period when management determines that achievement of the milestone is probable. Management evaluates when the achievement of a performance-based milestone is probable based on the expected satisfaction of the performance conditions at each reporting date. If no explicit service period is determined, the Company estimates the implicit service period based on the timing the employee is expected to achieve the related performance condition. When no future services are required to be performed by the grantee in exchange for an award of equity instruments, and if such award does not contain a performance condition, the cost of the award is expensed on the grant date. The Company estimates the fair value of stock options granted as share-based payment awards using a Black-Scholes options pricing model. The option-pricing model requires a number of assumptions, of which the most significant are expected volatility and the expected option term (the time from the grant date until the options are exercised or expire). Expected volatility is estimated based on the standard deviation of the Company’s closing prices according to the expected life (SAB107) for each of the grants. The Company has historically not paid dividends and has no foreseeable plans to issue dividends. The risk-free interest rate is based on the yield from governmental zero-coupon bonds with an equivalent term. For stock options that qualify as “plain-vanilla,” the expected term is calculated using the simplified method. For stock options that do not qualify as “plain-vanilla”, the Company’s management estimated that the expected stock option term is the contractual term of the options. Changes in the determination of each of the inputs can affect the fair value of the stock options granted and the results of operations of the Company.

Q. Income taxes: The Company provides for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of December 31, 2024, and 2023, the Company had a full valuation allowance against deferred tax assets. MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data) NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

R. Marketable securities: The Company invests in various debt securities and an equity security. Debt securities consist of U.S. treasury securities. Equity security consist of a mutual fund. The Company records these investments in the consolidated balance sheet at fair value. For all of the Company’s debt securities, the Company elected the fair value option and thus all unrealized gains or losses for these securities are reflected in the statements of comprehensive loss as financial income or expenses, as appropriate. Unrealized gains or losses for the equity security are reflected in the statements of comprehensive loss as financial income or expenses, as appropriate. The Company classifies its investments as current based on the nature of the investments and their availability for use in current operations.

S. Leases: The Company determines if an arrangement is a lease at inception. Operating lease assets are presented as operating lease long-term right-of-use assets (“ROU”), and corresponding as lease liabilities (current portion), and as operating long-term lease liabilities, on the Company’s consolidated balance sheets. Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the remaining lease payments over the lease term at commencement date. The Company’s leases do not provide an implicit interest rate. The Company calculates the incremental borrowing rate to reflect the interest rate that it would have to pay to borrow on a collateralized basis an amount equal to the lease payments in a similar economic environment over a similar term and considers the Company’s historical borrowing activities and market data in this determination. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that it will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. The Company has lease agreements with lease and non-lease components, which it accounts for as a single lease component. The Company has elected not to recognize ROU assets and lease liabilities for short-term leases that have a term of 12 months or less. The Company’s lease agreements do not contain any material residual value guarantees or material restrictive covenants. In addition, the Company does not have any related party leases. MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data) NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

T. Contingencies: Management records and discloses legal contingencies in accordance with ASC Topic 450 Contingencies. A provision is recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. The Company monitors the stage of progress of its litigation matters to determine if any adjustments are required. Refer to Note 9G below. The Company carries liability insurance to mitigate its exposure to losses, including litigation losses. The Company records the estimated amount of expected insurance proceeds for litigation losses incurred as an asset (typically a receivable from the insurer) and offset to losses up to the amount of the losses incurred when the amount is determinable and approved by the insurance company. Refer to Note 2O above and Note 9G below.

U. Government grants: Government grants which are received from the Israeli Ministry of Economy and Israel Innovation Authority (“IIA”) by way of participation in research and development that is conducted by Microbot Israel, are received in installments as the program progresses based on qualified research spending. Grants received are recognized when the grant becomes receivable, provided there was reasonable assurance that Microbot Israel will comply with the conditions attached to the grant and there was reasonable assurance the grant will be received. The grants are deducted from the research and development expenses as the applicable costs are incurred. Research and development expenses, net, for the years ended December 31, 2024 and 2023, include participation in research and development expenses in the amount of approximately $149 and $279, respectively.

149000 279000

V. Segment Reporting The Company has a single operating and reportable segment, which is the development of robotic devices for endoluminal surgery. See Note 1A for further details. The Company’s chief operating decision maker (the “CODM”), the Chief Executive Officer (“CEO”), reviews financial information presented on a consolidated basis for purposes of making operating decisions, assessing performance, and allocating resources. For further details, refer to Note 14.

W. Recently Adopted accounting pronouncements: In November 2023, the FASB issued ASU 2023-07, “Segment Reporting (Topic 280), Improvements to Reportable Segment Disclosures” (“ASU 2023-07”) to improve reportable segment disclosure requirements through enhanced disclosures about significant segment expenses on an interim and annual basis. All disclosure requirements of ASU 2023-07 are required also for entities with a single reportable segment. ASU 2023-07 is effective starting January 1, 2024 and should be applied on a retrospective basis to all periods presented. The adoption of this ASU did not have a material impact on the Company’s financial statements.

X. Accounting pronouncements not yet effective: In November 2024, the FASB issued ASU 2024-03, “Income Statement–Reporting Comprehensive Income–Expense Disaggregation Disclosures (Subtopic 220- 40): Disaggregation of Income Statement Expenses” (“ASU 2024-03”), which requires the disaggregation of certain expenses in the financial statements notes, to provide enhanced transparency into the expense captions presented on the face of the consolidated statement of operations. ASU 2024-03 is effective for annual reporting periods beginning January 1, 2027 and interim periods beginning January 1, 2028 and may be applied either prospectively or retrospectively. The Company is currently evaluating the impact that ASU 2024-03 will have on its related disclosures.

NOTE 3 – CASH AND CASH EQUIVALENTS AND MARKETABLE SECURITIES The following table sets forth our cash, cash equivalents and marketable securities as of December 31, 2024 and 2023: SCHEDULE OF CASH AND CASH EQUIVALENTS AND MARKETABLE SECURITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20241231_zdhRCqKDYCl2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20231231_zwkoq9qvyu2f" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Cash and cash equivalents:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn3n3_hus-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_zBqkkQOSLvvh" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; width: 60%">Cash</td><td style="padding-bottom: 1pt; width: 2%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">3,114</td><td style="padding-bottom: 1pt; width: 1%; text-align: left"> </td><td style="padding-bottom: 1pt; width: 2%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">2,468</td><td style="padding-bottom: 1pt; width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn3n3_zNu8kuTPSsC7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total cash and cash equivalents</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,114</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,468</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Marketable securities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_hus-gaap--InvestmentTypeAxis__us-gaap--MoneyMarketFundsMember_zQBC936FTEq4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Money market mutual funds</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2,356</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,420</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_hus-gaap--InvestmentTypeAxis__us-gaap--USTreasurySecuritiesMember_z4KEt4JhAxzd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">U.S. treasury securities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,497</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_zVVVxxHpiH25" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total marketable securities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,356</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,917</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--CashCashEquivalentsAndShortTermInvestments_iI_zb4dhCW8sExj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total cash, cash equivalents and marketable securities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,470</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,385</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The unrealized gains on our marketable securities were $0 and $59 for the years ended December 31, 2024 and 2023, respectively. Treasuries have contractual maturities of less than 12 months. MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data)

The following table sets forth our cash, cash equivalents and marketable securities as of December 31, 2024 and 2023: SCHEDULE OF CASH AND CASH EQUIVALENTS AND MARKETABLE SECURITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20241231_zdhRCqKDYCl2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20231231_zwkoq9qvyu2f" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Cash and cash equivalents:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn3n3_hus-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_zBqkkQOSLvvh" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; width: 60%">Cash</td><td style="padding-bottom: 1pt; width: 2%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">3,114</td><td style="padding-bottom: 1pt; width: 1%; text-align: left"> </td><td style="padding-bottom: 1pt; width: 2%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">2,468</td><td style="padding-bottom: 1pt; width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn3n3_zNu8kuTPSsC7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total cash and cash equivalents</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,114</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,468</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Marketable securities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_hus-gaap--InvestmentTypeAxis__us-gaap--MoneyMarketFundsMember_zQBC936FTEq4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Money market mutual funds</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2,356</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,420</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_hus-gaap--InvestmentTypeAxis__us-gaap--USTreasurySecuritiesMember_z4KEt4JhAxzd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">U.S. treasury securities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,497</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_zVVVxxHpiH25" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total marketable securities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,356</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,917</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--CashCashEquivalentsAndShortTermInvestments_iI_zb4dhCW8sExj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total cash, cash equivalents and marketable securities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,470</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,385</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

3114000

2468000

3114000

2468000

2356000

1420000

2497000

2356000

3917000

5470000

6385000

59000

NOTE 4 - FAIR VALUE MEASUREMENTS <p id="xdx_891_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zQmdjnskwP1c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The following table summarizes the Company’s financial assets subject to fair value measurement and the level of inputs used in such measurements as of December 31, 2024 and 2023: SCHEDULE OF FAIR VALUE MEASUREMENT INPUTS AND VALUATION TECHNIQUES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left">Marketable securities:</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Money market mutual funds</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FinancialInstrumentAxis__custom--MarketableSecuritiesMember_zOMDsu5KYDtb" style="border-bottom: Black 1pt solid; text-align: right" title="Assets, fair value">2,356</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98E_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FinancialInstrumentAxis__custom--MarketableSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zgpafQlu1OZg" style="border-bottom: Black 1pt solid; text-align: right" title="Assets, fair value">2,356</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FinancialInstrumentAxis__custom--MarketableSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zTxypKsRSB54" style="border-bottom: Black 1pt solid; text-align: right" title="Assets, fair value">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98A_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FinancialInstrumentAxis__custom--MarketableSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zBIMWauWR2Uf" style="border-bottom: Black 1pt solid; text-align: right" title="Assets, fair value">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FinancialInstrumentAxis__custom--MarketableSecuritiesMember_zZS600JxeB6a" style="border-bottom: Black 2.5pt double; text-align: right" title="Assets, fair value">2,356</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FinancialInstrumentAxis__custom--MarketableSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zjRSrL4vfYF2" style="border-bottom: Black 2.5pt double; text-align: right" title="Assets, fair value">2,356</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FinancialInstrumentAxis__custom--MarketableSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zNKdPCRotz2j" style="border-bottom: Black 2.5pt double; text-align: right" title="Assets, fair value">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FinancialInstrumentAxis__custom--MarketableSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z3iLkr4PNmK" style="border-bottom: Black 2.5pt double; text-align: right" title="Assets, fair value">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Marketable securities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 36%; text-align: left">U.S. treasury securities</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FinancialInstrumentAxis__custom--MarketableSecuritiesMember_z2FddyHL7yYj" style="width: 12%; text-align: right" title="Assets, fair value">2,497</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FinancialInstrumentAxis__custom--MarketableSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zYpAbx4sCsL4" style="width: 12%; text-align: right" title="Assets, fair value">2,497</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FinancialInstrumentAxis__custom--MarketableSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zb5HSKQBdRp4" style="width: 12%; text-align: right" title="Assets, fair value">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FinancialInstrumentAxis__custom--MarketableSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z7mhiN3DOvKd" style="width: 12%; text-align: right" title="Assets, fair value">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Money market mutual funds</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FinancialInstrumentAxis__custom--MarketableSecuritiesMember_zCb8efPrv0Hd" style="border-bottom: Black 1pt solid; text-align: right" title="Assets, fair value">1,420</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FinancialInstrumentAxis__custom--MarketableSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zEaSRb0WAqbg" style="border-bottom: Black 1pt solid; text-align: right" title="Assets, fair value">1,420</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FinancialInstrumentAxis__custom--MarketableSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zwtbdZREJKq4" style="border-bottom: Black 1pt solid; text-align: right" title="Assets, fair value">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FinancialInstrumentAxis__custom--MarketableSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zJGQCvTTJ6e6" style="border-bottom: Black 1pt solid; text-align: right" title="Assets, fair value">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FinancialInstrumentAxis__custom--MarketableSecuritiesMember_zxCMAhJ1AVHk" style="border-bottom: Black 2.5pt double; text-align: right" title="Assets, fair value">3,917</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FinancialInstrumentAxis__custom--MarketableSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zNSRTGXnmYSl" style="border-bottom: Black 2.5pt double; text-align: right" title="Assets, fair value">3,917</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FinancialInstrumentAxis__custom--MarketableSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zjTxjJw8QR2j" style="border-bottom: Black 2.5pt double; text-align: right" title="Assets, fair value">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FinancialInstrumentAxis__custom--MarketableSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zWDmM284c1W8" style="border-bottom: Black 2.5pt double; text-align: right" title="Assets, fair value">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The Company’s financial assets are measured at fair value on a recurring basis by level within the fair value hierarchy. The Company’s securities and money market funds are classified as Level 1. Other than that, the Company doesn’t have any other financial assets or financial liabilities marked to market at fair value as of December 31, 2024 and 2023.

<p id="xdx_891_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zQmdjnskwP1c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The following table summarizes the Company’s financial assets subject to fair value measurement and the level of inputs used in such measurements as of December 31, 2024 and 2023: SCHEDULE OF FAIR VALUE MEASUREMENT INPUTS AND VALUATION TECHNIQUES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left">Marketable securities:</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Money market mutual funds</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FinancialInstrumentAxis__custom--MarketableSecuritiesMember_zOMDsu5KYDtb" style="border-bottom: Black 1pt solid; text-align: right" title="Assets, fair value">2,356</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98E_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FinancialInstrumentAxis__custom--MarketableSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zgpafQlu1OZg" style="border-bottom: Black 1pt solid; text-align: right" title="Assets, fair value">2,356</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FinancialInstrumentAxis__custom--MarketableSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zTxypKsRSB54" style="border-bottom: Black 1pt solid; text-align: right" title="Assets, fair value">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98A_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FinancialInstrumentAxis__custom--MarketableSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zBIMWauWR2Uf" style="border-bottom: Black 1pt solid; text-align: right" title="Assets, fair value">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FinancialInstrumentAxis__custom--MarketableSecuritiesMember_zZS600JxeB6a" style="border-bottom: Black 2.5pt double; text-align: right" title="Assets, fair value">2,356</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FinancialInstrumentAxis__custom--MarketableSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zjRSrL4vfYF2" style="border-bottom: Black 2.5pt double; text-align: right" title="Assets, fair value">2,356</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FinancialInstrumentAxis__custom--MarketableSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zNKdPCRotz2j" style="border-bottom: Black 2.5pt double; text-align: right" title="Assets, fair value">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FinancialInstrumentAxis__custom--MarketableSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z3iLkr4PNmK" style="border-bottom: Black 2.5pt double; text-align: right" title="Assets, fair value">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Marketable securities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 36%; text-align: left">U.S. treasury securities</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FinancialInstrumentAxis__custom--MarketableSecuritiesMember_z2FddyHL7yYj" style="width: 12%; text-align: right" title="Assets, fair value">2,497</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FinancialInstrumentAxis__custom--MarketableSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zYpAbx4sCsL4" style="width: 12%; text-align: right" title="Assets, fair value">2,497</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FinancialInstrumentAxis__custom--MarketableSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zb5HSKQBdRp4" style="width: 12%; text-align: right" title="Assets, fair value">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FinancialInstrumentAxis__custom--MarketableSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z7mhiN3DOvKd" style="width: 12%; text-align: right" title="Assets, fair value">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Money market mutual funds</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FinancialInstrumentAxis__custom--MarketableSecuritiesMember_zCb8efPrv0Hd" style="border-bottom: Black 1pt solid; text-align: right" title="Assets, fair value">1,420</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FinancialInstrumentAxis__custom--MarketableSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zEaSRb0WAqbg" style="border-bottom: Black 1pt solid; text-align: right" title="Assets, fair value">1,420</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FinancialInstrumentAxis__custom--MarketableSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zwtbdZREJKq4" style="border-bottom: Black 1pt solid; text-align: right" title="Assets, fair value">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FinancialInstrumentAxis__custom--MarketableSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zJGQCvTTJ6e6" style="border-bottom: Black 1pt solid; text-align: right" title="Assets, fair value">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FinancialInstrumentAxis__custom--MarketableSecuritiesMember_zxCMAhJ1AVHk" style="border-bottom: Black 2.5pt double; text-align: right" title="Assets, fair value">3,917</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FinancialInstrumentAxis__custom--MarketableSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zNSRTGXnmYSl" style="border-bottom: Black 2.5pt double; text-align: right" title="Assets, fair value">3,917</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FinancialInstrumentAxis__custom--MarketableSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zjTxjJw8QR2j" style="border-bottom: Black 2.5pt double; text-align: right" title="Assets, fair value">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FinancialInstrumentAxis__custom--MarketableSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zWDmM284c1W8" style="border-bottom: Black 2.5pt double; text-align: right" title="Assets, fair value">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

2356000

2497000

1420000

3917000

NOTE 5 – PREPAID EXPENSES AND OTHER CURRENT ASSETS SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20241231_zSzvJLwiFuTg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20231231_zzrXBVKIPuyi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_400_eus-gaap--GovernmentContractReceivable_iI_pn3n3_maOACzRgI_zf7IYD5HcjL2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Amounts due from government institutions</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">89</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">61</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--PrepaidExpenseCurrent_iI_pn3n3_maOACzRgI_zbpM7hbReWCf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Prepaid expenses and other receivables</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">211</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">91</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pn3n3_mtOACzRgI_zBs2nrXpHklf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total prepaid expenses and other current assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">300</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">152</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data)

SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20241231_zSzvJLwiFuTg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20231231_zzrXBVKIPuyi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_400_eus-gaap--GovernmentContractReceivable_iI_pn3n3_maOACzRgI_zf7IYD5HcjL2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Amounts due from government institutions</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">89</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">61</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--PrepaidExpenseCurrent_iI_pn3n3_maOACzRgI_zbpM7hbReWCf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Prepaid expenses and other receivables</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">211</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">91</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pn3n3_mtOACzRgI_zBs2nrXpHklf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total prepaid expenses and other current assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">300</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">152</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

89000

61000

211000

91000

300000

152000

NOTE 6 - LEASES In November 2019, the Company signed an office space lease agreement for the period from November 2019 until October 2024. The monthly lease payments are approximately $16. To secure the lease payments the Company had issued a bank guarantee of $49 in favor of the facility’s lessor. In November 2024, the Company extended the lease for one year until October 2025. Additionally, the Company entered into agreements for car leases. The following table presents the components of the Company’s lease cost and the classification of such costs in the Company’s consolidated statements of comprehensive loss for the years ended December 31, 2024 and 2023: SCHEDULE OF STATEMENTS OF COMPREHENSIVE LOSS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"> <tr style="display: none; vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20240101__20241231_zaW1AOOGCuD7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20230101__20231231_zl0I5dAJTde" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">Component of Lease Cost</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Statements of Comprehensive Loss Line Item</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_405_eus-gaap--OperatingLeaseCost_pn3n3_hus-gaap--OtherComprehensiveIncomeLocationAxis__custom--ResearchAndDevelopmentNetMember_zWtISrfmJMrj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 32%; text-align: left; padding-bottom: 2.5pt">Operating lease cost</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="width: 30%; text-align: left; padding-bottom: 2.5pt">Research and development, net</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right">215</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right">279</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Supplemental cash flow information related to operating leases was as follows: SCHEDULE OF SUPPLEMENTAL CASH FLOW INFORMATION RELATED TO OPERATING LEASES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20240101__20241231_zsULS3MhP7e6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20230101__20231231_zYVEjoQSDBtl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_403_eus-gaap--OperatingLeasePayments_pn3n3_z2sc43v5Z4hc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left; padding-bottom: 2.5pt">Cash paid under operating lease agreements</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">219</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">283</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Undiscounted maturities of future operating lease payments as of December 31, 2024 are summarized as follows: SCHEDULE OF MATURITIES OF LEASE LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49E_20241231_zmgjM9mTbeKe" style="font-weight: bold; text-align: center">As of December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPzDag_zczlGEtwrDb6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">75</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPzDag_zfNNSnk2dLt9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">2026</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">42</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPzDag_zXXDDBi5q7Ng" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total future lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">117</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_zz7rVdg7zGO5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less imputed interest</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(6</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_zYweDK43eZWg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total lease liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">111</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The following table includes the weighted-average lease terms and discount rates for operating leases as of December 31, 2024 and 2023: SCHEDULE OF SUPPLEMENTAL INFORMATION RELATED TO LEASES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Operating leases weighted average remaining lease term (in years)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">1.58</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">0.8</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Operating leases weighted average discount rate</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20241231_zuwrLN1hiaD8" style="text-align: right" title="Operating leases weighted average discount rate">6.71</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20231231_zLwZHueRHPtf" style="text-align: right" title="Operating leases weighted average discount rate">7</td><td style="text-align: left">%</td></tr> </table> MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data)

16000

49000

The following table presents the components of the Company’s lease cost and the classification of such costs in the Company’s consolidated statements of comprehensive loss for the years ended December 31, 2024 and 2023: SCHEDULE OF STATEMENTS OF COMPREHENSIVE LOSS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"> <tr style="display: none; vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20240101__20241231_zaW1AOOGCuD7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20230101__20231231_zl0I5dAJTde" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">Component of Lease Cost</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Statements of Comprehensive Loss Line Item</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_405_eus-gaap--OperatingLeaseCost_pn3n3_hus-gaap--OtherComprehensiveIncomeLocationAxis__custom--ResearchAndDevelopmentNetMember_zWtISrfmJMrj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 32%; text-align: left; padding-bottom: 2.5pt">Operating lease cost</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="width: 30%; text-align: left; padding-bottom: 2.5pt">Research and development, net</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right">215</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right">279</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

215000

279000

Supplemental cash flow information related to operating leases was as follows: SCHEDULE OF SUPPLEMENTAL CASH FLOW INFORMATION RELATED TO OPERATING LEASES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20240101__20241231_zsULS3MhP7e6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20230101__20231231_zYVEjoQSDBtl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_403_eus-gaap--OperatingLeasePayments_pn3n3_z2sc43v5Z4hc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left; padding-bottom: 2.5pt">Cash paid under operating lease agreements</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">219</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">283</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

219000

283000

Undiscounted maturities of future operating lease payments as of December 31, 2024 are summarized as follows: SCHEDULE OF MATURITIES OF LEASE LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49E_20241231_zmgjM9mTbeKe" style="font-weight: bold; text-align: center">As of December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPzDag_zczlGEtwrDb6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">75</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPzDag_zfNNSnk2dLt9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">2026</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">42</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPzDag_zXXDDBi5q7Ng" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total future lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">117</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_zz7rVdg7zGO5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less imputed interest</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(6</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_zYweDK43eZWg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total lease liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">111</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

75000

42000

117000

6000

111000

The following table includes the weighted-average lease terms and discount rates for operating leases as of December 31, 2024 and 2023: SCHEDULE OF SUPPLEMENTAL INFORMATION RELATED TO LEASES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Operating leases weighted average remaining lease term (in years)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">1.58</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">0.8</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Operating leases weighted average discount rate</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20241231_zuwrLN1hiaD8" style="text-align: right" title="Operating leases weighted average discount rate">6.71</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20231231_zLwZHueRHPtf" style="text-align: right" title="Operating leases weighted average discount rate">7</td><td style="text-align: left">%</td></tr> </table>

P1Y6M29D

P0Y9M18D

0.0671

0.07

NOTE 7 - PROPERTY AND EQUIPMENT, NET SCHEDULE OF PROPERTY AND EQUIPMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20241231_zzw0aoOSkKNf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20231231_zJGlIN6V2oJ8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify">Historical Cost:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ResearchEquipmentAndSoftwareMember_zN79MHS9AL4f" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 60%; text-align: left">Research equipment and software</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">193</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">177</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zgRKwKIR4Bml" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Leasehold improvement</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">229</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">229</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_z0tiAdVS98d6" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Furniture and office equipment</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">242</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">233</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_z4a6BfcI88mh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Cost</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">664</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">639</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: justify">Accumulated Depreciation:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ResearchEquipmentAndSoftwareMember_zuXoRYWfGsRk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Research equipment and software</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">138</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">109</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zpCib1vlsfOb" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Leasehold improvement</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">210</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">181</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_z5CrDERwrtxa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Furniture and office equipment</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">236</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">203</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iI_pn3n3_zmIiw0iLWwRa" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Accumulated Depreciation</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">584</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">493</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_zwByyDP4R9xd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Net book value</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">80</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">146</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

SCHEDULE OF PROPERTY AND EQUIPMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20241231_zzw0aoOSkKNf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20231231_zJGlIN6V2oJ8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify">Historical Cost:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ResearchEquipmentAndSoftwareMember_zN79MHS9AL4f" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 60%; text-align: left">Research equipment and software</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">193</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">177</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zgRKwKIR4Bml" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Leasehold improvement</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">229</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">229</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_z0tiAdVS98d6" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Furniture and office equipment</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">242</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">233</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_z4a6BfcI88mh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Cost</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">664</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">639</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: justify">Accumulated Depreciation:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ResearchEquipmentAndSoftwareMember_zuXoRYWfGsRk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Research equipment and software</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">138</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">109</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zpCib1vlsfOb" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Leasehold improvement</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">210</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">181</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_z5CrDERwrtxa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Furniture and office equipment</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">236</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">203</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iI_pn3n3_zmIiw0iLWwRa" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Accumulated Depreciation</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">584</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">493</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_zwByyDP4R9xd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Net book value</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">80</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">146</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

193000

177000

229000

242000

233000

664000

639000

138000

109000

210000

181000

236000

203000

584000

493000

80000

146000

NOTE 8 - ACCRUED LIABILITIES SCHEDULE OF ACCRUED LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20241231_z3voPkvKbnni" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20231231_zlPiSJ7Q9xR9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_400_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pn3n3_maALCzrnP_zDePfb1ahEmi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Employee-related liabilities</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,409</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">725</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_maALCzrnP_zEbr8fVtO7Ma" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">811</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">223</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--OtherLiabilitiesCurrent_iI_pn3n3_maALCzrnP_z3ZRNm2AXvGc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Other current liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">5</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">79</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AccruedLiabilitiesCurrent_iTI_pn3n3_mtALCzrnP_zIj7wMiR27g9" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total Accrued Liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,225</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,027</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data)

SCHEDULE OF ACCRUED LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20241231_z3voPkvKbnni" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20231231_zlPiSJ7Q9xR9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_400_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pn3n3_maALCzrnP_zDePfb1ahEmi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Employee-related liabilities</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,409</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">725</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_maALCzrnP_zEbr8fVtO7Ma" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">811</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">223</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--OtherLiabilitiesCurrent_iI_pn3n3_maALCzrnP_z3ZRNm2AXvGc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Other current liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">5</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">79</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AccruedLiabilitiesCurrent_iTI_pn3n3_mtALCzrnP_zIj7wMiR27g9" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total Accrued Liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,225</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,027</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

1409000

725000

811000

223000

5000

79000

2225000

1027000

<p id="xdx_804_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zZGqMzYyoY72" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify; text-indent: -49.65pt">NOTE 9 - COMMITMENTS AND CONTINGENCIES A. Government grants: Microbot Israel has received grants from the IIA for participation in research and development since 2013 through December 31, 2024 totaling approximately $<span id="xdx_909_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pn3n3_c20240101__20241231__us-gaap--AwardDateAxis__custom--TwoThousandThirteenToJuneThirtyTwoThousandTwentyTwoMember__dei--LegalEntityAxis__custom--IsraeliInnovationAuthorityMember_zgqVVSlF3jv1" title="Revenues">1,878. This includes amounts received of approximately $378, in 2023 and 2024 which is a portion of an additional grant from the IIA in the amount of approximately NIS 1,620,000 (approximately $447) approved by the IIA on June 1, 2023, to further finance the development of the manufacturing process of the LIBERTY® Endovascular Robotic Surgical System. In addition, as a result of the agreement with Nitiloop, on October 6, 2022, Microbot Israel took over the liability to repay Nitiloop’s IIA grants in the aggregate amount of approximately $<span id="xdx_901_ecustom--RepaymentOfGovernmentGrants_pn3n3_c20221006__20221006__dei--LegalEntityAxis__custom--IsraeliInnovationAuthorityMember__us-gaap--BusinessAcquisitionAxis__custom--CardioSertLtdMember_zyx9QIl1PcFe" title="Repayment of government grants">925. In relation to the IIA grants described above, the Company is obligated to pay royalties amounting to <span id="xdx_904_ecustom--NetSalesRoyaltyPercentage_pid_dp_uPure_c20240101__20241231__dei--LegalEntityAxis__custom--IsraeliInnovationAuthorityMember__srt--RangeAxis__srt--MinimumMember_zjYrqxZIgU87" title="Net sales royalty percenatge">3.0%-<span id="xdx_904_ecustom--NetSalesRoyaltyPercentage_pid_dp_uPure_c20240101__20241231__dei--LegalEntityAxis__custom--IsraeliInnovationAuthorityMember__srt--RangeAxis__srt--MaximumMember_zuhOG0qxt0w4" title="Net sales royalty percenatge">5% of its future sales of the products relating to such grants. The grants are linked to the exchange rate of the dollar to the New Israeli Shekel and bears interest of SOFR per year (SOFR is a benchmark interest rate which replaced LIBOR). The repayment of the grants is contingent upon the successful completion of the Company’s research and development programs and generating sales. The Company has no obligation to repay these grants, if the project fails, is unsuccessful or aborted or if no sales are generated. The financial risk is assumed completely by the Government of Israel. The grants are received from the Government on a project-by-project basis. On December 11, 2022, the Company received approval for a grant from the Ministry of Economy, in the amount of NIS 300,000 (approximately $83), for participation in expenses related to the LIBERTY® Endovascular Robotic Surgical System in the U.S. market. As of December 31, 2024, the Company received approximately $50 of such grant. In relation with the Ministry of Economy grant, the Company is obligated to pay royalties amounting to 3% of future sales of the LIBERTY® Endovascular Robotic Surgical System up to the grant amount plus interest. B. TRDF agreement: Microbot Israel signed an agreement with the Technion Research and Development Foundation (“TRDF”) in June 2012 by which TRDF transferred to Microbot Israel a global, exclusive, royalty-bearing license (as amended, the “License Agreement”) with respect to the Company’s Self-Cleaning Shunt (SCS) project and its TipCat assets in addition to certain technology relating to the Company’s LIBERTY® Endovascular Robotic Surgical System. As partial consideration for the license, Microbot Israel shall pay TRDF royalties on net sales (between <span id="xdx_906_ecustom--NetSalesRoyaltyPercentage_pid_dp_uPure_c20120601__20120630__dei--LegalEntityAxis__custom--TechnionResearchAndDevelopmentFoundationLimitedMember__srt--RangeAxis__srt--MinimumMember_z30uFm4eGO03" title="Net sales">1.5%-<span id="xdx_908_ecustom--NetSalesRoyaltyPercentage_pid_dp_uPure_c20120601__20120630__dei--LegalEntityAxis__custom--TechnionResearchAndDevelopmentFoundationLimitedMember__srt--RangeAxis__srt--MaximumMember_zkRbBhjoDuV3" title="Net sales royalty percenatge">3.0%) and on sublicense income as detailed in the License Agreement. In October 2022 the Company suspended the SCS project and as a result of the Company’s May 2023 implementation of its core-business focus program and cost reduction plan, the Company returned the licensed intellectual property for the TipCat back to TRDF in June 2023 and returned the licensed intellectual property for the SCS (ViRob) back to TRDF in July 2023. As a result, as of the date of these financial statements, the License Agreement is limited to the certain technology relating to the Company’s LIBERTY® Endovascular Robotic Surgical System. MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data) NOTE 9 - COMMITMENTS AND CONTINGENCIES C. Agreement with CardioSert Ltd.: On January 4, 2018, Microbot Israel entered into an agreement with CardioSert (the “CardioSert Agreement”) to acquire certain of its patent-protected technology (the “Technology”). Pursuant to the CardioSert Agreement, Microbot Israel made aggregate payments of $<span id="xdx_902_eus-gaap--PaymentsToAcquireIntangibleAssets_pn3n3_c20180104__20180104__dei--LegalEntityAxis__custom--CardioSertLtdMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TechnologyMember_zOt4PVDnJK6e" title="Payment to acquire intangible assets">300 in cash and <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_pid_c20180104__20180104__dei--LegalEntityAxis__custom--CardioSertLtdMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TechnologyMember_z6WB4J5VVKwd" title="Number of common shares issued for acquisition">6,738 shares of common stock estimated at $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_pn3n3_c20180104__20180104__dei--LegalEntityAxis__custom--CardioSertLtdMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TechnologyMember_zx1YRtKq8S67" title="Number of common shares issued for acquisition, value">74 to complete the acquisition. As a result of its core-business focus program and its cost reduction plan enacted in May 2023, the Company terminated the CardioSert Agreement effective as of August 17, 2023 in accordance with its terms and ceased its research and development and commercialization efforts for, and maintaining, the Technology, which resulted in CardioSert triggering on March 3, 2024 its right to reacquire the Technology for nominal consideration. In July 2024, Microbot Israel transferred the Technology back to CardioSert, for nominal consideration, pursuant to the terms of the CardioSert Agreement. As a result, Microbot Israel’s liability to repay CardioSert’s IIA grants in the aggregate amount of approximately $530 was also transferred back to CardioSert. D. ATM agreement: On June 10, 2021, the Company entered into an At-the-Market Offering Agreement (the “ATM Agreement”) with H.C. Wainwright & Co. LLC (“Wainwright”), as sales agent, in connection with an “at the market offering” under which the Company may offer and sell, from time to time in its sole discretion, shares of its common stock having an aggregate offering price of up to $<span id="xdx_90E_ecustom--OfferingCosts_iI_pn3n3_c20210610__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketOfferingAgreementMember__dei--LegalEntityAxis__custom--HCWainwrightAndCoLLCMember_zyNqYyD6tTNh" title="Offering costs">10,000 at market prices or as otherwise agreed with Wainwright. The Company entered into an amendment, dated July 1, 2024, to the ATM Agreement with Wainwright dated June 10, 2021, relating to the offer and sale of shares of the Company’s common stock having an aggregate offering price of up to approximately $<span id="xdx_907_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn3n3_c20240701__20240701__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketOfferingAgreementMember_zuTnvKSVLXr7" title="Aggregate offering">4,820 from time to time through Wainwright, acting as sales agent. The compensation to Wainwright for sales of the shares is a placement fee of <span id="xdx_902_ecustom--PlacementFeePercent_pid_dp_c20240701__20240701__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketOfferingAgreementMember_zMLGwBPFMWg4" title="Percentage of placement fee">3.0% of the gross sales price of the shares of common stock sold pursuant to this ATM Agreement. See also Notes 10D and 17A below. MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data) NOTE 9 - COMMITMENTS AND CONTINGENCIES E. Engagement letters with H.C. Wainwright: In connection with registered direct and private placement offerings, the Company entered into engagement letters (the “Engagement Letters”) with Wainwright on October 3, 2022, on May 16, 2023, on October 24, 2023 and on May 29, 2024, pursuant to which Wainwright agreed to serve as the exclusive placement agent for the issuance and sale of securities of the Company. As compensation for such placement agent services, the Company has agreed to pay Wainwright an aggregate cash fee equal to 7.0% of the gross proceeds received by the Company from offerings contemplated by the Engagement Letters, plus a management fee equal to 1.0% of the gross proceeds received by the Company from such offerings, as well as other reimbursable expenses. <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20221003__20221003__dei--LegalEntityAxis__custom--HCWainwrightAndCoLLCMember_z0myy0RB7EXa" title="Warrant issued, descriptions">The Company has also agreed to issue to Wainwright or its designees preferred investment options upon the closing of such offerings, equal to five (5.0%) percent of the aggregate number of such shares of common stock in such offerings, including upon exercise for cash of any warrants issued to investors in such offering. F. Acquisition of Nitiloop’s assets: On October 6, 2022, Microbot Israel purchased substantially all of the assets, including intellectual property, devices, components and product related materials (the “Assets”), of Nitiloop Ltd., an Israeli limited liability company (“Nitiloop”). The Assets include intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter (the “Technology”) and the products or potential products incorporating the Technology owned by Nitiloop and designated by Nitiloop as “NovaCross”, “NovaCross Xtreme” and “NovaCross BTK” and any enhancements, modifications and improvements thereof (“Devices”). Microbot Israel did not assume any material liabilities of Nitiloop other than obligations Nitiloop has to the IIA and relating to certain renewal/maintenance fees for a European patent application. In consideration for the acquisition of the Assets, Microbot Israel shall pay royalties to Nitiloop, which shall not, in the aggregate, exceed $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20221006__20221006__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketOfferingAgreementMember__dei--LegalEntityAxis__custom--HCWainwrightAndCoLLCMember_zVnqESoSO0W4" title="Stock issued during period, value, new issues">8,000, as follows: Royalties at a rate of 3% of net revenue generated as a result of sales, license or other exploitation of the Devices; and Royalties at a rate of 1.5% of net revenue generated from the sale, license or other exploitation of commercialization of the technology as part of an integrated product. Based on the Company’s analysis, the Company concluded that the acquisition of the assets does not meet the definition of a business for the purpose of applying SEC Rules (S-X Rules of 3-05, 8-04 and 11-01). MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data) NOTE 9 - COMMITMENTS AND CONTINGENCIES G. Litigation resulting from the 2017 financing: The Company was named as the defendant in a lawsuit captioned Empery Asset Master Ltd., Empery Tax Efficient, LP, Empery Tax Efficient II, LP, Hudson Bay Master Fund Ltd., (the “Plaintiffs”), against Microbot Medical Inc., Defendant, in the Supreme Court of the State of New York, County of New York (Index No. 651182/2020) (the “Lawsuit”). The complaint alleged, among other things, that the Company breached multiple representations and warranties contained in the Securities Purchase Agreement (the “SPA”) related to the Company’s June 8, 2017 equity financing (the “2017 Financing”), of which the Plaintiffs participated, and fraudulently induced Plaintiffs into signing the SPA. The complaint sought rescission of the SPA and return of the Plaintiffs’ $<span id="xdx_907_eus-gaap--LossContingencyDamagesSoughtValue_pn3n3_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zavHBQ1eUnq4" title="Purchase price of plaintiffs">6,750 purchase price with respect to the 2017 Financing. On January 26, 2024 (the “Effective Date”), the Company entered into a settlement agreement and release with the Plaintiffs (the “Settlement Agreement”), effectively resolving the Lawsuit. Pursuant to the Settlement Agreement, the Company paid $2,154 consisting of a cash payment of $1,100, covered by the Company’s insurance company, and <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20240126__20240126__us-gaap--TypeOfArrangementAxis__custom--LitigationSettlementMember_zUXMo0ORpxh8" title="Restricted common shares issued for legal settlement">1,005,965 shares of restricted common stock which were subsequently registered for resale. Furthermore, the Company’s insurance company is responsible for covering legal expenses incurred by the Company in relation to the legal proceedings of the Lawsuit. In February 2024, the Plaintiffs filed a stipulation discontinuing the Lawsuit with prejudice. The Company concluded the Settlement Agreement gave rise to loss contingencies in the scope of ASC Subtopic 450-20, Contingencies – Loss Contingencies, and as of December 31, 2023, the Company recorded a contingent liability, as the Company deemed it both probable and reasonably estimable. The Company determined that the loss contingency should be recognized as non-operating losses, offset by loss recoveries received from the Company’s insurance company. As a result of the Settlement Agreement and the insurance recovery received from the insurance company, as of December 31, 2023, the Company recorded a current liability and a current asset on its consolidated balance sheet totaling $2,211 and $1,335, respectively. Within this asset, $1,100 represents the recovery of the cash payment of the settlement amount, and $235 represents recovery of legal expenses. A net non-operating loss of $1,111 from legal settlement was reflected in the Company’s consolidated statement of comprehensive loss for the year ended December 31, 2023. In the first quarter of 2024, the Company received $1,335 from the insurance company. Additionally, during the first quarter of 2024, the Company paid the settlement amount by transferring $1,100 in cash to the Plaintiffs and issuing <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20240331__us-gaap--TypeOfArrangementAxis__custom--LitigationSettlementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zYgof8TELPF5" title="Number of share issued">1,005,965 shares of the Company’s common stock, thereby settling the liability recorded as of December 31, 2023. H. Mona litigation: On April 28, 2019, the Company brought an action against Alliance Investment Management, Ltd. (“Alliance”), later amended to add Joseph Mona (“Mona”) as a defendant, in the Southern District of New York under Section 16(b) of the Securities Exchange Act of 1934 (the “Exchange Act”), to compel Alliance and/or Mona to disgorge short swing profits realized from purchases and sales of the Company’s securities within a period of less than six months. The amount of profits was estimated in the complaint to be approximately $<span id="xdx_901_eus-gaap--LitigationSettlementAmountAwardedFromOtherParty_pn3n3_c20190428__20190428__dei--LegalEntityAxis__custom--AllianceInvestmentManagementLtdMember_zpJhyOSGSXke" title="Litigation settlement">468. On March 31, 2021, the Court entered a judgment against Mona and in favor of the Company in the amount of approximately $485. Collection of the judgment was deferred pending resolution of Mona’s counterclaim. On August 22, 2023, the District Court dismissed the Section 10(b) counterclaim in its entirety. After the Company initiated efforts to execute on the $485 judgment against Mona (the “Judgment”), Mona urged the Court to decide the motion to vacate the 16(b) Judgment on the grounds that the Company purportedly lacks Constitutional standing to bring this case, which he originally filed prior to the final dismissal of his 10(b) counterclaim. On January 30, 2024, a Report & Recommendation was issued that the motion be denied, which the Court adopted in the entirety in an Order on March 5, 2024. Mona subsequently filed an appellate brief seeking to overturn the lower court and the Company filed opposition papers. The Judgment was released to the Company in March 2025. Refer to Note 17D below. I. Contingent bonus commitments based on capital raising: In February 2024, the Compensation Committee of the Board of Directors of the Company approved certain bonuses for the 2023 fiscal year contingent on capital raising efforts. These bonuses are detailed as follows: <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="width: 1in"> </td> <td style="text-align: justify; width: 0.25in">○</td> <td style="text-align: justify">The Company’s CEO was granted a contingent cash bonus of up to approximately $<span id="xdx_90D_eus-gaap--DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount_iI_pn3n3_c20240229__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__srt--RangeAxis__srt--MaximumMember_zudhWtTWFbM9">298, which is divided into two contingent portions. The first 50% of the CEO’s contingent bonus ($149) is payable upon the Company raising at least $3,000 in new funds by June 30, 2024. As of June 30, 2024, the Company did not raise $3,000 in new funds. However, on July 17, 2024, the Compensation Committee of the Board of Directors of the Company nevertheless approved the payment of the first 50% of the contingent bonus to the Company’s CEO in the amount of approximately $149.</td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="width: 1in"> </td> <td style="text-align: justify; width: 0.25in">○</td> <td style="text-align: justify">The remaining 50% ($149), payable upon the Company raising at least $6,000 in new funds by September 30, 2024 (cumulative, so if $3,000 is not raised by June 30, 2024 but the full $6,000 is raised by September 30, 2024, or if $10,000 is raised by December 31, 2024, the full amount is payable). The Company was unable to raise the additional capital. Therefore, as of December 31, 2024, the Company has not recorded a liability for any contingent bonus.</td></tr> </table> Other executives are entitled to an aggregate contingent total bonus of NIS 230,736 (approximately $61), which is payable upon the Company raising at least $3,000 in new funds by September 30, 2024. During the third quarter of 2024, the Company achieved a cumulative capital raise of $3,000. Therefore, on July 17, 2024, the Compensation Committee of the Board of Directors of the Company approved the payment of such bonuses to the Company’s CFO and CTO in the aggregate amount of approximately $<span id="xdx_908_eus-gaap--DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount_iI_pn3n3_c20240717__srt--TitleOfIndividualAxis__custom--ChiefFinancialOfficerAndChiefTechnologyOfficerMember_zZ9Te8oHrsp9" title="Contingent cash bonus">61. J. Accrued bonuses As of December 31, 2024, the Company recorded accrued bonuses to the CEO, executives and certain employees in the amount of $398 and $294, respectively, related to fiscal year 2024 (refer also to Note 17C). MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data)

1878000

378000

1620000 1620000 447000 447000 925000 0.030 0.05

300000

83000

50000

0.03 0.015 0.030

300000

6738

74000

530000

10000000

4820000

0.030 0.070 0.010

The Company has also agreed to issue to Wainwright or its designees preferred investment options upon the closing of such offerings, equal to five (5.0%) percent of the aggregate number of such shares of common stock in such offerings, including upon exercise for cash of any warrants issued to investors in such offering.

8000000

0.03 0.015

6750000

2154000

1100000

1005965

2211000

1335000

1100000

235000

-1111000

1335000

1100000

1005965

468000

485000

298000

0.50

149000

3000000

0.50

149000

0.50

149000

6000000

3000000

6000000

10000000

230736

61000

3000000

61000

398000

294000

NOTE 10 - SHARE CAPITAL A. Preferred investment options inducement On December 29, 2023, the Company entered into a preferred investment option exercise inducement offer letter with certain holders of existing (i) Series A preferred investment options to purchase <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20221025__20221025__us-gaap--SubsidiarySaleOfStockAxis__custom--SeriesAPreferredInvestmentOptionsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQKEPVc75sl9">1,022,495 shares of the Company’s common stock at an exercise price of $<span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20221025__us-gaap--SubsidiarySaleOfStockAxis__custom--SeriesAPreferredInvestmentOptionsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zbCuhL4YkK58">2.20 per share, issued on October 25, 2022, as amended on May 24, 2023, (ii) Series C preferred investment options to purchase <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230606__20230606__us-gaap--SubsidiarySaleOfStockAxis__custom--SeriesCPreferredInvestmentOptionsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zpGr4n3CtWc">350,878 shares of the Company’s common stock at an exercise price of $<span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230606__us-gaap--SubsidiarySaleOfStockAxis__custom--SeriesCPreferredInvestmentOptionsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zc3jz3W2jEa7">2.075 per share, issued on June 6, 2023, and (iii) Series D preferred investment options to purchase <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230626__20230626__us-gaap--SubsidiarySaleOfStockAxis__custom--SeriesDPreferredInvestmentOptionsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zKzRVuO2Ctje">312,309 shares of the Company’s common stock at an exercise price of $<span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230626__us-gaap--SubsidiarySaleOfStockAxis__custom--SeriesDPreferredInvestmentOptionsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z90LJnp5yAGg">3.19 per share issued on June 26, 2023 (clauses (i) through (iii) collectively, the “Existing Preferred Investment Options”), pursuant to which the holders agreed to exercise for cash their Existing Preferred Investment Options to purchase an aggregate of <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20231229__20231229__us-gaap--SubsidiarySaleOfStockAxis__custom--ExistingPreferredInvestmentOptionsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zeVawJPPymM">1,685,682 shares of the Company’s common stock, at a reduced exercised price of $<span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20231229__us-gaap--SubsidiarySaleOfStockAxis__custom--ExistingPreferredInvestmentOptionsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zYcC4aldgTK">1.62 per share, in consideration for the Company’s agreement to issue new series E preferred investment options having terms to purchase up to <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20231229__20231229__us-gaap--SubsidiarySaleOfStockAxis__custom--InducementInvestmentOptionsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2VGSxPXurk3">1,685,682 shares of the Company’s common stock (the “Inducement Investment Options”). Each Inducement Investment Option will have an exercise price equal to $<span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20231229__us-gaap--SubsidiarySaleOfStockAxis__custom--InducementInvestmentOptionsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z4gdOFgcfZXc">1.50 per share, and will be exercisable from the date of the issuance until five and one-half (5.5) years following the date of the issuance. The Company estimated the fair value of the Inducement Investment Options using a Black-Scholes options pricing model and concluded it is approximately $<span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pn3n3_c20231229__20231229__us-gaap--SubsidiarySaleOfStockAxis__custom--InducementInvestmentOptionsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z1ZSd9JalSxb">1,853. At the closing on January 3, 2024, the Company received aggregate gross proceeds of approximately $2,730 from the exercise of the Existing Preferred Investment Options by the Holders and the sale of the Inducement Investment Options, before deducting placement agent fees and other offering expenses of approximately $333. The Company also issued to Wainwright or its designees preferred investment options to purchase up to <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20231229__20231229__us-gaap--SubsidiarySaleOfStockAxis__custom--PreferredInvestmentOptionExerciseInducementOffersLetterMember__dei--LegalEntityAxis__custom--HCWainwrightAndCoLLCMember_z6ZLr9VeLV51">84,284 shares of common stock which have the same terms as the Inducement Investment Options except for an exercise price equal to $<span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20231229__us-gaap--SubsidiarySaleOfStockAxis__custom--PreferredInvestmentOptionExerciseInducementOffersLetterMember__dei--LegalEntityAxis__custom--HCWainwrightAndCoLLCMember_zRG8bPSevSW1">2.025 per share. The Company estimated the fair value of the preferred investment options using a Black-Scholes options pricing model and concluded it is approximately $<span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pn3n3_c20231229__20231229__us-gaap--SubsidiarySaleOfStockAxis__custom--PreferredInvestmentOptionExerciseInducementOffersLetterMember__dei--LegalEntityAxis__custom--HCWainwrightAndCoLLCMember_zFWmdq1kYZo">89. B. Registered direct and private placement offerings: On May 22, 2023, the Company entered into a securities purchase agreement with an institutional investor, pursuant to which it agreed to issue and sell in a registered direct offering an aggregate of <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230522__20230522__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_ziGtwTSVFNi6" title="Aggregate shares of common stock">655,569 shares of common stock, at an offering price of $<span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_c20230522__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zluQnkS73l5k" title="Issued, price per share">2.20 per share, for aggregate gross proceeds of $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn3n3_c20230522__20230522__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zeN9lr90mjH6" title="Gross proceeds">1,442 before deducting the placement agent fee and related offering expenses of approximately $<span id="xdx_901_eus-gaap--DeferredOfferingCosts_iI_pn3n3_c20230522__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zTRvnmW0lrw" title="Offering expenses">222 (the “First May Offering”). The Company also issued to Wainwright or its designees preferred investment options to purchase <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230522__20230522__us-gaap--SubsidiarySaleOfStockAxis__custom--SeriesDPreferredInvestmentOptionsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ziydW6LmBrEi" title="Aggregate shares of common stock">32,778 shares of common stock, which have a term of three and one-half years from the commencement of sales in the First May Offering, and have an exercise price of $<span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_c20230522__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zS6mkBUremY6" title="Issued, price per share">2.75 per share. The First May Offering was consummated on May 23, 2023. The Company estimated the fair value of the warrants using a Black-Scholes options pricing model and concluded it is approximately $46. On May 23, 2023, the Company entered into a securities purchase agreement with an institutional investor, pursuant to which it agreed to issue and sell in a registered direct offering (i) an aggregate of <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230523__20230523__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zIrLYJCw2dM3" title="Aggregate shares of common stock">975,000 shares of common stock, at an offering price of $<span id="xdx_903_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230523__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwf4HuUB58j1" title="Issued, price per share">2.20 per share and (ii) pre-funded warrants exercisable for up to <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230523__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zyPJjvLuCLJ6" title="Prefunded warrants exercisable">234,500 shares of the Company’s common stock, at an offering price of $<span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230523__us-gaap--SubsidiarySaleOfStockAxis__custom--SeriesDPreferredInvestmentOptionsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zeuNyIm7ZQh3" title="Issued, price per share">2.1999 per pre-funded warrant, for aggregate gross proceeds of $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn3n3_c20230523__20230523__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxsIlaW6sj6j" title="Gross proceeds">2,661 before deducting the placement agent fee and related offering expenses of approximately $<span id="xdx_905_eus-gaap--DeferredOfferingCosts_iI_pn3n3_c20230523__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zbo6wiBraIs1" title="Offering expenses">345 (the “Second May Offering”). The pre-funded warrants are exercisable immediately and may be exercised at any time until the pre-funded warrants are exercised in full. The Second May Offering was consummated on May 24, 2023. All of such pre-funded warrants were subsequently immediately exercised in accordance with their terms at an exercise price per share of $<span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20241231__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z1pvZlteQcBe" title="Exercise price per share">0.0001 into an equivalent number of shares of common stock. The Company also issued to Wainwright or its designees preferred investment options to purchase <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230523__20230523__us-gaap--SubsidiarySaleOfStockAxis__custom--SeriesDPreferredInvestmentOptionsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z81pUvMG5Ujl" title="Aggregate shares of common stock">60,476 shares of common stock, which have a term of three and one-half years from the closing of the Second May Offering, and have an exercise price of $<span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230523__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--WainwrightMember_z3SWoVfD5uD" title="Issued, price per share">2.75 per share. The Company estimated the fair value of the warrants using a Black-Scholes options pricing model and concluded it is approximately $72. MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data) NOTE 10 - SHARE CAPITAL Registered direct and private placement offerings: On June 2, 2023, the Company entered into a securities purchase agreement with institutional investors, pursuant to which it agreed to issue and sell in a registered direct offering an aggregate of <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230602__20230602__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z46n8ZuE57wl" title="Shares issued">701,756 shares of common stock, at an offering price of $<span id="xdx_907_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230602__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zUyPt5C1G3Sa">2.1375 per share, for aggregate gross proceeds, with the concurrent private placement described below, of $<span id="xdx_909_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn3n3_c20230602__20230602__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHTv0ZyGdD49">1,500 before deducting the placement agent fee and related offering expenses of approximately $<span id="xdx_90B_eus-gaap--DeferredOfferingCosts_iI_pn3n3_c20230602__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zbfsDaOFo5qe">227 (the “First June Offering”). The Company also issued to Wainwright or its designees preferred investment options to purchase <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230602__20230602__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zsNZx4QqHhB7" title="Shares">35,088 shares of its common stock, which have a term of five years from the commencement of sales in the First June Offering, and have an exercise price of $<span id="xdx_903_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230602__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxXbIHFphmgg" title="Share price">2.6719 per share. The Company estimated the fair value of the warrants using a Black-Scholes options pricing model and concluded it is approximately $58. The registered direct offering was consummated on June 6, 2023. In a concurrent private placement, the Company also issued to the purchasers of shares of common stock in the First June Offering, series C preferred investment options to purchase up to <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230602__20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--SeriesCPreferredInvestmentOptionsMember_zv2L5ezyL6jd" title="Shares issued">350,878 shares of common stock. Each series C preferred investment option is exercisable for one share of common stock at an exercise price of $<span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230602__us-gaap--SubsidiarySaleOfStockAxis__custom--SeriesCPreferredInvestmentOptionsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwkKoYEri4ei" title="Exercise price">2.075 commencing on the date of issuance and expiring five and one-half years from the issuance date. On June 26, 2023, the Company entered into a securities purchase agreement with institutional investors, pursuant to which it agreed to issue and sell in a registered direct offering an aggregate of <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230626__20230626__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zMzRmr8QDWMa" title="Shares issued">624,618 shares of its common stock, at an offering price of $<span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230626__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zlYf9ui7oUc1" title="Offering price">3.25 per share, for aggregate gross proceeds, with the concurrent private placement described below, of $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn3n3_c20230626__20230626__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zIJxTB27PBX1" title="Issuance of private placements">2,030 before deducting the placement agent fee and related offering expenses of approximately $<span id="xdx_903_eus-gaap--DeferredOfferingCosts_iI_pn3n3_c20230626__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ztENFzHGw61d" title="Offering expenses">281 (the “Second June Offering”). The Company also issued to Wainwright or its designees preferred investment options to purchase <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230626__20230626__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--HCWainwrightAndCoLLCMember_zIdjFk9sUTz7" title="Issuance">31,231 shares of its common stock, which have a term of five years from the commencement of sales in the Second June Offering, and have an exercise price of $<span id="xdx_905_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230626__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--HCWainwrightAndCoLLCMember_zqQqJee6u9mj" title="Exercise price">4.0625 per share. The Company estimated the fair value of the warrants using a Black-Scholes options pricing model and concluded it is approximately $68. The registered direct offering was consummated on June 28, 2023. In a concurrent private placement, the Company also issued to the purchasers of shares of common stock in the Second June Offering, series D preferred investment options to purchase up to <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230628__20230628__us-gaap--SubsidiarySaleOfStockAxis__custom--SeriesDPreferredInvestmentOptionsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zpuo8VUK7JYg" title="Issuance of shares">312,309 shares of the Company’s common stock. Each series D preferred investment option is exercisable for one share of common stock at an exercise price of $<span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230628__us-gaap--SubsidiarySaleOfStockAxis__custom--SeriesDPreferredInvestmentOptionsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zsnDkCeSLxq3" title="Exercise price">3.19 commencing on the date of issuance and expiring five and one-half years from the issuance date. On June 3, 2024, the Company entered into Securities Purchase Agreements with institutional investors, pursuant to which the Company agreed to issue and sell, in a registered direct offering priced at-the-market under the rules of The Nasdaq Stock Market, an aggregate of <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240603__20240603__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zyTcpp32Lms1" title="Issuance of common stock upon exercise of warrants, shares">1,566,669 shares of the Company’s common stock, par value $<span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20240603__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zXwImAewyE3" title="Common stock, par value">0.01 per share, at an offering price of $<span id="xdx_903_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20240603__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zsLHqvEHjCq" title="Share price per share">1.50 per share, for aggregate gross proceeds from the Offerings of approximately $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn3n3_c20240603__20240603__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zvMZnKwvNd89" title="Gross proceeds">2,350 before deducting the placement agent fee and related offering expenses of approximately $<span id="xdx_90B_eus-gaap--DeferredOfferingCosts_iI_pn3n3_c20240603__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zSVIoVvYhw0g" title="Offering expenses">328. In a concurrent private placement, the Company agreed to issue to the investors series F preferred investment options to purchase up to <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240603__20240603__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--SeriesFPreferredInvestmentOptionsMember_zni4cNr0gYeg" title="Issuance of common stock upon exercise of warrants, shares">3,133,338 shares of common stock at an exercise price of $<span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20240603__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--SeriesFPreferredInvestmentOptionsMember_zSq7osR3gqh2" title="Share price per share">1.50 per share. Each Series F preferred investment option is exercisable immediately and will expire two years from the initial exercise date. The Company estimated the fair value of the preferred investment options using a Black-Scholes options pricing model and concluded it is approximately $<span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pn3n3_c20240603__20240603__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--SeriesFPreferredInvestmentOptionsMember_z7nYWZooSYWb" title="Fair value of stock options">1,893. The Company also issued to Wainwright or its designees preferred investment options to purchase up to <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240603__20240603__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--HCWainwrightAndCoLLCMember_zfyse9bKBU98">78,333 shares of common stock which have the same terms as investors’ preferred investment options except for an exercise price equal to $<span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20240603__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--HCWainwrightAndCoLLCMember_zt1BojFWLY39">1.875 per share. The Company estimated the fair value of the preferred investment options using a Black-Scholes options pricing model and concluded it is approximately $<span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pn3n3_c20240603__20240603__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--HCWainwrightAndCoLLCMember_zdHaACPe8b14" title="Fair value of stock options">43. C. Equity Classification: The common stock of the Company are recognized as equity under the requirements of ASC Topic 505 Equity. The Company analyzed the accounting treatment for the series A, C, D, E and F preferred investment option, and all of the pre-funded warrants issued to investors. Based on the Company’s analysis all such warrants were classified as equity. The Company analyzed the accounting treatment for all of the preferred investment options issued to Wainwright in the aforementioned offerings. Since the Company did not identify any features causing liability classification according to ASC 718, it concluded that all such preferred investment options are equity-classified awards. D. At-the-market offerings: On July 1, 2024, the Company filed with the SEC a prospectus supplement relating to the offer, issuance and sale of up to $<span id="xdx_90B_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn3n3_c20240701__20240701__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketOfferingAgreementMember_zLVpsz9BnvHl">4,820 of the Company’s shares of common stock pursuant to the ATM Agreement. During the year 2024, the Company issued <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketOfferingAgreementMember_z2r3QMciJgf2">3,433,880 shares of the Company’s common stock pursuant to the ATM Agreement, for total gross proceeds of approximately $<span id="xdx_909_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn3n3_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketOfferingAgreementMember_ztjHQ7y7K2D">3,756 before deducting sales agent commissions and other offering expenses of $239. E. Preferred investment options amendment: In the Second May Offering, the Company amended the terms of (i) the Series A preferred investment options to purchase <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240101__20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--SeriesAPreferredInvestmentOptionsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8QjgvblBaZ2" title="Aggregate shares of common stock">1,022,495 shares of its common stock for an exercise price of $<span id="xdx_90A_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--SeriesAPreferredInvestmentOptionsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjrKleeG2ze1" title="Share price per share">4.64 per share which are scheduled to expire on <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_c20240101__20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--SeriesAPreferredInvestmentOptionsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zR7RFwQFvOBc" title="Expiry date">October 25, 2027 and (ii) the Series B preferred investment options to purchase <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240101__20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--SeriesBPreferredInvestmentOptionsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z4yz9jDvcPU5" title="Aggregate shares of common stock">1,022,495 shares of its common stock for an exercise price of $<span id="xdx_907_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--SeriesBPreferredInvestmentOptionsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zoHORetahyOd" title="Share price per share">4.64 per share which were initially scheduled to expire on <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_c20240101__20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--SeriesBPreferredInvestmentOptionsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z9TGYT2Cry2c" title="Expiry date">October 25, 2024 (the “Series B Preferred Investment Options”), in each case previously issued to the investor in October 2022 under the securities purchase agreement dated October 21, 2022 (collectively, the “Existing Preferred Investment Options”), which investor also participated in the Second May Offering, such that effective upon the closing of the Second May Offering, the Existing Preferred Investment Options have a reduced exercise price of $<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20231025__us-gaap--SubsidiarySaleOfStockAxis__custom--SeriesBPreferredInvestmentOptionsMember_zOKPH2wu1g9g" title="Options exercise price per share">2.20 per share and the Series B Preferred Investment Options expire on <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_c20231025__20231025__us-gaap--SubsidiarySaleOfStockAxis__custom--SeriesBPreferredInvestmentOptionsMember_zOEEP7iWdNdk" title="Expiry date">October 25, 2027. These modifications to the Existing Preferred Investment Options represent issuance costs associated with the Second May Offering. The Company estimated the amount of the effect of the modifications using a Black-Scholes option pricing model and concluded that is approximately $1,230. On June 16, 2023, the holder of the Series B Preferred Investment Options exercised all of such Series B Preferred Investment Options pursuant to its cashless exercise provision into <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20230616__20230616__us-gaap--StatementClassOfStockAxis__custom--SeriesBPreferredInvestmentOptionsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zkpBpvzEqAf8" title="Cashless exercise of shares">385,246 shares of common stock. <p id="xdx_89E_ecustom--ScheduleOfGrantDateFairValueOfPreferredInvestmentOptionsIssuedToInvestorsTableTextBlock_z97Nm0CHQyob" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The grant date fair values of preferred investment options issued to Wainwright and preferred investment options issued to investors including those that were modified in the years ended December 31, 2024 and 2023 were estimated using the Black-Scholes valuation model with the following: SCHEDULE OF GRANT DATE FAIR VALUE OF PREFERRED INVESTMENT OPTIONS ISSUED TO INVESTORS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td colspan="5" style="border-bottom: Black 1pt solid; text-align: center">For the Years Ended December 31, </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Expected volatility</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zvmD6MhqoOH1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">103.6%-<span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zjBd6orwp04a">111.4</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zxIUU5GgHGR7" title="Warrants measurement input">101.3%-<span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_z2WeSBocuyL7" title="Warrants measurement input">122.4</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk-free interest</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zqCFf8l5Yde9" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.9%- <span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zXi9YHR2C2h2">4.8</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zy6jffSNzoGb">3.9%- <span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zS7rBXErNgDf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zLltFZ8A8w3h" title="Warrants measurement input">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zFAx8eznQ114" title="Warrants measurement input">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected terms (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_z3QtG5mihyyd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.0-<span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_z5tY2qQgEwMf">5.5</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_zRtMTZauAKoa" title="Expected terms (years)">1.4-<span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_zVhAVsGmhYU3" title="Expected terms (years)">5.0</td><td style="text-align: left"> </td></tr> </table> MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data) NOTE 10 - SHARE CAPITAL F. Employee stock option grants: During the year ended December 31, 2023, the Company granted to the CEO, options to purchase an aggregate of <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_z2hzQ3zd1fp6" title="Number of stock options granted">80,000 shares of the Company’s common stock, at an exercise price per share of $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20230101__20231231__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zopNYkHVmht4" title="Weighted-average exercise price per share, granted">2.43. The stock options vest over a period of <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zczkXUBNXXjj" title="Stock option vested term">three years as outlined in the option agreements evidencing such grants. During the year ended December 31, 2023, the Company granted stock option awards to certain officers, directors and employees to purchase an aggregate of <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--EmployeesConsultantsAndDirectorsMember_zAE6KSUXSQu" title="Number of stock options granted">631,308 shares of the Company’s common stock, at an exercise price per share ranging from $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--EmployeesConsultantsAndDirectorsMember__srt--RangeAxis__srt--MinimumMember_zPF6qpoY5u9f" title="Weighted-average exercise price per share, granted">1.16-$<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--EmployeesConsultantsAndDirectorsMember__srt--RangeAxis__srt--MaximumMember_zyEkrvmRsu75" title="Weighted-average exercise price per share, granted">3.48 with a vesting period of <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--EmployeesConsultantsAndDirectorsMember_zdCsHTEMJ213" title="Stock option vested term">three years. During the year ended December 31, 2024: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.75in"> </td> <td style="width: 0.25in; text-align: justify">○</td><td style="text-align: justify">The Company granted the CEO, its executives and management, fully vested options to purchase an aggregate of <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_z3XWgbZ6Rov7" title="Agggregate number of options granted">80,000 and <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--ManagementMember_zivj0ane4Bc7" title="Agggregate number of options granted">50,000 shares of the Company’s common stock, respectively, at an exercise price per share of $<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--ManagementMember_zpe5cr55SE78" title="Weighted-average exercise price per share, granted">1.2684.</td> </tr> <tr style="vertical-align: top; text-align: justify"> <td> </td> <td style="text-align: justify"> </td><td style="text-align: justify"> </td></tr> <tr style="vertical-align: top; text-align: justify"> <td> </td> <td style="text-align: justify">○</td><td style="text-align: justify">The Company granted the CEO and certain executives, options to purchase an aggregate of <span id="xdx_90D_ecustom--AdditionalShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zhu4mBlEmW8k" title="Additional number of stock options granted">80,000 and <span id="xdx_902_ecustom--AdditionalShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--ManagementMember_zGDugup2jXwc" title="Additional number of stock options granted">52,500 shares of the Company’s common stock, respectively, at an exercise price per share of $1.25. The vesting of these options is subject to the achievement of specified performance conditions. For the year ended December 31, 2024, the Company recorded an expense of $<span id="xdx_908_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20240201__20240229__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficerAndOtherExecutivesMember_z8DPxpX2N3t1" title="Compensation expenses">38, reflecting management’s assessment that the specified performance milestones for 35,625 of the <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240201__20240229__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficerAndOtherExecutivesMember_zDRxBmguxa9f" title="Agggregate number of options granted">132,500 options were achieved by their due date. Refer to Note 17C.</td> </tr> <tr style="vertical-align: top; text-align: justify"> <td> </td> <td style="text-align: justify"> </td><td style="text-align: justify"> </td></tr> <tr style="vertical-align: top; text-align: justify"> <td> </td> <td style="text-align: justify">○</td><td style="text-align: justify">The Company granted the CEO, its executives, and certain employees, options to purchase an aggregate of <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficerAndExecutivesMember_zLTOHVAlBTkk" title="Agggregate number of options granted">80,000 and <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zRNyIB6CL591" title="Agggregate number of options granted">115,000 shares of the Company’s common stock, respectively, at an exercise price per share of $1.2684, with a vesting period of three years.</td> </tr> <tr style="vertical-align: top; text-align: justify"> <td> </td> <td style="text-align: justify"> </td><td style="text-align: justify"> </td></tr> <tr style="vertical-align: top; text-align: justify"> <td> </td> <td style="text-align: justify">○</td><td style="text-align: justify">The Company granted an advisor options to purchase an aggregate of <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--AdvisorsMember_zNjF044N6B14" title="Agggregate number of options granted">25,000 shares of the Company’s common stock, at an exercise price per share of $0.881, with a vesting period of three years.</td> </tr></table> With respect to the CEO’s 2023 annual bonus, during February 2024, the Company paid <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_dp_c20240201__20240229__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zwyLUUX2ClC8" title="Compensation percentage">25% of the CEO’s total 2023 bonus – amounting to approximately $99, through the grant of fully vested options to purchase an aggregate of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240201__20240229__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_z3sjeieWn786" title="Agggregate number of options granted">79,567 shares of the Company’s common stock with an exercise price per share of $1.25. A summary of the Company’s option activity related to options to employees and directors, and related information is as follows: MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data) NOTE 10 - SHARE CAPITAL Employee stock option grants: SUMMARY OF STOCK OPTION ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the Year Ended December 31, 2024</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of stock options</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted average exercise price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Outstanding as of December 31, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zk004bCApdNg" style="width: 16%; text-align: right" title="Number of stock options outstanding, Outstanding at beginning of period">2,095,362</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zpXuCYVsYfjf" style="width: 16%; text-align: right" title="Weighted average exercise price, Outstanding at beginning of period">5.51</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zqrdTiSFXFKi" style="text-align: right" title="Number of stock options outstanding, Granted">562,067</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zm8idAxNTLVb" style="text-align: right" title="Weighted average exercise price, Granted">1.24</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Forfeitures</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zykg7DeRAeL4" style="border-bottom: Black 1pt solid; text-align: right" title="Number of stock options outstanding, forfeitures">(160,063</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zk3eZiUty6w1" style="padding-bottom: 1pt; text-align: right" title="Weighted average exercise price, forfeitures">3.23</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Outstanding as of December 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zQINqXw31Oq4" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of stock options outstanding, Outstanding at end of period">2,497,366</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zYZuQCmpykD" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price, Outstanding at end of period">4.70</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Vested as of December 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zB1v8yS3JMm1" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of stock options outstanding, Vested at end of period">1,866,523</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zSbMIFgv1bcb" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price, Vested at end of period">5.63</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the Year Ended December 31, 2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of stock options</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted average exercise price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Outstanding as of December 31, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zoIA448yN7Uc" style="width: 16%; text-align: right" title="Number of stock options outstanding, Outstanding at beginning of period">1,507,137</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zRFYHVOTmOi5" style="width: 16%; text-align: right" title="Weighted average exercise price, Outstanding at beginning of period">7.31</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_z7eq8gNSPoF" style="text-align: right" title="Number of stock options outstanding, Granted">711,308</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_z8jF6pQgWYJf" style="text-align: right" title="Weighted average exercise price, Granted">1.75</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Forfeitures</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zFyWRvGqogHk" style="border-bottom: Black 1pt solid; text-align: right" title="Number of stock options outstanding, forfeitures">(123,083</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zTk3vK7MQHj3" style="padding-bottom: 1pt; text-align: right" title="Weighted average exercise price, forfeitures">5.78</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Outstanding as of December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zZu0sOZqkMV1" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of stock options outstanding, Outstanding at end of period">2,095,362</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_z44SQFvYJywe" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price, Outstanding at end of period">5.51</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Vested as of December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zEC46zLaV7Kh" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of stock options outstanding, Vested at end of period">1,176,118</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zzAzbA66lqgc" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price, Vested at end of period">7.74</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The Company recognizes forfeitures of outstanding options as they occur. The intrinsic value is calculated as the difference between the fair market value of the common stock and the exercise price, multiplied by the number of in-the-money stock options on those dates that would have been received by the stock option holders had all stock option holders exercised their stock options on those dates as of December 31, 2024 and 2023, respectively. As of December 31, 2024, and 2023, the aggregate intrinsic value of the outstanding options is $<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231_zJD8M6lsl1W9" title="Aggregate intrinsic value of outstanding options">75 and $<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20231231_z6B8y3bHCvYe" title="Aggregate intrinsic value of outstanding options">277, respectively, and the aggregate intrinsic value of the exercisable options is $<span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231_zcj40yp5IFSl" title="Aggregate intrinsic value of exercisable options">69 and $<span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20231231_zyEnWKLerU7h" title="Aggregate intrinsic value of exercisable options">102, respectively. The weighted average grant date fair value of options granted during the years ended December 31, 2024 and 2023 was $<span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iI_pid_c20241231_zDnGziif2Jqc" title="Weighted average grant date fair value of options granted">0.99 and $<span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iI_pid_c20231231_zKB6WyyNCHl3" title="Weighted average grant date fair value of options granted">1.40, respectively. MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data) NOTE 10 - SHARE CAPITAL Employee stock option grants: As of December 31, 2024, there were approximately $<span id="xdx_90E_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn3n3_c20241231_zFPemBN2KRth" title="Unrecognized compensation costs, net of expected forfeitures">921 of total unrecognized compensation costs related to unvested share-based compensation awards granted under the Share Incentive Plan. The costs are expected to be recognized over a weighted average period of <span id="xdx_907_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20241231_zPbg4ouQjpTj" title="Unrecognized compensation weighted average period">1.48 years. <p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_z6jBZ95snH31" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The stock options outstanding as of December 31, 2024 and 2023, summarized by exercise prices, are as follows: SCHEDULE OF STOCK OPTIONS OUTSTANDING <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise price $</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Stock options outstanding as of December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Stock options outstanding as of December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted average remaining contractual life – years as of December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted average remaining contractual life – years as of December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Stock options exercisable as of December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Stock options exercisable as of December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 16%; text-align: center"><span id="xdx_90F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember__srt--RangeAxis__srt--MinimumMember_zJbT0W25WPq3" title="Exercise price"><span id="xdx_902_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember__srt--RangeAxis__srt--MinimumMember_zNpWBstaK7K1" title="Exercise price">0.00-<span id="xdx_900_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember__srt--RangeAxis__srt--MaximumMember_zN2HkDktBW79" title="Exercise price"><span id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember__srt--RangeAxis__srt--MaximumMember_z6u07AQdMck5" title="Exercise price">0.99</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z9mRTIgk5sgd" style="width: 10%; text-align: right" title="Stock options outstanding">86,577</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zaedXjnreCua" style="width: 10%; text-align: right" title="Stock options outstanding">61,577</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zFyKvyIbXfml" title="Weighted average remaining contractual life">3.8</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zXMSJLbfdZri" title="Weighted average remaining contractual life">2.3</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zymreWPrHngb" style="width: 10%; text-align: right" title="Stock options exercisable">61,577</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zOautB6JYVv8" style="width: 10%; text-align: right" title="Stock options exercisable">61,577</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"><span id="xdx_904_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember__srt--RangeAxis__srt--MinimumMember_zLhfMWyKFud8" title="Exercise price"><span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember__srt--RangeAxis__srt--MinimumMember_zv90h2XZJEG7" title="Exercise price">1.00-<span id="xdx_908_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember__srt--RangeAxis__srt--MaximumMember_znLHGr6IPaAc" title="Exercise price"><span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember__srt--RangeAxis__srt--MaximumMember_zYVMLeNJM0Z" title="Exercise price">3.73</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zbiVAjOAvm21" style="text-align: right" title="Stock options outstanding">1,299,562</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z94fNuKttDpf" style="text-align: right" title="Stock options outstanding">860,808</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zKO1P965kAg6" title="Weighted average remaining contractual life">8.7</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_ztsNJ3B6Gpad" title="Weighted average remaining contractual life">9.6</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_ztQnC6DVpqT6" style="text-align: right" title="Stock options exercisable">731,559</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_za9Bu4xWt4xg" style="text-align: right" title="Stock options exercisable">95,925</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center"><span id="xdx_900_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember__srt--RangeAxis__srt--MinimumMember_zGEkp6IS4d87" title="Exercise price"><span id="xdx_902_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember__srt--RangeAxis__srt--MinimumMember_zLooIktEZWO3" title="Exercise price">4.2-<span id="xdx_902_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember__srt--RangeAxis__srt--MaximumMember_zjmw1wX6Ukia" title="Exercise price"><span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember__srt--RangeAxis__srt--MaximumMember_zIub21jfjUg6" title="Exercise price">7.26</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zNQR6ws7D92j" style="text-align: right" title="Stock options outstanding">577,482</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zuSDlaEv7CHh" style="text-align: right" title="Stock options outstanding">639,232</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zLQCAixvmqd2" title="Weighted average remaining contractual life">5.9</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_z47dA671UPR8">6.3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zikiDEVdgdOa" style="text-align: right" title="Stock options exercisable">539,642</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zHUOHPDGz37i" style="text-align: right" title="Stock options exercisable">484,871</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"><span id="xdx_900_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember__srt--RangeAxis__srt--MinimumMember_zjbW2jpCY39g" title="Exercise price"><span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember__srt--RangeAxis__srt--MinimumMember_z2fNB0yIlvV6" title="Exercise price">8.16-<span id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember__srt--RangeAxis__srt--MaximumMember_zBHMevplphTj" title="Exercise price"><span id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember__srt--RangeAxis__srt--MaximumMember_zSzrbm2lSWrf" title="Exercise price">9.64</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zMSOIJMIQQt7" style="text-align: right" title="Stock options outstanding">380,872</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zB7hWusWbOVe" style="text-align: right" title="Stock options outstanding">380,872</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zpMieXnILd3e" title="Weighted average remaining contractual life">5.6</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zna64supMgLf" title="Weighted average remaining contractual life">6.6</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_z4YPFYlSZrEa" style="text-align: right" title="Stock options exercisable">380,872</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zMa1CRMVvvy8" style="text-align: right" title="Stock options exercisable">380,872</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-bottom: 1pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember__srt--RangeAxis__srt--MinimumMember_zZUoEPoVUsyc" title="Exercise price"><span id="xdx_90E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember__srt--RangeAxis__srt--MinimumMember_zgseAnSYVMI6" title="Exercise price">15.3-<span id="xdx_90E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember__srt--RangeAxis__srt--MaximumMember_zQcgHbw60CJe" title="Exercise price"><span id="xdx_90C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember__srt--RangeAxis__srt--MaximumMember_zDPrzrG7Uqdd" title="Exercise price">15.75</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zZdEtXqksGng" style="border-bottom: Black 1pt solid; text-align: right" title="Stock options outstanding">152,873</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_z02UCaeWBeo2" style="border-bottom: Black 1pt solid; text-align: right" title="Stock options outstanding">152,873</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zVLenZJaT6u8" title="Weighted average remaining contractual life">2.7</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_z81RCj9dGIBb" title="Weighted average remaining contractual life">3.7</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zao4PlBl169l" style="border-bottom: Black 1pt solid; text-align: right" title="Stock options exercisable">152,873</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zUqh6uY0JZJ6" style="border-bottom: Black 1pt solid; text-align: right" title="Stock options exercisable">152,873</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20241231_znXMg5ezgtcf" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock options outstanding">2,497,366</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20231231_zEifKpDk2hk" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock options outstanding">2,095,362</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20241231_zhDZZ6izOEql" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock options exercisable">1,866,523</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20231231_zNZYLem38Sp8" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock options exercisable">1,176,118</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data) NOTE 10 - SHARE CAPITAL Employee stock option grants: <p id="xdx_895_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zJhFskNDll5f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The grant date fair values of employee stock options granted in the years ended December 31, 2024 and 2023 were estimated using the Black-Scholes valuation model with the following: SCHEDULE OF STOCK OPTIONS VALUATION ASSUMPTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20240101__20241231_zflvnwBgFJMd" title="Expected volatility, minimum">90.4%-<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20240101__20241231_zj4WQHaOslEg" title="Expected volatility, maximum">100.7%</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20230101__20231231_zZ4UPE7wUQx3" title="Expected volatility, minimum">86.5%-<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20230101__20231231_z13ZQTMhNwOh" title="Expected volatility, maximum">98.2%</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk-free interest</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20240101__20241231_ziLWecOMeS69" title="Risk-free interest, minimum">3.5%- <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20240101__20241231_zZwV77je8fC" title="Risk-free interest, maximum">4.3%</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20230101__20231231_zROPzkH6EbLd" title="Risk-free interest, minimum">3.3%- <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20230101__20231231_zQPZyQGBH9Dj" title="Risk-free interest, maximum">4.7%</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-%</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-%</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left">Expected terms (years)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_z4d2JJMfIi11" title="Expected terms (years)">5-<span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_zQ4MqDtVp4T6" title="Expected terms (years)">10</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">5.8</td><td style="width: 1%; text-align: left"> </td></tr> </table> E. Warrants: The remaining outstanding warrants and terms as of December 31, 2024 and 2023 are as follows: SCHEDULE OF WARRANTS OUTSTANDING <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Issuance date</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Outstanding and exercisable as of December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Outstanding and exercisable as of December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: center">Exercisable Through</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 24%">Series A October 2022</td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--SeriesAWarrantOctoberTwoThousandTwentyTwoMember_zRjCNy6jDzn5" style="text-align: right; width: 14%" title="Number of outstanding warrants">-</td><td style="text-align: left; width: 1%"> </td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--SeriesAWarrantOctoberTwoThousandTwentyTwoMember_zaDyHM5Sg3db" style="text-align: right; width: 14%" title="Number of outstanding warrants">1,022,495</td><td style="text-align: left; width: 1%"> </td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%">$</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--SeriesAWarrantOctoberTwoThousandTwentyTwoMember_zgny955DyyYk" style="text-align: right; width: 14%" title="Exercise price">2.20</td><td style="text-align: left; width: 1%"> </td><td style="width: 2%"> </td> <td style="text-align: center; width: 20%"><span id="xdx_909_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--SeriesAWarrantOctoberTwoThousandTwentyTwoMember_zbdd5KB7JTZg" title="Exercisable Through">(*)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant to underwriters October 2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersOctoberTwoThousandTwentyTwoMember_zN8eGFAFzTt9" style="text-align: right" title="Number of outstanding warrants">51,125</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersOctoberTwoThousandTwentyTwoMember_z54eQD6Fp588" style="text-align: right" title="Number of outstanding warrants">51,125</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersOctoberTwoThousandTwentyTwoMember_zJHkZvMlrFTi" style="text-align: right" title="Exercise price">6.11</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_906_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersOctoberTwoThousandTwentyTwoMember_zeBY94qj5ws4" title="Exercisable Through">October 21, 2027</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrant to underwriters May 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersOneMayTwoThousandTwentyThreeMember_zY5Lh5vQhFzb" style="text-align: right" title="Number of outstanding warrants">32,778</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersOneMayTwoThousandTwentyThreeMember_zbUvQaM4y0D9" style="text-align: right" title="Number of outstanding warrants">32,778</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersOneMayTwoThousandTwentyThreeMember_zI9zZPzXmAQl" style="text-align: right" title="Exercise price">2.75</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_906_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersOneMayTwoThousandTwentyThreeMember_zvEwa4pzHXU2" title="Exercisable Through">November 23, 2026</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant to underwriters May 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersTwoMayTwoThousandTwentyThreeMember_zQPoKhXQv9ec" style="text-align: right" title="Number of outstanding warrants">60,476</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersTwoMayTwoThousandTwentyThreeMember_zqivsBlkZ4Sh" style="text-align: right" title="Number of outstanding warrants">60,476</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersTwoMayTwoThousandTwentyThreeMember_zCMrbjlrRqQ" style="text-align: right" title="Exercise price">2.75</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_901_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersTwoMayTwoThousandTwentyThreeMember_zhgbjdD17Ko" title="Exercisable Through">November 24, 2026</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrant to underwriters June 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersOneJuneTwoThousandTwentyThreeMember_zIVg3aF5tNq7" style="text-align: right" title="Number of outstanding warrants">35,088</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersOneJuneTwoThousandTwentyThreeMember_zizHzeeNbAGi" style="text-align: right" title="Number of outstanding warrants">35,088</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersOneJuneTwoThousandTwentyThreeMember_zU2f724fUno8" style="text-align: right" title="Exercise price">2.67</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_904_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersOneJuneTwoThousandTwentyThreeMember_zXxv2npXMpY6" title="Exercisable Through">June 2, 2028</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant series C June 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesCJuneTwoThousandTwentyThreeMember_zH02A2rDQRk8" style="text-align: right" title="Number of outstanding warrants">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesCJuneTwoThousandTwentyThreeMember_zAHJKeHaimGh" style="text-align: right" title="Number of outstanding warrants">350,878</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesCJuneTwoThousandTwentyThreeMember_z0kRJSBjcUy2" style="text-align: right" title="Exercise price">2.08</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_905_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesCJuneTwoThousandTwentyThreeMember_ziST1INoFri8" title="Exercisable Through">(*)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrant to underwriters June 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersTwoJuneTwoThousandTwentyThreeMember_zPHiepbsGzO1" style="text-align: right" title="Number of outstanding warrants">31,231</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersTwoJuneTwoThousandTwentyThreeMember_zbao244dvM9b" style="text-align: right" title="Number of outstanding warrants">31,231</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersTwoJuneTwoThousandTwentyThreeMember_zDoawVsahIHh" style="text-align: right" title="Exercise price">4.06</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_906_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersTwoJuneTwoThousandTwentyThreeMember_zfXPwFyon65i" title="Exercisable Through">June 28, 2028</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant series D June 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesDJuneTwoThousandTwentyThreeMember_zR7DFz2S3n3g" style="text-align: right" title="Number of outstanding warrants">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesDJuneTwoThousandTwentyThreeMember_zKtko0VRfp06" style="text-align: right" title="Number of outstanding warrants">312,309</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesDJuneTwoThousandTwentyThreeMember_zFKajrjFGALg" style="text-align: right" title="Exercise price">3.19</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_901_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesDJuneTwoThousandTwentyThreeMember_zPIRGyO70aMf" title="Exercisable Through">(*)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrant series E January 2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Number of outstanding warrants"><p id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesEJanuaryTwoThousandTwentyFourMember_zxsDMTdLZcTk" style="font: 10pt Times New Roman, Times, Serif; margin: 0" title="Number of outstanding warrants">1,685,682</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"></td><td style="text-align: right" title="Number of outstanding warrants"><p id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesEJanuaryTwoThousandTwentyFourMember_zmbX7jFbTG56" style="font: 10pt Times New Roman, Times, Serif; margin: 0" title="Number of outstanding warrants">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesEJanuaryTwoThousandTwentyFourMember_zAm2xFDkDRga" style="text-align: right" title="Exercise price">1.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_901_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesEJanuaryTwoThousandTwentyFourMember_zi5mFpCtR9o7" title="Exercisable Through">July 3, 2029</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant to underwriters January 2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Number of outstanding warrants"><p id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFourMember_zv3E5eWleY69" style="font: 10pt Times New Roman, Times, Serif; margin: 0" title="Number of outstanding warrants">84,284</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Number of outstanding warrants"><p id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFourMember_z41QbiYIlAe1" style="font: 10pt Times New Roman, Times, Serif; margin: 0" title="Number of outstanding warrants">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFourMember_zElxhDfHR0ug" style="text-align: right" title="Exercise price">2.03</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_900_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFourMember_zJgIoXrtUUs5" title="Exercisable Through">July 3, 2029</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrant series F June 2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Number of outstanding warrants"><p id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesFJuneTwoThousandTwentyFourMember_z8QBxe0a3Y0b" style="font: 10pt Times New Roman, Times, Serif; margin: 0" title="Number of outstanding warrants">3,133,338</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Number of outstanding warrants"><p id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesFJuneTwoThousandTwentyFourMember_zt7j0Agc8aK" style="font: 10pt Times New Roman, Times, Serif; margin: 0" title="Number of outstanding warrants">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesFJuneTwoThousandTwentyFourMember_z4c0tmhKMZk9" style="text-align: right" title="Exercise price">1.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_90F_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesFJuneTwoThousandTwentyFourMember_zIC7WWM2WDQ5" title="Exercisable Through">June 3, 2026</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant to underwriters June 2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Number of outstanding warrants"><p id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJuneTwoThousandTwentyFourMember_zY4nqfQ409Mc" style="font: 10pt Times New Roman, Times, Serif; margin: 0" title="Number of outstanding warrants">78,333</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Number of outstanding warrants"><p id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJuneTwoThousandTwentyFourMember_zJLokHVWCt16" style="font: 10pt Times New Roman, Times, Serif; margin: 0" title="Number of outstanding warrants">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJuneTwoThousandTwentyFourMember_zFqC95BoJ4q6" style="text-align: right" title="Exercise price">1.88</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_904_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJuneTwoThousandTwentyFourMember_z9e4Lp2Cys3a" title="Exercisable Through">June 3, 2026</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 1in">(*)</td> <td style="width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 82%">Exercised during 2024. Refer to Note 10A.</td></tr> </table> MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data)

1022495

2.20

350878

2.075

312309

3.19

1685682

1.62

1685682

1.50

1853000

2730000

333000

84284

2.025

89000

655569

2.20

1442000

222000

32778

2.75

46000

975000

2.20

234500

2.1999

2661000

345000

0.0001

60476

2.75

72000

701756

2.1375

1500000

227000

35088

2.6719

58000

350878

2.075

624618

3.25

2030000

281000

31231

4.0625

68000

312309

3.19

1566669

0.01

1.50

2350000

328000

3133338

1.50

1893000

78333

1.875

43000

4820000

3433880

3756000

239000

1022495

4.64

2027-10-25

1022495

4.64

2024-10-25

2.20

2027-10-25

1230000

385246

<p id="xdx_89E_ecustom--ScheduleOfGrantDateFairValueOfPreferredInvestmentOptionsIssuedToInvestorsTableTextBlock_z97Nm0CHQyob" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The grant date fair values of preferred investment options issued to Wainwright and preferred investment options issued to investors including those that were modified in the years ended December 31, 2024 and 2023 were estimated using the Black-Scholes valuation model with the following: SCHEDULE OF GRANT DATE FAIR VALUE OF PREFERRED INVESTMENT OPTIONS ISSUED TO INVESTORS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td colspan="5" style="border-bottom: Black 1pt solid; text-align: center">For the Years Ended December 31, </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Expected volatility</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zvmD6MhqoOH1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">103.6%-<span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zjBd6orwp04a">111.4</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zxIUU5GgHGR7" title="Warrants measurement input">101.3%-<span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_z2WeSBocuyL7" title="Warrants measurement input">122.4</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk-free interest</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zqCFf8l5Yde9" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.9%- <span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zXi9YHR2C2h2">4.8</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zy6jffSNzoGb">3.9%- <span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zS7rBXErNgDf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zLltFZ8A8w3h" title="Warrants measurement input">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zFAx8eznQ114" title="Warrants measurement input">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected terms (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_z3QtG5mihyyd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.0-<span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_z5tY2qQgEwMf">5.5</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_zRtMTZauAKoa" title="Expected terms (years)">1.4-<span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_zVhAVsGmhYU3" title="Expected terms (years)">5.0</td><td style="text-align: left"> </td></tr> </table>

103.6

111.4

101.3

122.4

3.9

4.8

3.9

4.9

P2Y

P5Y6M

P1Y4M24D

P5Y

80000

2.43

P3Y

631308

1.16

3.48

P3Y

80000

50000

1.2684

80000 52500

1.25

38000

35625

132500

80000

115000

1.2684

25000

0.881

0.25

99000

79567

1.25

SUMMARY OF STOCK OPTION ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the Year Ended December 31, 2024</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of stock options</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted average exercise price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Outstanding as of December 31, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zk004bCApdNg" style="width: 16%; text-align: right" title="Number of stock options outstanding, Outstanding at beginning of period">2,095,362</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zpXuCYVsYfjf" style="width: 16%; text-align: right" title="Weighted average exercise price, Outstanding at beginning of period">5.51</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zqrdTiSFXFKi" style="text-align: right" title="Number of stock options outstanding, Granted">562,067</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zm8idAxNTLVb" style="text-align: right" title="Weighted average exercise price, Granted">1.24</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Forfeitures</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zykg7DeRAeL4" style="border-bottom: Black 1pt solid; text-align: right" title="Number of stock options outstanding, forfeitures">(160,063</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zk3eZiUty6w1" style="padding-bottom: 1pt; text-align: right" title="Weighted average exercise price, forfeitures">3.23</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Outstanding as of December 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zQINqXw31Oq4" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of stock options outstanding, Outstanding at end of period">2,497,366</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zYZuQCmpykD" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price, Outstanding at end of period">4.70</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Vested as of December 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zB1v8yS3JMm1" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of stock options outstanding, Vested at end of period">1,866,523</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zSbMIFgv1bcb" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price, Vested at end of period">5.63</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the Year Ended December 31, 2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of stock options</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted average exercise price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Outstanding as of December 31, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zoIA448yN7Uc" style="width: 16%; text-align: right" title="Number of stock options outstanding, Outstanding at beginning of period">1,507,137</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zRFYHVOTmOi5" style="width: 16%; text-align: right" title="Weighted average exercise price, Outstanding at beginning of period">7.31</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_z7eq8gNSPoF" style="text-align: right" title="Number of stock options outstanding, Granted">711,308</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_z8jF6pQgWYJf" style="text-align: right" title="Weighted average exercise price, Granted">1.75</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Forfeitures</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zFyWRvGqogHk" style="border-bottom: Black 1pt solid; text-align: right" title="Number of stock options outstanding, forfeitures">(123,083</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zTk3vK7MQHj3" style="padding-bottom: 1pt; text-align: right" title="Weighted average exercise price, forfeitures">5.78</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Outstanding as of December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zZu0sOZqkMV1" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of stock options outstanding, Outstanding at end of period">2,095,362</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_z44SQFvYJywe" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price, Outstanding at end of period">5.51</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Vested as of December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zEC46zLaV7Kh" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of stock options outstanding, Vested at end of period">1,176,118</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zzAzbA66lqgc" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price, Vested at end of period">7.74</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

2095362

5.51

562067

1.24

160063

3.23

2497366

4.70

1866523

5.63

1507137

7.31

711308

1.75

123083

5.78

2095362

5.51

1176118

7.74

75000

277000

69000

102000

0.99

1.40

921000

P1Y5M23D

<p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_z6jBZ95snH31" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The stock options outstanding as of December 31, 2024 and 2023, summarized by exercise prices, are as follows: SCHEDULE OF STOCK OPTIONS OUTSTANDING <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise price $</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Stock options outstanding as of December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Stock options outstanding as of December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted average remaining contractual life – years as of December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted average remaining contractual life – years as of December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Stock options exercisable as of December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Stock options exercisable as of December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 16%; text-align: center"><span id="xdx_90F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember__srt--RangeAxis__srt--MinimumMember_zJbT0W25WPq3" title="Exercise price"><span id="xdx_902_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember__srt--RangeAxis__srt--MinimumMember_zNpWBstaK7K1" title="Exercise price">0.00-<span id="xdx_900_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember__srt--RangeAxis__srt--MaximumMember_zN2HkDktBW79" title="Exercise price"><span id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember__srt--RangeAxis__srt--MaximumMember_z6u07AQdMck5" title="Exercise price">0.99</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z9mRTIgk5sgd" style="width: 10%; text-align: right" title="Stock options outstanding">86,577</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zaedXjnreCua" style="width: 10%; text-align: right" title="Stock options outstanding">61,577</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zFyKvyIbXfml" title="Weighted average remaining contractual life">3.8</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zXMSJLbfdZri" title="Weighted average remaining contractual life">2.3</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zymreWPrHngb" style="width: 10%; text-align: right" title="Stock options exercisable">61,577</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zOautB6JYVv8" style="width: 10%; text-align: right" title="Stock options exercisable">61,577</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"><span id="xdx_904_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember__srt--RangeAxis__srt--MinimumMember_zLhfMWyKFud8" title="Exercise price"><span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember__srt--RangeAxis__srt--MinimumMember_zv90h2XZJEG7" title="Exercise price">1.00-<span id="xdx_908_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember__srt--RangeAxis__srt--MaximumMember_znLHGr6IPaAc" title="Exercise price"><span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember__srt--RangeAxis__srt--MaximumMember_zYVMLeNJM0Z" title="Exercise price">3.73</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zbiVAjOAvm21" style="text-align: right" title="Stock options outstanding">1,299,562</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z94fNuKttDpf" style="text-align: right" title="Stock options outstanding">860,808</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zKO1P965kAg6" title="Weighted average remaining contractual life">8.7</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_ztsNJ3B6Gpad" title="Weighted average remaining contractual life">9.6</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_ztQnC6DVpqT6" style="text-align: right" title="Stock options exercisable">731,559</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_za9Bu4xWt4xg" style="text-align: right" title="Stock options exercisable">95,925</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center"><span id="xdx_900_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember__srt--RangeAxis__srt--MinimumMember_zGEkp6IS4d87" title="Exercise price"><span id="xdx_902_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember__srt--RangeAxis__srt--MinimumMember_zLooIktEZWO3" title="Exercise price">4.2-<span id="xdx_902_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember__srt--RangeAxis__srt--MaximumMember_zjmw1wX6Ukia" title="Exercise price"><span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember__srt--RangeAxis__srt--MaximumMember_zIub21jfjUg6" title="Exercise price">7.26</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zNQR6ws7D92j" style="text-align: right" title="Stock options outstanding">577,482</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zuSDlaEv7CHh" style="text-align: right" title="Stock options outstanding">639,232</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zLQCAixvmqd2" title="Weighted average remaining contractual life">5.9</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_z47dA671UPR8">6.3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zikiDEVdgdOa" style="text-align: right" title="Stock options exercisable">539,642</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zHUOHPDGz37i" style="text-align: right" title="Stock options exercisable">484,871</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"><span id="xdx_900_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember__srt--RangeAxis__srt--MinimumMember_zjbW2jpCY39g" title="Exercise price"><span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember__srt--RangeAxis__srt--MinimumMember_z2fNB0yIlvV6" title="Exercise price">8.16-<span id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember__srt--RangeAxis__srt--MaximumMember_zBHMevplphTj" title="Exercise price"><span id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember__srt--RangeAxis__srt--MaximumMember_zSzrbm2lSWrf" title="Exercise price">9.64</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zMSOIJMIQQt7" style="text-align: right" title="Stock options outstanding">380,872</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zB7hWusWbOVe" style="text-align: right" title="Stock options outstanding">380,872</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zpMieXnILd3e" title="Weighted average remaining contractual life">5.6</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zna64supMgLf" title="Weighted average remaining contractual life">6.6</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_z4YPFYlSZrEa" style="text-align: right" title="Stock options exercisable">380,872</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zMa1CRMVvvy8" style="text-align: right" title="Stock options exercisable">380,872</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-bottom: 1pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember__srt--RangeAxis__srt--MinimumMember_zZUoEPoVUsyc" title="Exercise price"><span id="xdx_90E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember__srt--RangeAxis__srt--MinimumMember_zgseAnSYVMI6" title="Exercise price">15.3-<span id="xdx_90E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember__srt--RangeAxis__srt--MaximumMember_zQcgHbw60CJe" title="Exercise price"><span id="xdx_90C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember__srt--RangeAxis__srt--MaximumMember_zDPrzrG7Uqdd" title="Exercise price">15.75</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zZdEtXqksGng" style="border-bottom: Black 1pt solid; text-align: right" title="Stock options outstanding">152,873</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_z02UCaeWBeo2" style="border-bottom: Black 1pt solid; text-align: right" title="Stock options outstanding">152,873</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zVLenZJaT6u8" title="Weighted average remaining contractual life">2.7</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_z81RCj9dGIBb" title="Weighted average remaining contractual life">3.7</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zao4PlBl169l" style="border-bottom: Black 1pt solid; text-align: right" title="Stock options exercisable">152,873</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zUqh6uY0JZJ6" style="border-bottom: Black 1pt solid; text-align: right" title="Stock options exercisable">152,873</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20241231_znXMg5ezgtcf" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock options outstanding">2,497,366</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20231231_zEifKpDk2hk" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock options outstanding">2,095,362</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20241231_zhDZZ6izOEql" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock options exercisable">1,866,523</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20231231_zNZYLem38Sp8" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock options exercisable">1,176,118</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

0.00

0.99

86577

61577

P3Y9M18D

P2Y3M18D

61577

1.00

3.73

1299562

860808

P8Y8M12D

P9Y7M6D

731559

95925

4.2

7.26

577482

639232

P5Y10M24D

P6Y3M18D

539642

484871

8.16

9.64

380872

P5Y7M6D

P6Y7M6D

380872

15.3

15.75

152873

P2Y8M12D

P3Y8M12D

152873

2497366

2095362

1866523

1176118

<p id="xdx_895_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zJhFskNDll5f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The grant date fair values of employee stock options granted in the years ended December 31, 2024 and 2023 were estimated using the Black-Scholes valuation model with the following: SCHEDULE OF STOCK OPTIONS VALUATION ASSUMPTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20240101__20241231_zflvnwBgFJMd" title="Expected volatility, minimum">90.4%-<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20240101__20241231_zj4WQHaOslEg" title="Expected volatility, maximum">100.7%</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20230101__20231231_zZ4UPE7wUQx3" title="Expected volatility, minimum">86.5%-<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20230101__20231231_z13ZQTMhNwOh" title="Expected volatility, maximum">98.2%</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk-free interest</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20240101__20241231_ziLWecOMeS69" title="Risk-free interest, minimum">3.5%- <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20240101__20241231_zZwV77je8fC" title="Risk-free interest, maximum">4.3%</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20230101__20231231_zROPzkH6EbLd" title="Risk-free interest, minimum">3.3%- <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20230101__20231231_zQPZyQGBH9Dj" title="Risk-free interest, maximum">4.7%</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-%</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-%</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left">Expected terms (years)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_z4d2JJMfIi11" title="Expected terms (years)">5-<span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_zQ4MqDtVp4T6" title="Expected terms (years)">10</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">5.8</td><td style="width: 1%; text-align: left"> </td></tr> </table>

0.904

1.007

0.865

0.982

0.035

0.043

0.033

0.047

P5Y

P10Y

P5Y9M18D

The remaining outstanding warrants and terms as of December 31, 2024 and 2023 are as follows: SCHEDULE OF WARRANTS OUTSTANDING <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Issuance date</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Outstanding and exercisable as of December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Outstanding and exercisable as of December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: center">Exercisable Through</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 24%">Series A October 2022</td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--SeriesAWarrantOctoberTwoThousandTwentyTwoMember_zRjCNy6jDzn5" style="text-align: right; width: 14%" title="Number of outstanding warrants">-</td><td style="text-align: left; width: 1%"> </td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--SeriesAWarrantOctoberTwoThousandTwentyTwoMember_zaDyHM5Sg3db" style="text-align: right; width: 14%" title="Number of outstanding warrants">1,022,495</td><td style="text-align: left; width: 1%"> </td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%">$</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--SeriesAWarrantOctoberTwoThousandTwentyTwoMember_zgny955DyyYk" style="text-align: right; width: 14%" title="Exercise price">2.20</td><td style="text-align: left; width: 1%"> </td><td style="width: 2%"> </td> <td style="text-align: center; width: 20%"><span id="xdx_909_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--SeriesAWarrantOctoberTwoThousandTwentyTwoMember_zbdd5KB7JTZg" title="Exercisable Through">(*)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant to underwriters October 2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersOctoberTwoThousandTwentyTwoMember_zN8eGFAFzTt9" style="text-align: right" title="Number of outstanding warrants">51,125</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersOctoberTwoThousandTwentyTwoMember_z54eQD6Fp588" style="text-align: right" title="Number of outstanding warrants">51,125</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersOctoberTwoThousandTwentyTwoMember_zJHkZvMlrFTi" style="text-align: right" title="Exercise price">6.11</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_906_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersOctoberTwoThousandTwentyTwoMember_zeBY94qj5ws4" title="Exercisable Through">October 21, 2027</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrant to underwriters May 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersOneMayTwoThousandTwentyThreeMember_zY5Lh5vQhFzb" style="text-align: right" title="Number of outstanding warrants">32,778</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersOneMayTwoThousandTwentyThreeMember_zbUvQaM4y0D9" style="text-align: right" title="Number of outstanding warrants">32,778</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersOneMayTwoThousandTwentyThreeMember_zI9zZPzXmAQl" style="text-align: right" title="Exercise price">2.75</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_906_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersOneMayTwoThousandTwentyThreeMember_zvEwa4pzHXU2" title="Exercisable Through">November 23, 2026</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant to underwriters May 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersTwoMayTwoThousandTwentyThreeMember_zQPoKhXQv9ec" style="text-align: right" title="Number of outstanding warrants">60,476</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersTwoMayTwoThousandTwentyThreeMember_zqivsBlkZ4Sh" style="text-align: right" title="Number of outstanding warrants">60,476</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersTwoMayTwoThousandTwentyThreeMember_zCMrbjlrRqQ" style="text-align: right" title="Exercise price">2.75</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_901_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersTwoMayTwoThousandTwentyThreeMember_zhgbjdD17Ko" title="Exercisable Through">November 24, 2026</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrant to underwriters June 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersOneJuneTwoThousandTwentyThreeMember_zIVg3aF5tNq7" style="text-align: right" title="Number of outstanding warrants">35,088</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersOneJuneTwoThousandTwentyThreeMember_zizHzeeNbAGi" style="text-align: right" title="Number of outstanding warrants">35,088</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersOneJuneTwoThousandTwentyThreeMember_zU2f724fUno8" style="text-align: right" title="Exercise price">2.67</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_904_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersOneJuneTwoThousandTwentyThreeMember_zXxv2npXMpY6" title="Exercisable Through">June 2, 2028</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant series C June 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesCJuneTwoThousandTwentyThreeMember_zH02A2rDQRk8" style="text-align: right" title="Number of outstanding warrants">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesCJuneTwoThousandTwentyThreeMember_zAHJKeHaimGh" style="text-align: right" title="Number of outstanding warrants">350,878</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesCJuneTwoThousandTwentyThreeMember_z0kRJSBjcUy2" style="text-align: right" title="Exercise price">2.08</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_905_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesCJuneTwoThousandTwentyThreeMember_ziST1INoFri8" title="Exercisable Through">(*)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrant to underwriters June 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersTwoJuneTwoThousandTwentyThreeMember_zPHiepbsGzO1" style="text-align: right" title="Number of outstanding warrants">31,231</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersTwoJuneTwoThousandTwentyThreeMember_zbao244dvM9b" style="text-align: right" title="Number of outstanding warrants">31,231</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersTwoJuneTwoThousandTwentyThreeMember_zDoawVsahIHh" style="text-align: right" title="Exercise price">4.06</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_906_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersTwoJuneTwoThousandTwentyThreeMember_zfXPwFyon65i" title="Exercisable Through">June 28, 2028</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant series D June 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesDJuneTwoThousandTwentyThreeMember_zR7DFz2S3n3g" style="text-align: right" title="Number of outstanding warrants">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesDJuneTwoThousandTwentyThreeMember_zKtko0VRfp06" style="text-align: right" title="Number of outstanding warrants">312,309</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesDJuneTwoThousandTwentyThreeMember_zFKajrjFGALg" style="text-align: right" title="Exercise price">3.19</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_901_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesDJuneTwoThousandTwentyThreeMember_zPIRGyO70aMf" title="Exercisable Through">(*)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrant series E January 2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Number of outstanding warrants"><p id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesEJanuaryTwoThousandTwentyFourMember_zxsDMTdLZcTk" style="font: 10pt Times New Roman, Times, Serif; margin: 0" title="Number of outstanding warrants">1,685,682</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"></td><td style="text-align: right" title="Number of outstanding warrants"><p id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesEJanuaryTwoThousandTwentyFourMember_zmbX7jFbTG56" style="font: 10pt Times New Roman, Times, Serif; margin: 0" title="Number of outstanding warrants">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesEJanuaryTwoThousandTwentyFourMember_zAm2xFDkDRga" style="text-align: right" title="Exercise price">1.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_901_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesEJanuaryTwoThousandTwentyFourMember_zi5mFpCtR9o7" title="Exercisable Through">July 3, 2029</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant to underwriters January 2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Number of outstanding warrants"><p id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFourMember_zv3E5eWleY69" style="font: 10pt Times New Roman, Times, Serif; margin: 0" title="Number of outstanding warrants">84,284</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Number of outstanding warrants"><p id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFourMember_z41QbiYIlAe1" style="font: 10pt Times New Roman, Times, Serif; margin: 0" title="Number of outstanding warrants">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFourMember_zElxhDfHR0ug" style="text-align: right" title="Exercise price">2.03</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_900_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFourMember_zJgIoXrtUUs5" title="Exercisable Through">July 3, 2029</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrant series F June 2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Number of outstanding warrants"><p id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesFJuneTwoThousandTwentyFourMember_z8QBxe0a3Y0b" style="font: 10pt Times New Roman, Times, Serif; margin: 0" title="Number of outstanding warrants">3,133,338</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Number of outstanding warrants"><p id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesFJuneTwoThousandTwentyFourMember_zt7j0Agc8aK" style="font: 10pt Times New Roman, Times, Serif; margin: 0" title="Number of outstanding warrants">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesFJuneTwoThousandTwentyFourMember_z4c0tmhKMZk9" style="text-align: right" title="Exercise price">1.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_90F_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesFJuneTwoThousandTwentyFourMember_zIC7WWM2WDQ5" title="Exercisable Through">June 3, 2026</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant to underwriters June 2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Number of outstanding warrants"><p id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJuneTwoThousandTwentyFourMember_zY4nqfQ409Mc" style="font: 10pt Times New Roman, Times, Serif; margin: 0" title="Number of outstanding warrants">78,333</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Number of outstanding warrants"><p id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJuneTwoThousandTwentyFourMember_zJLokHVWCt16" style="font: 10pt Times New Roman, Times, Serif; margin: 0" title="Number of outstanding warrants">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJuneTwoThousandTwentyFourMember_zFqC95BoJ4q6" style="text-align: right" title="Exercise price">1.88</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_904_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJuneTwoThousandTwentyFourMember_z9e4Lp2Cys3a" title="Exercisable Through">June 3, 2026</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 1in">(*)</td> <td style="width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 82%">Exercised during 2024. Refer to Note 10A.</td></tr> </table>

1022495

2.20

(*)

51125

6.11

October 21, 2027

32778

2.75

November 23, 2026

60476

2.75

November 24, 2026

35088

2.67

June 2, 2028

350878

2.08

(*)

31231

4.06

June 28, 2028

312309

3.19

(*)

1685682

1.50

July 3, 2029

84284

2.03

July 3, 2029

3133338

1.50

June 3, 2026

78333

1.88

June 3, 2026

NOTE 11 - BASIC AND DILUTED NET LOSS PER SHARE The basic and diluted net loss per share and weighted average number of shares of common stock used in the calculation of basic and diluted net loss per share were presented in the consolidated statements of comprehensive loss for the years ended December 31, 2024 and 2023. In the calculation of the basic and diluted net loss, the Company included warrants that would be exercised for no or little consideration and are exercisable with no contingencies. Due to the net loss to common shareholders in each of the periods presented above, diluted loss per share was computed without consideration to potentially dilutive instruments as their inclusion would have been anti-dilutive. As of December 31, 2024 and 2023, potentially dilutive securities excluded from the diluted loss per share calculation are as follows: <p id="xdx_89D_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zR8EjnTkRTMk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES EXCLUDED FROM DILUTED LOSS PER SHARE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20240101__20241231_zLzbHxSb2kw5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20230101__20231231_zBfaMmAj5uO2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesAWarrantOctoberTwoThousandTwentyTwoMember_zwjwpjyVuUVf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Series A warrants October 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">1,022,495</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantToUnderwritersOctoberTwoThousandTwentyTwoMember_zrbwcr1XejNd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant to underwriters October 2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">51,125</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">51,125</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantToUnderwritersOneMayTwoThousandTwentyThreeMember_zmwM8z8TTqR2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrant to underwriters May 2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">32,778</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">32,778</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantToUnderwritersTwoMayTwoThousandTwentyThreeMember_zvkJutweZo4k" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant to underwriters May 2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">60,476</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">60,476</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantToUnderwritersJuneTwoThousandTwentyThreeMember_zZVTVPCipR6k" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrant to underwriters June 2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">35,088</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">35,088</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantSeriesCJuneTwoThousandTwentyThreeMember_z2fjuYWTR312" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant series C June 2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">350,878</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantToUnderwritersJuneTwoThousandTwentyThreeTwoMember_znfsVthvvvj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrant to underwriters June 2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">31,231</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">31,231</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantSeriesDJuneTwoThousandTwentyThreeMember_zw2g9y20ceM1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant series D June 2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">312,309</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantSeriesEJanuaryTwoThousandTwentyFourMember_zm54z2USAYJ2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrant series E January 2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,685,682</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFourMember_zhNpaUSLXlY9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant to underwriters January 2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">84,284</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantSeriesFJuneTwoThousandTwentyFourMember_zoOWbMAgpVQ1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrant series F June 2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,133,338</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantToUnderwritersJuneTwoThousandTwentyFourMember_zq1us3hmTlq5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant to underwriters June 2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">78,333</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zbxHw40orxZ9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Outstanding employee stock options to purchase common stock</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right">2,497,366</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right">2,095,362</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zW07hWAtTfza" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Potentially dilutive securities excluded from diluted loss per share</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">2,584,991</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">2,095,362</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data)

<p id="xdx_89D_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zR8EjnTkRTMk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES EXCLUDED FROM DILUTED LOSS PER SHARE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20240101__20241231_zLzbHxSb2kw5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20230101__20231231_zBfaMmAj5uO2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesAWarrantOctoberTwoThousandTwentyTwoMember_zwjwpjyVuUVf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Series A warrants October 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">1,022,495</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantToUnderwritersOctoberTwoThousandTwentyTwoMember_zrbwcr1XejNd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant to underwriters October 2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">51,125</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">51,125</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantToUnderwritersOneMayTwoThousandTwentyThreeMember_zmwM8z8TTqR2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrant to underwriters May 2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">32,778</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">32,778</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantToUnderwritersTwoMayTwoThousandTwentyThreeMember_zvkJutweZo4k" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant to underwriters May 2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">60,476</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">60,476</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantToUnderwritersJuneTwoThousandTwentyThreeMember_zZVTVPCipR6k" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrant to underwriters June 2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">35,088</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">35,088</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantSeriesCJuneTwoThousandTwentyThreeMember_z2fjuYWTR312" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant series C June 2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">350,878</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantToUnderwritersJuneTwoThousandTwentyThreeTwoMember_znfsVthvvvj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrant to underwriters June 2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">31,231</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">31,231</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantSeriesDJuneTwoThousandTwentyThreeMember_zw2g9y20ceM1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant series D June 2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">312,309</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantSeriesEJanuaryTwoThousandTwentyFourMember_zm54z2USAYJ2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrant series E January 2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,685,682</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFourMember_zhNpaUSLXlY9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant to underwriters January 2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">84,284</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantSeriesFJuneTwoThousandTwentyFourMember_zoOWbMAgpVQ1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrant series F June 2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,133,338</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantToUnderwritersJuneTwoThousandTwentyFourMember_zq1us3hmTlq5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant to underwriters June 2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">78,333</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zbxHw40orxZ9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Outstanding employee stock options to purchase common stock</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right">2,497,366</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right">2,095,362</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zW07hWAtTfza" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Potentially dilutive securities excluded from diluted loss per share</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">2,584,991</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">2,095,362</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

1022495000

51125000

32778000

60476000

35088000

350878000

31231000

312309000

1685682000

84284000

3133338000

78333000

2497366000

2095362000

2584991000

2095362000

NOTE 12 - RESEARCH AND DEVELOPMENT EXPENSES, NET <p id="xdx_890_eus-gaap--ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock_z58Fpm7gjSQ1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SCHEDULE OF RESEARCH AND DEVELOPMENT EXPENSES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zJAA8coJLYFb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zdfSn9g0ozM" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_409_eus-gaap--LaborAndRelatedExpense_maRADEzGXN_zIr5AEQjURj5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Payroll and related expenses</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,382</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,455</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--ShareBasedCompensation_maRADEzGXN_zwMytK4VDfb1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Share-based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">292</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">406</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--CostDirectMaterial_maRADEzGXN_z1pEQoxPXCB1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Materials and subcontractors</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,165</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,362</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--RoyaltyExpense_maRADEzGXN_zX093pI3xct3" style="vertical-align: bottom; background-color: White"> <td>Patents</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">178</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">157</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--OtherResearchAndDevelopmentExpense_maRADEzGXN_z5wW4K3TNJs7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Rent</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">225</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">213</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--OfficeAndMaintenanceExpenses_maRADEzGXN_zrBRNoA1Lbta" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Office and maintenance expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">67</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">55</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--Depreciation_maRADEzGXN_zS2hYHva0FTa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Depreciation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">93</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">106</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--OtherExpenses_maRADEzGXN_zIOgNqlpoQNk" style="vertical-align: bottom; background-color: White"> <td>Other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">377</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">249</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--Grants_iN_di_msRADEzGXN_zquu8eyMjLA2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Less - grants</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(149</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(279</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--ResearchAndDevelopmentExpense_iT_pn3n3_mtRADEzGXN_zf9fKl3fgeNf" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Research and development expense</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,630</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,724</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

<p id="xdx_890_eus-gaap--ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock_z58Fpm7gjSQ1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SCHEDULE OF RESEARCH AND DEVELOPMENT EXPENSES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zJAA8coJLYFb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zdfSn9g0ozM" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_409_eus-gaap--LaborAndRelatedExpense_maRADEzGXN_zIr5AEQjURj5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Payroll and related expenses</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,382</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,455</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--ShareBasedCompensation_maRADEzGXN_zwMytK4VDfb1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Share-based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">292</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">406</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--CostDirectMaterial_maRADEzGXN_z1pEQoxPXCB1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Materials and subcontractors</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,165</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,362</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--RoyaltyExpense_maRADEzGXN_zX093pI3xct3" style="vertical-align: bottom; background-color: White"> <td>Patents</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">178</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">157</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--OtherResearchAndDevelopmentExpense_maRADEzGXN_z5wW4K3TNJs7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Rent</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">225</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">213</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--OfficeAndMaintenanceExpenses_maRADEzGXN_zrBRNoA1Lbta" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Office and maintenance expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">67</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">55</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--Depreciation_maRADEzGXN_zS2hYHva0FTa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Depreciation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">93</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">106</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--OtherExpenses_maRADEzGXN_zIOgNqlpoQNk" style="vertical-align: bottom; background-color: White"> <td>Other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">377</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">249</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--Grants_iN_di_msRADEzGXN_zquu8eyMjLA2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Less - grants</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(149</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(279</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--ResearchAndDevelopmentExpense_iT_pn3n3_mtRADEzGXN_zf9fKl3fgeNf" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Research and development expense</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,630</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,724</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

3382000

2455000

292000

406000

2165000

2362000

178000

157000

225000

213000

67000 55000

93000

106000

377000

249000

149000 279000

6630000

5724000

NOTE 13 - GENERAL AND ADMINISTRATIVE EXPENSES, NET SCHEDULE OF GENERAL AND ADMINISTRATIVE EXPENSES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zLW8Hh4Dnms1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zQTxQ7XXxbs8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40A_eus-gaap--LaborAndRelatedExpense_maGAAEzja1_zq241k49Bhy9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Payroll and related expenses</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,994</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,223</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--GovernmentalFees_maGAAEzja1_zPKomT5AO1Sh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Government fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">58</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--ShareBasedCompensation_maGAAEzja1_zVMzjgijGWSk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Share-based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,057</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">988</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--ProfessionalFees_maGAAEzja1_zRxFrpDyZ4Qc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Professional services</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,059</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,204</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--GeneralInsuranceExpense_maGAAEzja1_z4ST5pfU8rCk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Insurance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">442</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">442</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_ecustom--PublicAndInvestorRelationsExpenses_maGAAEzja1_zPa0r13Hzdm5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Public and investor relations</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">132</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">148</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--OfficeAndMaintenanceExpenses_maGAAEzja1_zRYl9fTiQDfc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Office and maintenance expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">74</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">95</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--TravelAndEntertainmentExpense_maGAAEzja1_ztQAZGhMiLTb" style="vertical-align: bottom; background-color: White"> <td>Travel</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">84</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">160</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--OtherGeneralAndAdministrativeExpense_maGAAEzja1_zAER77zOifEh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">153</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">94</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--InsuranceRecoveries_iN_di_msGAAEzja1_zG7iYCjtV2Q" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less – insurance loss recoveries</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(281</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--GeneralAndAdministrativeExpense_iT_pn3n3_mtGAAEzja1_zaff85zUhi4e" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">General and administrative expenses</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,995</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,131</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data) SCHEDULE OF GENERAL AND ADMINISTRATIVE EXPENSES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zLW8Hh4Dnms1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zQTxQ7XXxbs8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40A_eus-gaap--LaborAndRelatedExpense_maGAAEzja1_zq241k49Bhy9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Payroll and related expenses</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,994</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,223</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--GovernmentalFees_maGAAEzja1_zPKomT5AO1Sh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Government fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">58</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--ShareBasedCompensation_maGAAEzja1_zVMzjgijGWSk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Share-based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,057</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">988</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--ProfessionalFees_maGAAEzja1_zRxFrpDyZ4Qc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Professional services</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,059</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,204</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--GeneralInsuranceExpense_maGAAEzja1_z4ST5pfU8rCk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Insurance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">442</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">442</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_ecustom--PublicAndInvestorRelationsExpenses_maGAAEzja1_zPa0r13Hzdm5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Public and investor relations</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">132</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">148</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--OfficeAndMaintenanceExpenses_maGAAEzja1_zRYl9fTiQDfc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Office and maintenance expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">74</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">95</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--TravelAndEntertainmentExpense_maGAAEzja1_ztQAZGhMiLTb" style="vertical-align: bottom; background-color: White"> <td>Travel</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">84</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">160</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--OtherGeneralAndAdministrativeExpense_maGAAEzja1_zAER77zOifEh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">153</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">94</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--InsuranceRecoveries_iN_di_msGAAEzja1_zG7iYCjtV2Q" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less – insurance loss recoveries</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(281</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--GeneralAndAdministrativeExpense_iT_pn3n3_mtGAAEzja1_zaff85zUhi4e" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">General and administrative expenses</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,995</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,131</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

1994000

1223000

58000

1057000

988000

1059000

1204000

442000

132000 148000 74000 95000

84000

160000

153000

94000

281000

4995000

4131000

NOTE 14 – SEGMENT REPORTING Segment information is prepared on the same basis that the Company’s chief operating decision maker (“CODM”), the Chief Executive Officer, manages the business, makes business decisions and assesses performance. The Company has one operating and reportable segment, which is the development of robotic devices for endoluminal surgery. See Note 1A for further details. The CODM assesses performance for this segment and decides how to allocate resources based on net loss. The measure of segment assets is reported on the balance sheet as cash and cash equivalents and marketable securities. The chief executive officer performs the assessment of segment performance by using the reported measure of segment loss to monitor actual results. The table below summarizes the significant expense categories regularly reviewed by the CODM for the years ended December 31, 2024 and 2023: SCHEDULE OF STATEMENT OF OPERATION BY SEGMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20240101__20241231_z39SDDsoztJd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20230101__20231231_z3v77eTaeyRh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; text-align: left">Significant segment expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--PayrollAndPayrollRelated_maNILzcOv_zAM7Seq0Gas2" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; width: 60%; text-align: left">Payroll and payroll related</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(5,376</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">(3,678</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_404_ecustom--MaterialsAndSubcontractors_maNILzcOv_zlLkzEJLr5K8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left">Materials and subcontractors</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,165</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,362</td><td style="text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--ShareBasedCompensation_iN_di_msNILzcOv_zkDzZJnfreij" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left">Share-based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,349</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,394</td><td style="text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--GainLossRelatedToLitigationSettlement_maNILzcOv_z1GXI5BlmHj4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left">Loss on legal settlement, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,111</td><td style="text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--SegmentReportingOtherItemAmount_iN_di_msNILzcOv_z8iL7DkdX7M5" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Other segment items (*)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,553</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,195</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--NetIncomeLoss_iT_mtNILzcOv_zODmNuk5LiS" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(11,443</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(10,740</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 89%; margin-left: 0.75in"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right">(*)</td><td style="text-align: justify">Other segment expense items included within net loss include professional services, patents, overhead and depreciation, travel expenses, financial income, net and other miscellaneous expenses net of grants received. See the consolidated financial statements for other financial information regarding the Company’s operating segment.</td> </tr></table> <p id="xdx_89A_ecustom--ScheduleOfLongLivedAssetsAndOperatingLeaseRightOfUseAssetsByGeographicalAreasTableTextBlock_z2RPpORjgG65" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Long-lived assets and operating lease right-of-use assets by geographical areas were as follows: SCHEDULE OF LONG LIVED ASSETS AND OPERATING LEASE RIGHT OF USE ASSETS BY GEOGRAPHICAL AREAS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"> <tr style="display: none; vertical-align: bottom"> <td style="font-size: 12pt"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_499_20241231_zQHPFxsu0hb4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49F_20231231_zX7G2ov6Uoqh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 12pt"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 12pt"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_40D_ecustom--LongLivedAssetsAndOperatingLeaseRightOfUseAssets_iI_hsrt--StatementGeographicalAxis__country--IL_zh1h43UUA62k" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Israel</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">209</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">406</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_ecustom--LongLivedAssetsAndOperatingLeaseRightOfUseAssets_iI_hsrt--StatementGeographicalAxis__country--US_zK2G5uXwCOM5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">United States</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--LongLivedAssetsAndOperatingLeaseRightOfUseAssets_iI_zWbruA5RF2t" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Long lived assets and operating lease right of use assets</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">212</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">406</td><td style="text-align: left"> </td></tr> </table>

The table below summarizes the significant expense categories regularly reviewed by the CODM for the years ended December 31, 2024 and 2023: SCHEDULE OF STATEMENT OF OPERATION BY SEGMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20240101__20241231_z39SDDsoztJd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20230101__20231231_z3v77eTaeyRh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; text-align: left">Significant segment expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--PayrollAndPayrollRelated_maNILzcOv_zAM7Seq0Gas2" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; width: 60%; text-align: left">Payroll and payroll related</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(5,376</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">(3,678</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_404_ecustom--MaterialsAndSubcontractors_maNILzcOv_zlLkzEJLr5K8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left">Materials and subcontractors</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,165</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,362</td><td style="text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--ShareBasedCompensation_iN_di_msNILzcOv_zkDzZJnfreij" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left">Share-based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,349</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,394</td><td style="text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--GainLossRelatedToLitigationSettlement_maNILzcOv_z1GXI5BlmHj4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left">Loss on legal settlement, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,111</td><td style="text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--SegmentReportingOtherItemAmount_iN_di_msNILzcOv_z8iL7DkdX7M5" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Other segment items (*)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,553</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,195</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--NetIncomeLoss_iT_mtNILzcOv_zODmNuk5LiS" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(11,443</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(10,740</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 89%; margin-left: 0.75in"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right">(*)</td><td style="text-align: justify">Other segment expense items included within net loss include professional services, patents, overhead and depreciation, travel expenses, financial income, net and other miscellaneous expenses net of grants received. See the consolidated financial statements for other financial information regarding the Company’s operating segment.</td> </tr></table>

-5376000 -3678000 -2165000 -2362000

1349000

1394000

-1111000

2553000

2195000

-11443000

-10740000

<p id="xdx_89A_ecustom--ScheduleOfLongLivedAssetsAndOperatingLeaseRightOfUseAssetsByGeographicalAreasTableTextBlock_z2RPpORjgG65" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Long-lived assets and operating lease right-of-use assets by geographical areas were as follows: SCHEDULE OF LONG LIVED ASSETS AND OPERATING LEASE RIGHT OF USE ASSETS BY GEOGRAPHICAL AREAS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"> <tr style="display: none; vertical-align: bottom"> <td style="font-size: 12pt"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_499_20241231_zQHPFxsu0hb4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49F_20231231_zX7G2ov6Uoqh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 12pt"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 12pt"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_40D_ecustom--LongLivedAssetsAndOperatingLeaseRightOfUseAssets_iI_hsrt--StatementGeographicalAxis__country--IL_zh1h43UUA62k" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Israel</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">209</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">406</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_ecustom--LongLivedAssetsAndOperatingLeaseRightOfUseAssets_iI_hsrt--StatementGeographicalAxis__country--US_zK2G5uXwCOM5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">United States</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--LongLivedAssetsAndOperatingLeaseRightOfUseAssets_iI_zWbruA5RF2t" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Long lived assets and operating lease right of use assets</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">212</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">406</td><td style="text-align: left"> </td></tr> </table> 209000 406000 3000 212000 406000

NOTE 15 - RELATED PARTIES There were no material related party transactions in each of the years ended December 31, 2024 and 2023 that were outside of the Company’s normal course of business.

NOTE 16 - TAXES ON INCOME The Company is subject to U.S. federal tax rate of <span id="xdx_906_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20240101__20241231__us-gaap--IncomeTaxAuthorityNameAxis__custom--USTaxAuthorityMember_z5GNd8nDmRr1" title="Corporate income tax rate"><span id="xdx_902_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20230101__20231231__us-gaap--IncomeTaxAuthorityNameAxis__custom--USTaxAuthorityMember_zuGUaHsFndj2" title="Corporate income tax rate">21% for the years ended December 31, 2024 and 2023. The Company has not been audited by the Internal Revenue Service since its incorporation. As of December 31, 2024 and 2023, the Company has generated accumulated net operating losses in the U.S. of approximately $511,371 and $506,317, respectively. The Company has available carryforward net operating losses amounting to approximately $<span id="xdx_907_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_c20241231__us-gaap--IncomeTaxAuthorityNameAxis__custom--USTaxAuthorityMember_zhc8JE7pZtB3" title="Operating loss carryforwards">106,313 at the U.S. federal level. This consists of pre-2017 net operating losses subject to a 20-year limitation per Section 382, amounting to approximately $85,415, and post-2017 net operating losses which can be carried forward indefinitely, amounting to approximately $20,898. Utilization of U.S. net operating losses may be subject to substantial annual limitation due to the “change in ownership” provisions of the Internal Revenue Code of 1986 and similar state provisions. The annual limitation may result in the expiration of net operating losses before utilization. Microbot Israel is subject to Israeli corporate tax rate of <span id="xdx_90C_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20240101__20241231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--IsraelTaxAuthorityMember_zwJ9upo77Wt9" title="Corporate income tax rate"><span id="xdx_907_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20230101__20231231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--IsraelTaxAuthorityMember_z3f3Er0mpl8" title="Corporate income tax rate">23% for the years ended 2024 and 2023. Microbot Israel has not received a final tax assessment since 2018. As of December 31, 2024 and 2023, Microbot Israel has generated accumulated net operating losses in Israel of approximately $47,553 and $41,164, respectively, which may be carried forward and offset against taxable income in the future for an indefinite period. MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data) NOTE 16 - TAXES ON INCOME The Company is still in its development stage and has not yet generated revenues, therefore, it is more likely than not that sufficient taxable income will not be available for the tax losses to be utilized in the future. Therefore, a valuation allowance was recorded to reduce the deferred tax assets to its recoverable amounts. SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20241231_zPOCg4GJMQ05" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20231231_zbhgVrj22Jte" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_407_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTAGzH1x_maDTAGzhML_zk8jm4d7Gr0j" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Net operating loss carryforwards</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">118,309</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">115,778</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_ecustom--DeferredTaxAssetsOperationLeaseLiabilities_iI_pn3n3_maDTAGzH1x_maDTAGzhML_zQcluArQReZ2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Operating lease liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">26</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">53</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--DeferredTaxAssetsAccruedVacationPay_iI_pn3n3_maDTAGzH1x_maDTAGzhML_z7y3qFghjrdc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accrued vacation pay</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">69</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">59</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_ecustom--DeferredTaxAssetsLegalSettlementAccrual_iI_pn3n3_maDTAGzhML_zL3BDm9RykM" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Legal settlement accrual</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">464</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--DeferredTaxAssetsAdvancePaymentFromIia_iI_pn3n3_maDTAGzhML_z9wHWGBlDJL5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Advance payment from IIA</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">17</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsGross_iTI_pn3n3_maDTANzNI9_mtDTAGzhML_za2UbJp6O1aj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total deferred tax assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">118,404</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">116,371</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTANzNI9_zoLeNCZQ9D9a" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Less: valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(118,374</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(116,014</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsNet_iTI_pn3n3_mtDTANzNI9_maDTLzaPY_zFNQ6MsVYSlf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Net deferred tax assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">30</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">357</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--DeferredTaxLiabilitiesOperatingLeasesRightofUseAssets_iNI_pn3n3_di_maDITLzqnl_maDTLzwq6_zdVRAXyZuoqk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Operating leases, right-of-use assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(30</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(60</td><td style="text-align: left">)</td></tr> <tr id="xdx_40D_ecustom--DeferredTaxLiabilitiesGrantReceivable_iNI_pn3n3_di_maDTLzwq6_zsvtFZERFBgh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Grant receivable (Ministry of Economy)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(5</td><td style="text-align: left">)</td></tr> <tr id="xdx_40F_ecustom--DeferredTaxLiabilitiesInsuranceRecoveryReceivable_iNI_pn3n3_di_maDTLzwq6_zv3LmRLhOFFe" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Insurance recovery receivable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(280</td><td style="text-align: left">)</td></tr> <tr id="xdx_401_ecustom--DeferredTaxLiabilitiesMarketableSecurities_iNI_pn3n3_di_maDTLzwq6_z1Ae3hCjFTud" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Marketable securities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(12</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxLiabilities_iNTI_di_msDTLzaPY_mtDTLzwq6_zBcEkAwuX3Ni" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Total deferred tax liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(30</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(357</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_mtDTLzaPY_zg5Vcj9ji9z2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total net deferred tax assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Reconciliation of Income Taxes: The main reconciling item between the statutory tax rate of the Company and the effective tax rate is the recognition of valuation allowance in respect of deferred taxes relating to accumulated net operating losses carried forward due to the uncertainty of the realization of such deferred taxes. MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data)

0.21

511371000

506317000

106313000

85415000

20898000

0.23

47553000

41164000

SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20241231_zPOCg4GJMQ05" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20231231_zbhgVrj22Jte" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_407_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTAGzH1x_maDTAGzhML_zk8jm4d7Gr0j" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Net operating loss carryforwards</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">118,309</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">115,778</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_ecustom--DeferredTaxAssetsOperationLeaseLiabilities_iI_pn3n3_maDTAGzH1x_maDTAGzhML_zQcluArQReZ2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Operating lease liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">26</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">53</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--DeferredTaxAssetsAccruedVacationPay_iI_pn3n3_maDTAGzH1x_maDTAGzhML_z7y3qFghjrdc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accrued vacation pay</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">69</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">59</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_ecustom--DeferredTaxAssetsLegalSettlementAccrual_iI_pn3n3_maDTAGzhML_zL3BDm9RykM" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Legal settlement accrual</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">464</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--DeferredTaxAssetsAdvancePaymentFromIia_iI_pn3n3_maDTAGzhML_z9wHWGBlDJL5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Advance payment from IIA</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">17</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsGross_iTI_pn3n3_maDTANzNI9_mtDTAGzhML_za2UbJp6O1aj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total deferred tax assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">118,404</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">116,371</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTANzNI9_zoLeNCZQ9D9a" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Less: valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(118,374</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(116,014</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsNet_iTI_pn3n3_mtDTANzNI9_maDTLzaPY_zFNQ6MsVYSlf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Net deferred tax assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">30</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">357</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--DeferredTaxLiabilitiesOperatingLeasesRightofUseAssets_iNI_pn3n3_di_maDITLzqnl_maDTLzwq6_zdVRAXyZuoqk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Operating leases, right-of-use assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(30</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(60</td><td style="text-align: left">)</td></tr> <tr id="xdx_40D_ecustom--DeferredTaxLiabilitiesGrantReceivable_iNI_pn3n3_di_maDTLzwq6_zsvtFZERFBgh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Grant receivable (Ministry of Economy)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(5</td><td style="text-align: left">)</td></tr> <tr id="xdx_40F_ecustom--DeferredTaxLiabilitiesInsuranceRecoveryReceivable_iNI_pn3n3_di_maDTLzwq6_zv3LmRLhOFFe" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Insurance recovery receivable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(280</td><td style="text-align: left">)</td></tr> <tr id="xdx_401_ecustom--DeferredTaxLiabilitiesMarketableSecurities_iNI_pn3n3_di_maDTLzwq6_z1Ae3hCjFTud" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Marketable securities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(12</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxLiabilities_iNTI_di_msDTLzaPY_mtDTLzwq6_zBcEkAwuX3Ni" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Total deferred tax liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(30</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(357</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_mtDTLzaPY_zg5Vcj9ji9z2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total net deferred tax assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

118309000

115778000

26000 53000 69000 59000 464000 17000

118404000

116371000

118374000

116014000

30000

357000

30000 60000 5000 280000 12000

30000

357000

NOTE 17 – SUBSEQUENT EVENTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">A.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">January and February 2025 Offerings: </td></tr></table> On January 6, 2025, the Company entered into Securities Purchase Agreements with investors, pursuant to which the Company agreed to issue and sell, in a registered direct offering priced at-the-market under the rules of the Nasdaq Stock Market, an aggregate of <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250106__20250106__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zceH9DIjyCyb" title="Number of shares issued and sold">4,000,001 shares of the Company’s common stock, par value $<span id="xdx_907_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20250106__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zX0X7aR1odW8" title="Common stock, par value">0.01 per share, at an offering price of $<span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250106__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zeVN48Sty594" title="Offering price per share">1.75 per share, for aggregate gross proceeds from the offerings of approximately $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn3n3_c20250106__20250106__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zVfQpdwyqTX4" title="Gross proceeds from offering">7,000 before deducting the placement agent fee and related offering expenses of approximately $<span id="xdx_906_eus-gaap--PaymentsOfStockIssuanceCosts_pn3n3_c20250106__20250106__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_znXaxJeoHbl5" title="Issuance costs">636. In a concurrent private placement, the Company agreed to issue to the investors series G preferred investment options to purchase up to <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250106__20250106__us-gaap--StatementClassOfStockAxis__custom--SeriesGPreferredInvestmentOptionsMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zIfw5aPdMQMc" title="Aggregate shares of common stock">8,000,002 shares of common stock at an exercise price of $<span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250106__us-gaap--StatementClassOfStockAxis__custom--SeriesGPreferredInvestmentOptionsMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zX1VHdU0QaKh" title="Exercise price">1.75 per share. Each Series G preferred investment option is exercisable immediately and will expire <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20250106__20250106__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesGPreferredInvestmentOptionsMember_z07iV2HAqZj2" title="Exercisable expire period">two years from the initial exercise date. The Company also issued to Wainwright or its designees preferred investment options to purchase up to <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250107__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zDeqwflgPCmj" title="Number of warrants to purchase">200,000 shares of common stock which have the same terms as investors’ preferred investment options except for an exercise price equal to $<span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250107__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zZV50IZhC533" title="Exercise price per share">2.1875 per share. On January 7, 2025, the Company entered into Securities Purchase Agreements with investors, pursuant to which the Company agreed to issue and sell, in a registered direct offering priced at-the-market under the rules of the Nasdaq Stock Market, an aggregate of <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250107__20250107__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zggUITRsZUH9" title="Number of shares issued and sold">3,788,550 shares of the Company’s common stock, par value $<span id="xdx_90B_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20250107__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zMPzbOFSF6zc" title="Common stock par value">0.01 per share, at an offering price of $<span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250107__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zd2gGPNbkfii" title="Offering price per share">2.27 per share, for aggregate gross proceeds from the offerings of approximately $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn3n3_c20250107__20250107__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zOH71fC9S7Ya" title="Gross proceeds from offering">8,600 before deducting the placement agent fee and related offering expenses of approximately $<span id="xdx_90A_eus-gaap--PaymentsOfStockIssuanceCosts_pn3n3_c20250107__20250107__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zM9BKoYNdjoc" title="Issuance costs">764. In a concurrent private placement, the Company agreed to issue to the investors series H preferred investment options to purchase up to <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250106__20250106__us-gaap--StatementClassOfStockAxis__custom--SeriesHPreferredInvestmentOptionsMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zS3Hd2UFGArh" title="Aggregate shares of common stock">7,577,100 shares of common stock at an exercise price of $<span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250106__us-gaap--StatementClassOfStockAxis__custom--SeriesHPreferredInvestmentOptionsMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zYyYwmlYjxQc" title="Share price per share">2.10 per share. Each Series H preferred investment option is exercisable immediately and will expire <span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20250107__20250107__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesHPreferredInvestmentOptionsMember_zUNABFGrAcL4" title="Exercisable expire period">two years from the initial exercise date. The Company also issued to Wainwright or its designees preferred investment options to purchase up to <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250110__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zz7VdhfpY1M8" title="Warrants to purchase common stock">189,428 shares of common stock which have the same terms as investors’ preferred investment options except for an exercise price equal to $<span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250110__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zlp0hAPBwX7" title="Exercise price per share">2.8375 per share. On February 9, 2025, the Company entered into Securities Purchase Agreements with investors, pursuant to which the Company agreed to issue and sell, in a registered direct offering priced at-the-market under the rules of the Nasdaq Stock Market, an aggregate of <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250209__20250209__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zGbtyjjpz9Sd" title="Number of shares issued and sold">6,103,289 shares of the Company’s common stock, par value $<span id="xdx_90D_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20250209__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zBM6G9UR1L8f" title="Common stock, par value">0.01 per share, at an offering price of $<span id="xdx_903_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250209__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zLmFjS5ltdT5" title="Offering price per share">2.13 per share, for aggregate gross proceeds from the offerings of approximately $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn3n3_c20250209__20250209__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zCUCPfUqUiNf" title="Gross proceeds from offering">13,000 before deducting the placement agent fee and related offering expenses of approximately $<span id="xdx_90F_eus-gaap--PaymentsOfStockIssuanceCosts_pn3n3_c20250209__20250209__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zpXikpEKfOEc" title="Issuance costs">1,116. In a concurrent private placement, the Company agreed to issue to the investors series I preferred investment options to purchase up to <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250209__20250209__us-gaap--StatementClassOfStockAxis__custom--SeriesIPreferredInvestmentOptionsMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z4CYyysMTpCf" title="Aggregate shares of common stock">12,206,578 shares of common stock at an exercise price of $<span id="xdx_90A_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250209__us-gaap--StatementClassOfStockAxis__custom--SeriesIPreferredInvestmentOptionsMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zDbwLcoCWWEg" title="Share price per share">2.13 per share. Each Series I preferred investment option is exercisable on the later of (i) the date on which the amendment to the Company’s articles of incorporation that increases the number of authorized shares of common stock to an amount of shares of common stock sufficient for the exercise in full of the series I preferred investment options is filed and accepted with the State of Delaware law (such date, the “Authorized Share Increase Date”) and (ii) the date on which approval as may be required by the applicable rules and regulations of the Nasdaq Stock Market (or any successor entity) from the stockholders of the Company with respect to the issuance of all the series I preferred investment options and the shares of common stock issuable upon the exercise thereof, is received and deemed effective under Delaware law (the “Initial exercise date”), and will expire <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20250209__20250209__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesIPreferredInvestmentOptionsMember_zU4JuCPAxFpf" title="Exercisable expire period">two years from the initial exercise date. The Company also issued to Wainwright or its designees preferred investment options to purchase up to <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250209__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zpcMsBuZ5Ple" title="Warrants to purchase common stock">305,164 shares of common stock which have the same terms as investors’ preferred investment options except for an exercise price equal to $<span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250209__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zx6nz3EOcc2k" title="Exercise price per share">2.6625 per share. ATM Offering During January 2025, the Company issued <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250101__20250131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ATMAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zf8kHHXPVmZ5" title="Issued and sold shares">842,606 shares of the Company’s common stock pursuant to the ATM Agreement, for total gross proceeds of approximately $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn3n3_c20250101__20250131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ATMAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zDSOJxVvTQhd" title="Gross proceeds from offering">1,062. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">B.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Exercise of Investment Options:</td></tr></table> In January 2025, the Company raised approximately $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_pn3n3_c20250101__20250131__us-gaap--TypeOfArrangementAxis__custom--ExerciseOfInvestmentOptionsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesEPreferredInvestmentOptionsMember_zj0CPXATPrml" title="Gross proceeds from exercise of shares">916 in gross proceeds from the exercise of <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20250101__20250131__us-gaap--TypeOfArrangementAxis__custom--ExerciseOfInvestmentOptionsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesEPreferredInvestmentOptionsMember_zSKjY8qZX2rf" title="Number of shares exercised">610,517 outstanding Series E preferred investment options. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"> <tr style="vertical-align: top"> <td style="width: 0.75in"> </td> <td style="text-align: justify; width: 0.25in">C.</td> <td style="text-align: justify">Stock option grants and other compensation:</td></tr> </table> In January 2025, the Company paid the CEO a total bonus amounting to approximately $<span id="xdx_905_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_pn3n3_c20250101__20250131__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zx3hxpjAX8S" title="Special bonus paid">548, out of which an approximate amount of $<span id="xdx_908_ecustom--AnnualBonus_pn3n3_c20250101__20250131__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zoew5NGTP7El" title="Annual bonus">398 is related to fiscal year 2024, which was authorized and approved in January 2025. In January 2025, the Company authorized and approved bonuses to executives and certain employees in the amount of approximately $<span id="xdx_905_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_pn3n3_c20250101__20250131__srt--TitleOfIndividualAxis__custom--ExecutivesAndCertainEmployeesMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zA4eN8uiuHT1">294, related to fiscal year 2024, and approved salary increases for the CEO and other executives. In January and February 2025, the Company granted the CEO, executives and certain employees, and certain board members <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250101__20250131__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zhN4EQUjpUyi" title="Number of options granted"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250201__20250228__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zXxGanPdZFZe" title="Number of options granted">228,000, <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250101__20250131__srt--TitleOfIndividualAxis__custom--ExecutivesMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zfOTAZsrWKdh" title="Number of options granted"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250201__20250228__srt--TitleOfIndividualAxis__custom--ExecutivesMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zBHSjtChaxWh" title="Number of options granted">293,875 and <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250101__20250131__srt--TitleOfIndividualAxis__custom--CertainEmployeesAndCertainBoardMembersMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zaC4loQ5uckk" title="Number of options granted"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250201__20250228__srt--TitleOfIndividualAxis__custom--CertainEmployeesAndCertainBoardMembersMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zIrYKNDp7eXl" title="Number of options granted">70,000 options, respectively. In addition, the Company determined that <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250201__20250228__srt--TitleOfIndividualAxis__custom--BoardMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zaa3Xo24NYw8" title="Number of options granted">35,625 out of <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20250201__20250228__srt--TitleOfIndividualAxis__custom--BoardMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zL4B4MjGAo1b" title="Number of options vested">132,500 performance-based options granted in February 2024 had met their milestones and been vested, while the remainder <span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_pid_c20250201__20250228__srt--TitleOfIndividualAxis__custom--BoardMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zG7FHFsGN3O1" title="Number of options forfeited">96,875 options which did not meet their milestones had been forfeited. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">D.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Mona litigation:</td></tr> </table> In March 2025, the appellate court in the Mona litigation (see Note 9H above) held in favor of the Company and the Judgment was released to the Company. The Company received approximately $316 of the Judgment, net of legal fees and expenses.

4000001

0.01

1.75

7000000

636000

8000002

1.75

P2Y

200000

2.1875

3788550

0.01

2.27

8600000

764000

7577100

2.10

P2Y

189428

2.8375

6103289

0.01

2.13

13000000

1116000

12206578

2.13

P2Y

305164

2.6625

842606

1062000

916000

610517

548000

398000

294000

228000

293875

70000

35625

132500

96875

316000

Net of issuance costs in the amount of $1,075. Net of issuance costs in the amount of $661. See note 9G. Net of issuance costs in the amount of $239. Other segment expense items included within net loss include professional services, patents, overhead and depreciation, travel expenses, financial income, net and other miscellaneous expenses net of grants received. See the consolidated financial statements for other financial information regarding the Company’s operating segment.